:: CLDF ::

Home | Contact Us | Bookmark

HBV

HCC

HCV

Centers of Educational Expertise

Webcasts Slide Library Abstract Library

Conference Highlights

HBV | Abstract Library

The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.

1.	Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations
	Piaserico S¹, Messina F², Russo FP³. Am J Clin Dermatol. 2019 Jun 20. doi: 10.1007/s40257-019-00457-3. [Epub ahead of print]

2.	Hepatitis B in Pregnant Women and their Infants
	Cryer AM¹, Imperial JC². Clin Liver Dis. 2019 Aug;23(3):451-462. doi: 10.1016/j.cld.2019.04.007. Epub 2019 Jun 4.

3.	Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease
	Wyles DL¹. Clin Liver Dis. 2019 Aug;23(3):473-486. doi: 10.1016/j.cld.2019.04.004. Epub 2019 May 24.

4.	HBV/HCV Coinfection in the Era of HCV-DAAs
	Abdelaal R¹, Yanny B², El Kabany M³. Clin Liver Dis. 2019 Aug;23(3):463-472. doi: 10.1016/j.cld.2019.04.003. Epub 2019 May 27.

5.	Global Perspective on Hepatitis B Virus Infections in the Era of Effective Vaccines
	Gomes C¹, Wong RJ², Gish RG³. Clin Liver Dis. 2019 Aug;23(3):383-399. doi: 10.1016/j.cld.2019.04.001. Epub 2019 May 23.

6.	Will Infant Hepatitis B Immunization Protect Adults?
	Scheifele DW¹. Pediatr Infect Dis J. 2019 Jun;38(6S Suppl 1):S64-S66. doi: 10.1097/INF.0000000000002326.

7.	Evaluating non-invasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV coinfected adults
	Sterling RK¹, King WC², Wahed AS², Kleiner DE³, Khalili M⁴, Sulkowski M⁵, Chung RT⁶, Jain MK⁷, Lisker-Melman M⁸, Wong DK⁹, Ghany MG³; HIV-HBV Cohort Study of the Hepatitis B Research Network. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30825. [Epub ahead of print]

8.	Exploration of long-acting implant formulations of hepatitis B drug entecavir
	Henry SJ¹, Barrett SE², Forster SP¹, Teller RS¹, Yang Z¹, Li L¹, Mackey MA¹, Doto GJ³, Ruth MP³, Tsuchiya T³, Klein LJ¹, Gindy ME¹. Eur J Pharm Sci. 2019 Jun 15;136:104958. doi: 10.1016/j.ejps.2019.104958. [Epub ahead of print]

9.	Underreporting of Hepatitis B and C virus infections - Pennsylvania, 2001-2015
	Roberts H¹, Boktor SW², Waller K², Daar ZS³, Boscarino JA³, Dubin PH^1,4, Suryaprasad A^1,5, Moorman AC¹. PLoS One. 2019 Jun 6;14(6):e0217455. doi: 10.1371/journal.pone.0217455. eCollection 2019.

10.	Patient-Reported Outcomes in Patients Chronic Viral Hepatitis without Cirrhosis: The Impact of Hepatitis B and C Viral Replication
	Younossi ZM^1,2, Stepanova M³, Younossi I³, Papatheodoridis G⁴, Janssen HLA⁵, Agarwal K⁶, Nguyen MH⁷, Gane E⁸, Tsai N⁹, Nader F³. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print]

11.	Management of Fulminant Hepatitis B
	Ichai P^1,2,3, Samuel D^4,5,6. Curr Infect Dis Rep. 2019 Jun 4;21(7):25. doi: 10.1007/s11908-019-0682-9.

12.	Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data
	Kazory A¹, Ronco C^2,3. Cardiorenal Med. 2019;9(1):1-7. doi: 10.1159/000492791. Epub 2018 Sep 17.

13.	Associations Between Hepatitis B Virus Infection and Risk of All Cancer Types
	Song C¹, Lv J², Liu Y³, Chen JG⁴, Ge Z¹, Zhu J⁴, Dai J¹, Du LB⁵, Yu C², Guo Y⁶, Bian Z⁶, Yang L^6,7, Chen Y^6,7, Chen Z^6,7, Liu J⁸, Jiang J⁹, Zhu L⁹, Zhai X⁹, Jiang Y¹, Ma H¹, Jin G¹, Shen H¹, Li L², Hu Z¹; China Kadoorie Biobank Collaborative Group. JAMA Netw Open. 2019 Jun 5;2(6):e195718. doi: 10.1001/jamanetworkopen.2019.5718.

14.	Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis Bvirus infection
	Marcellin P¹, Wong D², Sievert W³, Buggisch P⁴, Petersen J⁴, Flisiak R⁵, Manns M^6,7, Kaita K⁸, Krastev Z⁹, Lee SS¹⁰, Cathcart AL¹¹, Crans G¹¹, Op den Brouw M¹², Jump B¹¹, Gaggar A¹¹, Flaherty J¹¹, Buti-Ferret M¹³. Liver Int. 2019 May 28. doi: 10.1111/liv.14155. [Epub ahead of print]

15.	High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation
	Choi GH¹, Kim GA², Choi J³, Han S⁴, Lim YS³. Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15311. [Epub ahead of print]

16.	Metabolic Syndrome and Liver Steatosis occur at lower body mass index in US Asian patients with Chronic Hepatitis B
	Clarke WT¹, Miranda J¹, Neidich E¹, Hudock R¹, Peters MG¹, Kelly EM². J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13147. [Epub ahead of print]

17.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients

Lo Re V 3rd¹, Newcomb CW¹, Carbonari DM¹, Roy JA¹, Althoff KN², Kitahata MM³, Reddy KR¹, Lim JK⁴, Silverberg MJ⁵, Mayor AM⁶, Horberg MA⁷, Cachay ER⁸, Kirk GD², Hull M⁹, Gill J¹⁰, Sterling TR¹¹, Kostman JR¹², Peters MG¹³, Moore RD², Klein MB¹⁴, Kim HN³; North American AIDS Cohort Collaboration on Research and Design of IeDEA. J Acquir Immune Defic Syndr. 2019 Apr 29. doi: 10.1097/QAI.0000000000002094. [Epub ahead of print]

18.	Updates on Chronic HBV: Current Challenges and Future Goals
	Lee HM¹, Banini BA². Curr Treat Options Gastroenterol. 2019 May 10. doi: 10.1007/s11938-019-00236-3. [Epub ahead of print]

19.	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells
	Dias J¹, Hengst J², Parrot T¹, Leeansyah E³, Lunemann S⁴, Malone DFG¹, Hardtke S⁵, Strauss O¹, Zimmer CL¹, Berglin L¹, Schirdewahn T⁵, Ciesek S⁶, Marquardt N¹, von Hahn T⁵, Manns MP⁵, Cornberg M⁵, Ljunggren HG¹, Wedemeyer H⁷, Sandberg JK¹, Björkström NK⁸. J Hepatol. 2019 May 6. pii: S0168-8278(19)30270-3. doi: 10.1016/j.jhep.2019.04.009. [Epub ahead of print]

20.	Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers
	O'Neil CR¹, Congly SE², Rose MS³, Lee SS², Borman MA², Charlton CL⁴, Osiowy C⁵, Swain MG², Burak KW², Coffin CS⁶. Ann Hepatol. 2018 Mar - Apr;17(2):232-241. doi: 10.5604/01.3001.0010.8640.

21.	Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study
	Bzowej NH¹, Tran TT², Li R³, Belle SH⁴, Smith CI⁵, Khalili M⁶, Chung R⁷, Tsai N⁸, Terrault N⁹; Hepatitis B Research Network (HBRN). Am J Gastroenterol. 2019 May 1. doi: 10.14309/ajg.0000000000000221. [Epub ahead of print]

22.	Management Approaches to Hepatitis B Virus Vaccination Nonresponse
	Yanny B^1,2, Konyn P^1,2, Najarian LM^1,2, Mitry A^1,2, Saab S^1,2. Gastroenterol Hepatol (N Y). 2019 Feb;15(2):93-99.

23.	Treatment of Viral Infections During Pregnancy
	Rogan SC¹, Beigi RH². Clin Perinatol. 2019 Jun;46(2):235-256. doi: 10.1016/j.clp.2019.02.009. Epub 2019 Mar 28.

24.	Hepatitis B Virus and HIV Coinfection: Fibrosis, Fat, and Future Directions
	Kim AY¹. Am J Gastroenterol. 2019 Apr 12. doi: 10.14309/ajg.0000000000000231. [Epub ahead of print]

25.

A global scientific strategy to cure hepatitis B

Revill PA¹, Chisari FV², Block JM³, Dandri M⁴, Gehring AJ⁵, Guo H⁶, Hu J⁷, Kramvis A⁸, Lampertico P⁹, Janssen HLA¹⁰, Levrero M¹¹, Li W¹², Liang TJ¹³, Lim SG¹⁴, Lu F¹⁵, Penicaud MC¹⁶, Tavis JE¹⁷, Thimme R¹⁸; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F¹⁹. Lancet Gastroenterol Hepatol. 2019 Apr 10. pii: S2468-1253(19)30119-0. doi: 10.1016/S2468-1253(19)30119-0. [Epub ahead of print]

26.	Countdown to 2030: eliminating hepatitis B disease, China
	Liu J¹, Liang W², Jing W¹, Liu M¹. Bull World Health Organ. 2019 Mar 1;97(3):230-238. doi: 10.2471/BLT.18.219469. Epub 2019 Jan 28.

27.	Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection
	Post G^1,2, Shalev N³, Baumgarten A², Shimakawa Y⁴, Lemoine M⁵, Krznaric I², Dupke S², Carganico A², Arastéh K⁶, Ingiliz P². Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001409. [Epub ahead of print]

28.	Evidence for Use of Tenofovir in Pregnancy to Prevent Perinatal Transmission of Hepatitis B Infection
	Sylvester-Armstrong KR¹, Duff WP. Clin Obstet Gynecol. 2019 Mar 27. doi: 10.1097/GRF.0000000000000438. [Epub ahead of print]

29.

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Salvadori N^1,2, Fan B³, Teeyasoontranon W⁴, Ngo-Giang-Huong N^1,2,5, Phanomcheong S⁶, Luvira A⁷, Puangsombat A⁸, Suwannarat A⁹, Srirompotong U¹⁰, Putiyanun C¹¹, Cressey TR^1,2,5,12, Decker L^1,2, Khamduang W², Harrison L¹³, Tierney C¹³, Shepherd JA^3,14, Kourtis AP¹⁵, Bulterys M^15,16, Siberry GK¹⁷, Jourdain G^1,2,5. Clin Infect Dis. 2019 Mar 29. pii: ciy982. doi: 10.1093/cid/ciy982. [Epub ahead of print]

30.	Immunetolerant Hepatitis B: Maybe a misnomer but still hard to treat
	Martin P¹. Hepatology. 2019 Apr 9. doi: 10.1002/hep.30654. [Epub ahead of print]

31.	Sociodemographic, clinical and birth hospitalization characteristics and infant Hepatitis B vaccination in Washington State
	Oster NV¹, Williams EC², Unger JM³, Newcomb PA⁴, Jacobson EN⁵, deHart MP⁶, Englund JA⁷, Hofstetter AM⁷. Vaccine. 2019 Mar 28. pii: S0264-410X(19)30384-6. doi: 10.1016/j.vaccine.2019.03.050. [Epub ahead of print]

32.

Age, race and viral genotype are associated with the prevalence of Hepatitis B e antigen in children and adults with chronic Hepatitis B

Di Bisceglie AM¹, King WC², Lisker-Melman M³, Khalili M⁴, Belle SH², Feld JJ⁵, Ghany MG⁶, Janssen HLA⁵, Lau D⁷, Lee WM⁸, Ling SC⁵, Cooper S⁹, Rosenthal P⁴, Schwarz KB¹⁰, Sterling RK¹¹, Teckman JH¹, Terrault N⁴; Hepatitis B Research Network (HBRN). J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13104. [Epub ahead of print]

Collaborators (37)

33.	Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients
	Harris AM¹, Millman AJ², Lora M³, Osinubi A⁴, Lom J⁵, Miller LS⁶. Vaccine. 2019 Apr 10;37(16):2188-2193. doi: 10.1016/j.vaccine.2019.03.012. Epub 2019 Mar 19.

34.	Screening of Donor and Candidate Prior to Solid Organ Transplantation - Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
	Malinis M¹, Boucher HW²; AST Infectious Diseases Community of Practice. Clin Transplant. 2019 Mar 21:e13548. doi: 10.1111/ctr.13548. [Epub ahead of print]

35.	Recent advances in the development of HBV capsid assembly modulators
	Nijampatnam B¹, Liotta DC². Curr Opin Chem Biol. 2019 Apr 2;50:73-79. doi: 10.1016/j.cbpa.2019.02.009. [Epub ahead of print]

36.	Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients
	Harris AM¹, Millman AJ², Lora M³, Osinubi A⁴, Lom J⁵, Miller LS⁶. Vaccine. 2019 Apr 10;37(16):2188-2193. doi: 10.1016/j.vaccine.2019.03.012. Epub 2019 Mar 19.

37.	Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
	Lee TY^1,2, Hsu YC^3,4,5,6, Tseng HC⁷, Yu SH¹, Lin JT^4,8, Wu MS⁹, Wu CY^7,10,11,12. JAMA Intern Med. 2019 Mar 18. doi: 10.1001/jamainternmed.2018.8342. [Epub ahead of print]

38.	Sexual Behaviors and Health Practices Among Student Service Members and Veterans
	Albright DL¹, Landor AA², McDaniel JT³, Godfrey K⁴, Fletcher KL⁵, Thomas KH⁶, Bertram J⁴. Arch Sex Behav. 2019 Mar 11. doi: 10.1007/s10508-018-1331-3. [Epub ahead of print]

39.	Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease
	Soi V¹, Daifi C², Yee J², Adams E². Adv Chronic Kidney Dis. 2019 Jan;26(1):41-50. doi: 10.1053/j.ackd.2018.10.004.

40.	Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
	Tillmann HL^1,2, Samuel G¹. Expert Opin Pharmacother. 2019 Mar 11:1-13. doi: 10.1080/14656566.2019.1583744. [Epub ahead of print]

41.	Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B
	Hsu CW^1,2, Yeh C³, Yeh CT^1,2. J Med Virol. 2019 Feb 28. doi: 10.1002/jmv.25443. [Epub ahead of print]

42.	Predictive Factors for Successful Vaccination Against Hepatitis B Surface Antigen in Patients Who Have Undergone Orthotopic Liver Transplantation
	Ikeda A¹, Takaki A, Yasunaka T, Oyama A, Adachi T, Wada N, Onishi H, Ikeda F, Shiraha H, Yoshida K, Kuise T, Nobuoka D, Yoshida R, Umeda Y, Yagi T, Fujiwara T, Okada H. Acta Med Okayama. 2019 Feb;73(1):41-50. doi: 10.18926/AMO/56457.

43.	The necessity of education and hepatitis B vaccination for young people: A study of high risk behaviour for blood borne viruses in the United Kingdom
	Sira J¹, Brown M¹, Ambegaokar S², Modin L¹, Kelly DA¹. J Child Health Care. 2019 Feb 28:1367493519831499. doi: 10.1177/1367493519831499. [Epub ahead of print]

44.	Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials
	Buti M¹, Wong DK², Gane E³, Flisiak R⁴, Manns M⁵, Kaita K⁶, Janssen HLA², Op den Brouw M⁷, Jump B⁸, Kitrinos K⁸, Crans G⁸, Flaherty J⁸, Gaggar A⁸, Marcellin P⁹. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.

45.	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals
	Popping S¹, Bade D², Boucher C^1,2, van der Valk M³, El-Sayed M⁴, Sigurour O⁵, Sypsa V⁶, Morgan T⁷, Gamkrelidze A⁸, Mukabatsinda C⁹, Deuffic-Burban S¹⁰, Ninburg M¹¹, Feld J¹², Hellard M¹³, Ward J^14,15. J Virus Erad. 2019 Jan 1;5(1):60-66.

46.	Achieving Excellence in Hepatitis B Virus Care for Veterans in the Veterans Health Administration
	Chartier M¹, Maier MM¹, Morgan TR¹, Lowy E¹, Hoffman-Högg L¹, Ross D¹, Beste LA¹. Fed Pract. 2018 Mar;35(Suppl 2):S49-S53.

47.	Hepatitis B: Screening, Prevention, Diagnosis, and Treatment
	Wilkins T¹, Sams R¹, Carpenter M¹.Author informationAm Fam Physician. 2019 Mar 1;99(5):314-323.

48.	Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - Western Pacific Region, 2005-2017
	Woodring J, Pastore R, Brink A, Ishikawa N, Takashima Y, Tohme RA. MMWR Morb Mortal Wkly Rep. 2019 Mar 1;68(8):195-200. doi: 10.15585/mmwr.mm6808a2.

49.	Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B
	Wei MT¹, Le AK¹, Chang MS², Hsu H³, Nguyen P¹, Zhang JQ⁴, Wong C⁵, Wong C⁶, Cheung R⁷, Nguyen MH¹. J Med Virol. 2019 Feb 18. doi: 10.1002/jmv.25433. [Epub ahead of print]

50.	A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?
	Leung J¹, Peacock A¹, Colledge S², Grebely J³, Cunningham EB³, Hickman M⁴, Vickerman P⁴, Stone J⁴, Trickey A⁴, Dumchev K⁵, Lynskey M⁶, Hines L⁴, Griffiths P⁷, Mattick RP¹, Degenhardt L¹, Larney S¹. J Infect Dis. 2019 Feb 6. doi: 10.1093/infdis/jiz058. [Epub ahead of print]

51.	Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses
	Zhou K¹, Contag C², Whitaker E³, Terrault N⁴. Lancet Gastroenterol Hepatol. 2019 Jan 21. pii: S2468-1253(18)30308-X. doi: 10.1016/S2468-1253(18)30308-X. [Epub ahead of print]

52.	Bridging the access gap: Medicare ineligibility in people living with chronic hepatitis B
	MacLachlan JH¹,², Cowie BC¹,²,³. Intern Med J. 2019 Jan;49(1):122-125. doi: 10.1111/imj.14175.

53.	Primary Care for Persons Who Inject Drugs
	Visconti AJ¹, Sell J², Greenblatt AD³. Am Fam Physician. 2019 Jan 15;99(2):109-116.

54.	Characteristics of Deceased Solid Organ Donors and Screening Results for Hepatitis B, C, and Human Immunodeficiency Viruses - United States, 2010-2017
	Abara WE, Collier MG, Moorman A, Bixler D, Jones J, Annambhotla P, Bowman J, Levi ME, Brooks JT, Basavaraju SV. MMWR Morb Mortal Wkly Rep. 2019 Jan 25;68(3):61-66. doi: 10.15585/mmwr.mm6803a2.

55.	Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices
	Ramsey SD¹, Unger JM²,³, Baker LH⁴, Little RF⁵, Loomba R⁶, Hwang JP⁷, Chugh R⁴, Konerman MA⁴, Arnold K²,³, Menter AR⁸, Thomas E⁹, Michels RM¹⁰, Jorgensen CW¹⁰, Burton GV¹¹, Bhadkamkar NA⁷, Hershman DL¹². JAMA Oncol. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6437. [Epub ahead of print]

56.	Hepatitis B Virus Infection: What Is Current and New
	Peters MG¹. Top Antivir Med. 2019 Jan;26(4):112-116.

57.	Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
	Suk-Fong Lok A¹. Hepatol Commun. 2018 Nov 15;3(1):8-19. doi: 10.1002/hep4.1281. eCollection 2019 Jan.

58.

Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir

Kong Y¹, Sun Y¹, Zhou J¹, Wu X¹, Chen Y², Piao H³, Lu L⁴, Ding H⁵, Nan Y⁶, Jiang W⁷, Xu Y⁸, Xie W⁹, Li H¹⁰, Feng B¹¹, Shi G¹², Chen G¹³, Li H¹⁴, Zheng H¹⁵, Cheng J¹⁶, Wang T¹⁷, Liu H¹⁸, Fudong L¹⁸, Chen S¹⁷, Mao Y¹⁹, Sun J²⁰, Chen T²¹, Han T²², Han Y²³, Wang L¹, Ou X¹, Zhang H²⁴, Jia J¹, You H¹. J Viral Hepat. 2019 Jan 9. doi: 10.1111/jvh.13058. [Epub ahead of print]

59.	Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016
	Patel EU¹, Thio CL², Boon D³, Thomas DL², Tobian AAR¹. Clin Infect Dis. 2019 Jan 3. doi: 10.1093/cid/ciz001. [Epub ahead of print]

60.	Discovery of half-life of circulating HBsAg in patients with chronic hepatitis B infection using heavy water labeling
	Loomba R¹, Decaris M², Li KW²,³, Shankaran M³, Mohammed H²,³, Matthews M²,³, Richards LM¹, Nguyen P¹, Rizo E¹, Andrews B¹, Soto R¹, Angel T³, Suri V⁴, Kitrinos KM⁴, Barnes D⁴, Czerwieniec G⁴, Brendza K⁴, Subramanian GM⁴, Gaggar A⁴, Hellerstein MK²,³. Clin Infect Dis. 2018 Dec 24. doi: 10.1093/cid/ciy1100. [Epub ahead of print]

61.	New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection
	Coffin CS¹, Zhou K², Terrault NA³. Gastroenterology. 2018 Nov 22. pii: S0016-5085(18)35285-5. doi: 10.1053/j.gastro.2018.11.037. [Epub ahead of print]

62.	The push is on to cure hepatitis B, a long-overlooked scourge of millions
	Jon Cohen

63.	Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study
	Wilkinson N¹, Tsakok T², Dand N², Bloem K³, Duckworth M⁴, Baudry D⁴, Pushpa-Rajah A⁴, Griffiths CE⁵, Reynolds N⁶, Barker J², Warren RB⁵, Burden AD⁷, Rispens T³, Stocken D⁸, Smith C⁹; BSTOP study group and PSORT consortium. J Invest Dermatol. 2018 Aug 18. pii: S0022-202X(18)32482-5. doi: 10.1016/j.jid.2018.07.028. [Epub ahead of print]

64.	Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C
	Siegel S¹, Winthrop K², Ehst B³, Ortega Loayza A⁴. Br J Dermatol. 2018 Nov 20. doi: 10.1111/bjd.17444. [Epub ahead of print]

65.	Prevalent misconceptions about opioid use disorders in the United States produce failed policy and public health responses
	Heimer R¹,², Hawk K³, Vermund SH¹,⁴. Clin Infect Dis. 2018 Nov 17. doi: 10.1093/cid/ciy977. [Epub ahead of print]

66.	Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis
	Song J¹, Yang F¹, Wang S¹, Tikande S¹, Deng Y¹, Tang W¹, Cao G¹. J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13036. [Epub ahead of print]

67.	Assessing the Impact of Electronic Health Record Interventions on Hepatitis B Screening and Vaccination
	Weir RC, Toyoji M, McKee M, Li V, Wang CC. J Health Care Poor Underserved. 2018;29(4):1587-1605. doi: 10.1353/hpu.2018.0114.

68.	Acute Hepatitis B with Pancreatitis and Cholecystitis Leading to Acute Liver Failure and Death
	Albert AR¹, Valencia R², Smereck JA². Clin Pract Cases Emerg Med. 2018 Aug 15;2(4):304-308. doi: 10.5811/cpcem.2018.7.38344. eCollection 2018 Nov.

69.

Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues

Chevaliez S¹,², Rodriguez C¹,², Poiteau L¹,², Soulier A¹,², Donati F¹,², Darty-Mercier M¹,², Pioche C³, Leroy V⁴,⁵, Brodard V⁶, Zoulim F⁷,⁸, Brouard C³, Larsen C³, Semaille C³, Roudot-Thoraval F⁹, Pawlotsky JM¹,²; Hepatology Reference Centers Laboratories Network for Chronic Hepatitis BSurveillance. J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13025. [Epub ahead of print]

70.	Combination of entecavir/ peginterferon alfa-2a in children with HBeAg-positive immune tolerant chronic hepatitis B virus infection
	Rosenthal P¹, Ling SC², Belle SH³, Murray KF⁴, Rodriguez-Baez N⁵, Schwarzenberg SJ⁶, Teckman J⁷, Lin HS³, Schwarz KB⁸; Hepatitis B Research Network (HBRN). Hepatology. 2018 Oct 15. doi: 10.1002/hep.30312. [Epub ahead of print]

71.	Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection
	Liu S¹, Zhou B¹,², Valdes JD², Sun J¹, Guo H². Hepatology. 2018 Oct 25. doi: 10.1002/hep.30325. [Epub ahead of print]

72.	Management of chronic hepatitis B during pregnancy
	Aslam A¹, Campoverde Reyes KJ¹,², Malladi VR¹, Ishtiaq R¹, Lau DTY¹. Gastroenterol Rep (Oxf). 2018 Nov;6(4):257-262. doi: 10.1093/gastro/goy025. Epub 2018 Jul 24.

73.	Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States
	Klein NP¹, Abu-Elyazeed R², Cheuvart B³, Janssens W³, Mesaros N³. Hum Vaccin Immunother. 2018 Nov 16. doi: 10.1080/21645515.2018.1549449. [Epub ahead of print]

74.	What is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats
	Ward JW¹, Hinman AR². Gastroenterology. 2018 Nov 1. pii: S0016-5085(18)35205-3. doi: 10.1053/j.gastro.2018.10.048. [Epub ahead of print]

75.	Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs
	Bakacs T¹, Safadi R², Kovesdi I³. Hepatol Med Policy. 2018 Jan 5;3:2. doi: 10.1186/s41124-017-0028-x. eCollection 2018.

76.	Lichen striatus-like eruption in an adult following hepatitis B vaccination: a case report and review of the literature
	Jones J¹, Marquart JD, Logemann NF, DiBlasi DR. Dermatol Online J. 2018 Jul 15;24(7). pii: 13030/qt1hr764kv.

77.	The impact of currently licensed therapies on viral and immune responses in Chronic Hepatitis B: considerations for future novel therapeutics
	Gill US¹,², Kennedy PTF¹,². J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13040. [Epub ahead of print]

78.	A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease
	da Silva EN¹,²,³, Baker A⁴, Alshekaili J¹,², Karpe K⁵, Cook MC¹,²,³. PLoS One. 2018 Oct 10;13(10):e0204477. doi: 10.1371/journal.pone.0204477. eCollection 2018.

79.	Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California
	Toy M¹, Wei B¹, Virdi TS¹, Le A², Trinh H³, Li J⁴, Zhang J⁵, Hsing AW⁶, So SK¹, Nguyen MH². Hepatol Med Policy. 2018 Jun 5;3:6. doi: 10.1186/s41124-018-0034-7. eCollection 2018.

80.	Hepatitis B Prevalence and Risk Factors in a Foreign-Born Asian and Pacific Islander Population at a Community Health Center in Hawai'i
	Ferrer A¹, Katz AR¹, Hurwitz EL¹, Pham T². Asia Pac J Public Health. 2018 Sep 22:1010539518800359. doi: 10.1177/1010539518800359. [Epub ahead of print]

81.	Risk factors for liver disease among adults of Mexican descent in the United States and Mexico
	Flores YN¹, Zhang ZF², Bastani R³, Leng M⁴, Crespi CM⁵, Ramírez-Palacios P¹, Stevens H⁶, Salmerón J¹. World J Gastroenterol. 2018 Oct 7;24(37):4281-4290. doi: 10.3748/wjg.v24.i37.4281.

82.	B in IT - a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool
	O'Leary DA¹, Cropp E¹, Isaac D²,³, Desmond PV¹, Bell S¹, Nguyen T¹, Wong D¹, Howell J¹, Richmond J⁴,⁵,⁶, O'Neill J⁷, Thompson AJ¹. Hepatol Med Policy. 2018 Jan 4;3:1. doi: 10.1186/s41124-017-0031-2. eCollection 2018.

83.	Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis
	Chen HY^#¹, Shen DT^#¹, Ji DZ^#², Han PC¹, Zhang WM², Ma JF¹, Chen WS³, Goyal H⁴, Pan S¹, Xu HG¹. Gut. 2018 Sep 18. pii: gutjnl-2018-316601. doi: 10.1136/gutjnl-2018-316601. [Epub ahead of print]

84.	Declining in liver stiffness can not indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study
	Dong XQ¹, Wu Z¹, Li J¹,², Wang GQ¹,³,², Zhao H¹,²; China HepB-Related Fibrosis Assessment Research Group. J Gastroenterol Hepatol. 2018 Oct 5. doi: 10.1111/jgh.14498. [Epub ahead of print]

85.	Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
	Ford N¹, Scourse R², Lemoine M³, Hutin Y¹, Bulterys M¹, Shubber Z⁴, Donchuk D⁵, Wandeler G⁶. Hepatol Commun. 2018 Sep 25;2(10):1160-1167. doi: 10.1002/hep4.1247. eCollection 2018 Oct.

86.	Healthcare Resource Utilization and Costs by Disease Severity in an Insured National Sample of US Patients with Chronic Hepatitis B
	Nguyen MH¹, Ozbay AB², Liou I³, Meyer N⁴, Gordon SC⁵, Dusheiko G⁶, Lim JK⁷. J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32440-1. doi: 10.1016/j.jhep.2018.09.021. [Epub ahead of print]

87.	Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood
	McNaughton AL¹, D'Arienzo V², Ansari MA¹, Lumley SF³, Littlejohn M⁴, Revill P⁴, McKeating JA², Matthews PC³. Gastroenterology. 2018 Sep 27. pii: S0016-5085(18)35076-5. doi: 10.1053/j.gastro.2018.07.058. [Epub ahead of print]

88.	Hepatitis B and C
	Mysore KR¹, Leung DH². Clin Liver Dis. 2018 Nov;22(4):703-722. doi: 10.1016/j.cld.2018.06.002. Epub 2018 Aug 22.

89.	Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis
	Kennedy K¹, Graham SM¹,², Arora N³, Shuhart MC⁴, Kim HN¹,². PLoS One. 2018 Sep 25;13(9):e0204031. doi: 10.1371/journal.pone.0204031. eCollection 2018.

90.	The prevalence of undetectable vaccine-induced immunity against hepatitis B virus in US adults at high risk for infection
	Yeo YH¹, Le MH¹, Chang ET², Henry L¹, Nguyen MH¹. Hepatology. 2018 Sep 23. doi: 10.1002/hep.30285. [Epub ahead of print]

91.	Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study
	Groom HC¹, Irving SA², Koppolu P², Smith N², Vazquez-Benitez G³, Kharbanda EO³, Daley MF⁴, Donahue JG⁵, Getahun D⁶, Jackson LA⁷, Tse Kawai A⁸, Klein NP⁹, McCarthy NL¹⁰, Nordin JD³, Sukumaran L¹⁰, Naleway AL². Vaccine. 2018 Oct 1;36(41):6111-6116. doi: 10.1016/j.vaccine.2018.08.074. Epub 2018 Sep 5.

92.	Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection?
	Dodd RY¹, Nguyen ML², Krysztof DE², Notari EP¹, Stramer SL². Transfusion. 2018 Sep;58(9):2166-2170. doi: 10.1111/trf.14784. Epub 2018 Aug 24.

93.	Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B
	Nguyen MH¹, Lim JK², Ozbay AB³, Fraysse J³, Liou I⁴, Meyer N⁵, Dusheiko G⁶,⁷, Gordon SC⁸. Hepatology. 2018 Sep 2. doi: 10.1002/hep.30246. [Epub ahead of print]

94.	HBV core variants, liver fibrosis and hepatocellular carcinoma
	Ligat G¹,², Schuster C¹,², Baumert TF¹,²,³,⁴. Hepatology. 2018 Aug 23. doi: 10.1002/hep.30231. [Epub ahead of print]

95.	Towards the elimination of hepatitis B and hepatocellular carcinoma
	Spearman CW¹. S Afr Med J. 2018 Aug 8;108(8b):13-16. doi: 10.7196/SAMJ.2018.v108i8b.13496.

96.	A Review of the Hepatitis B Foundation Website
	Spratt S¹, Stewart M¹, Paige SR², Stellefson M¹. Health Promot Pract. 2018 Aug 15:1524839918790938. doi: 10.1177/1524839918790938. [Epub ahead of print]

97.	Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States
	Kim M¹, Paik J², Golabi P¹,², Jeffers T², Mishra A¹, Younossi ZM¹,². J Clin Gastroenterol. 2018 Aug 13. doi: 10.1097/MCG.0000000000001110. [Epub ahead of print]

98.	Preventing Perinatal Transmission of Hepatitis B Necessitates Consideration of Antiviral Treatment in Pregnancy
	Terrault N¹, Brown R Jr², Lok A³, Wong J⁴, Chang KM⁵, Jonas M⁶, McMahon B⁷. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30137. [Epub ahead of print]

99.	The efficacy of Tenofivir to prevent perinatal transmission in chronic hepatitis B mothers'. a clinical perspective
	Mubarak G¹, Ferstenberg R². Hepatology. 2018 Aug 2. doi: 10.1002/hep.30138. [Epub ahead of print]

100.	Mortality among Patients with Chronic Hepatitis B (CHB) Infection: the Chronic Hepatitis Cohort Study (CHeCS)
	Bixler D¹, Zhong Y¹, Ly KN¹, Moorman AC¹, Spradling PR¹, Teshale EH¹, Rupp L LB², Gordon SC², Boscarino JA³, Schmidt MA⁴, Daida YG⁵, Holmberg SD¹; CHeCS Investigators. Clin Infect Dis. 2018 Jul 28. doi: 10.1093/cid/ciy598. [Epub ahead of print]

101.	Global HBV burden: guesstimates and facts
	Ginzberg D¹,², Wong RJ³, Gish R¹,². Hepatol Int. 2018 Jul;12(4):315-329. doi: 10.1007/s12072-018-9884-8. Epub 2018 Jul 27.

102.	Commentary: A review of risk of hepatitis B and C transmission through biting or spitting
	Pintilie H¹, Brook G². J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12976. [Epub ahead of print]

103.	Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001-2012
	Moore MS¹, Bocour A¹, Tran OC², Qiao B³, Schymura MJ³, Laraque F⁴, Winters A⁴. Open Forum Infect Dis. 2018 Jun 16;5(7):ofy144. doi: 10.1093/ofid/ofy144. eCollection 2018 Jul.

104.	Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016
	Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, Bulterys M. MMWR Morb Mortal Wkly Rep. 2018 Jul 20;67(28):773-777. doi: 10.15585/mmwr.mm6728a2.

105.	Maternal Hepatitis B Infection and Pregnancy Outcomes in the United States: A Population-Based Cohort Study
	Bajema KL¹, Stankiewicz Karita HC¹, Tenforde MW¹, Hawes SE², Heffron R²,³. Open Forum Infect Dis. 2018 Jun 9;5(6):ofy134. doi: 10.1093/ofid/ofy134. eCollection 2018 Jun.

106.	Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices
	Schillie S¹, Vellozzi C¹, Reingold A², Harris A¹, Haber P³, Ward JW¹, Nelson NP¹. MMWR Recomm Rep. 2018 Jan 12;67(1):1-31. doi: 10.15585/mmwr.rr6701a1.

107.	Association Between Hepatitis B Infection and Pancreatic Cancer: A Population-Based Analysis in the United States
	Desai R, Patel U¹, Sharma S², Singh S³, Doshi S⁴, Shaheen S⁵, Shamim S⁶, Korlapati LS⁷, Balan S⁸, Bray C⁴, Williams R⁹, Shah N¹⁰. Pancreas. 2018 Aug;47(7):849-855. doi: 10.1097/MPA.0000000000001095.

108.	Exploring the feasibility of targeted chronic hepatitis B screening in the emergency department: A pilot study
	Brock C¹, Yi Y¹, Papaluca T², Lucas B³, Angus PW¹,², Taylor D¹,⁴, Leung C¹,². Emerg Med Australas. 2018 Jun 9. doi: 10.1111/1742-6723.13118. [Epub ahead of print]

109.	Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment
	Agarwal K¹, Ahn SH², Elkhashab M³, Lau AH⁴, Gaggar A⁴, Bulusu A⁴, Tian X⁴, Cathcart AL⁴, Woo J⁴, Subramanian GM⁴, Andreone P⁵, Kim HJ⁶, Chuang WL⁷, Nguyen MH⁸. J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12942. [Epub ahead of print]

110.	Strategies for the treatment of HBV/HDV
	Krause A¹, Haberkorn U¹, Mier W¹. Eur J Pharmacol. 2018 Jun 20. pii: S0014-2999(18)30360-1. doi: 10.1016/j.ejphar.2018.06.030. [Epub ahead of print]

111.	Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand
	Maini MK¹, Pallett LJ². Lancet Gastroenterol Hepatol. 2018 Mar;3(3):192-202. doi: 10.1016/S2468-1253(18)30007-4.

112.	Hepatitis B vaccination and screening among foreign-born women of reproductive age in the United States: 2013-2015
	Kilmer GA¹, Barker LK¹, Ly KN¹, Jiles RB¹. Clin Infect Dis. 2018 Jun 1. doi: 10.1093/cid/ciy479. [Epub ahead of print]

113.	Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians
	Koffas A¹, Dolman GE², Kennedy PT³. Clin Med (Lond). 2018 Jun;18(3):212-218. doi: 10.7861/clinmedicine.18-3-212.

114.

Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study

Stasi C¹, Silvestri C¹, Berni R², Brunetto MR³, Zignego AL⁴, Orsini C², Milani S⁵, Ricciardi L⁶, De Luca A⁷, Blanc P⁸, Nencioni C⁹, Aquilini D¹⁰, Bartoloni A¹¹, Bresci G¹², Marchi S¹³, Filipponi F¹⁴, Colombatto P³, Forte P⁵, Galli A⁵, Luchi S⁶, Chigiotti S⁹, Nerli A¹⁰, Corti G¹¹, Sacco R¹², Carrai P¹⁴, Ricchiuti A¹³, Giusti M¹⁵, Almi P¹⁶, Cozzi A⁵, Carloppi S¹⁷, Laffi G¹⁸, Voller F¹, Cipriani F¹⁹. World J Hepatol. 2018 May 27;10(5):409-416. doi: 10.4254/wjh.v10.i5.409.

115.	An ultra-sensitive Abbott ARCHITECT® assay for the detection of hepatitis Bvirus surface antigen (HBsAg)
	Lou S¹, Taylor R², Pearce S³, Kuhns M⁴, Leary T⁵. J Clin Virol. 2018 May 21;105:18-25. doi: 10.1016/j.jcv.2018.05.009. [Epub ahead of print]

116.	Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial
	Yim HJ¹, Kim IH², Suh SJ¹, Jung YK¹,³, Kim JH⁴, Seo YS⁵, Yeon JE⁴, Kim CW⁶, Kwon SY⁷, Park SH⁸, Lee MS⁸, Um SH⁵, Byun KS⁴. J Viral Hepat. 2018 May 17. doi: 10.1111/jvh.12934. [Epub ahead of print]

117.	Hepatitis B Virus Testing and Care among Pregnant Women Using Commercial Claims Data, United States, 2011-2014
	Harris AM¹, Isenhour C¹, Schillie S¹, Vellozzi C¹. Infect Dis Obstet Gynecol. 2018 Apr 1;2018:4107329. doi: 10.1155/2018/4107329. eCollection 2018.

118.	Hepatitis D Viremia Among Injection Drug Users in San Francisco
	Mahale P¹, Aka PV¹,², Chen X³,⁴, Liu P³, Fram BJ⁵, Wang AS¹, Simenel S⁵, Tseng FC¹, Chen S⁶, Edlin BR⁷,⁸, Glenn JS³,⁵, O'Brien TR¹. J Infect Dis. 2018 May 25;217(12):1902-1906. doi: 10.1093/infdis/jiy157.

119.	Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C
	Davison J¹, O'Shea A²,³, Waterbury N⁴,⁵, Villalvazo Y²,⁶. J Community Health. 2018 May 30. doi: 10.1007/s10900-018-0530-0. [Epub ahead of print]

120.	Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV)
	Blackard JT¹, Sherman KE¹. Rev Med Virol. 2018 May 15:e1984. doi: 10.1002/rmv.1984. [Epub ahead of print]

121.	Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal
	Manini MA¹, Whitehouse G², Bruce M², Passerini M³, Lim TY², Carey I², Considine A², Lampertico P³, Suddle A², Heaton N², Heneghan M², Agarwal K². Dig Liver Dis. 2018 Apr 13. pii: S1590-8658(18)30673-X. doi: 10.1016/j.dld.2018.03.032. [Epub ahead of print]

122.	Community-Based Services to Improve Testing and Linkage to Care Among Non-U.S.-Born Persons with Chronic Hepatitis B Virus Infection - Three U.S. Programs, October 2014-September 2017
	Harris AM, Link-Gelles R, Kim K, Chandrasekar E, Wang S, Bannister N, Pong P, Chak E, Chen MS Jr, Bowlus C, Nelson NP. MMWR Morb Mortal Wkly Rep. 2018 May 18;67(19):541-546. doi: 10.15585/mmwr.mm6719a2.

123.	Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists
	Pauly MP¹, Tucker LY², Szpakowski JL², Ready JB², Baer D², Hwang JP³, Lok AS⁴. Clin Gastroenterol Hepatol. 2018 Apr 24. pii: S1542-3565(18)30394-X. doi: 10.1016/j.cgh.2018.04.033. [Epub ahead of print]

124.	Why, who and when to start treatment for chronic hepatitis B infection
	Dolman GE¹, Koffas A², Mason WS³, Kennedy PT⁴. Curr Opin Virol. 2018 Apr 11;30:39-47. doi: 10.1016/j.coviro.2018.03.006. [Epub ahead of print]

125.	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
	Hill A¹, Hughes SL², Gotham D², Pozniak AL³. J Virus Erad. 2018 Apr 1;4(2):72-79.

126.	Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children with Chronic Hepatitis B: The PEG-B-ACTIVE Study
	Wirth S¹, Zhang H², Hardikar W³, Schwarz KB⁴, Sokal E⁵, Yang W⁶, Fan H⁷, Morozov V⁸, Mao Q⁹, Deng H¹⁰, Yang Huang¹¹, Yang L¹¹, Frey N¹², Nasmyth-Miller C¹³, Pavlovic V¹³, Wat C¹³. Hepatology. 2018 Apr 24. doi: 10.1002/hep.30050. [Epub ahead of print]

127.	When do co-infections matter?
	McArdle AJ¹, Turkova A², Cunnington AJ³. Curr Opin Infect Dis. 2018 Jun;31(3):209-215. doi: 10.1097/QCO.0000000000000447.

128.	Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant
	Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. MMWR Morb Mortal Wkly Rep. 2018 Apr 20;67(15):455-458. doi: 10.15585/mmwr.mm6715a5.

129.	Cost Analysis of Single-Dose Hepatitis B Revaccination Among Infants Born to Hepatitis B Surface Antigen-Positive Mothers and Not Responding to the Initial Vaccine Series
	Hall EW¹, Rosenberg ES², Trigg M¹, Nelson N³, Schillie S³. Public Health Rep. 2018 Jan 1:33354918768224. doi: 10.1177/0033354918768224. [Epub ahead of print]

130.	From Infancy and Beyond… Ensuring a lifetime of hepatitis B virus (HBV) vaccine-induced immunity
	Osiowy C¹. Hum Vaccin Immunother. 2018 Apr 11:1-21. doi: 10.1080/21645515.2018.1462428. [Epub ahead of print]

131.	Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?
	Bloom K¹, Maepa MB², Ely A³, Arbuthnot P⁴. Genes (Basel). 2018 Apr 12;9(4). pii: E207. doi: 10.3390/genes9040207.

132.	Chronic hepatitis B virus and liver fibrosis: A mathematical model
	Friedman A¹, Siewe N². PLoS One. 2018 Apr 10;13(4):e0195037. doi: 10.1371/journal.pone.0195037. eCollection 2018.

133.	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial
	Blanco JL¹, Rojas J¹, Paredes R², Negredo E², Mallolas J¹, Casadella M², Clotet B², Gatell JM¹, de Lazzari E¹, Martinez E¹; DOLAM Study Team. J Antimicrob Chemother. 2018 Mar 28. doi: 10.1093/jac/dky093. [Epub ahead of print]

134.	Social Media for Hepatitis B Awareness: Young Adult and Community Leader Perspectives
	Cohen C¹, Alber JM², Bleakley A³, Grossman S⁴, Freeland C¹, Alarcon K¹, Merchant RM³. Health Promot Pract. 2018 Mar 1:1524839918765438. doi: 10.1177/1524839918765438. [Epub ahead of print]

135.	Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
	Kelling M¹, Sokol L², Dalia S³. Cancer Control. 2018 Jan-Mar;25(1):1073274818767879. doi: 10.1177/1073274818767879.

136.	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B
	Khalili M¹, Shuhart MC², Lombardero M³, Feld JJ⁴, Kleiner DE⁵, Chung RT⁶, Terrault NA⁷, Lisker-Melman M⁸, Sanyal A⁹, Lok AS¹⁰; Hepatitis B Research Network (HBRN). Collaborators (36) Diabetes Care. 2018 Mar 29. pii: dc180040. doi: 10.2337/dc18-0040. [Epub ahead of print]

137.	Mathematical model of immune response to hepatitis B
	Fatehi Chenar F¹, Kyrychko YN¹, Blyuss KB². J Theor Biol. 2018 Mar 21;447:98-110. doi: 10.1016/j.jtbi.2018.03.025. [Epub ahead of print]

138.	A Public Health Analysis on Gaps in Disease Monitoring and Opportunities for Improved Care for the Management of Hepatitis B and C
	Akhtar F¹, Rehman S². Cureus. 2018 Jan 16;10(1):e2077. doi: 10.7759/cureus.2077.

139.	Long-term immunity to hepatitis B following vaccination in infancy: Real-world data analysis
	Klinger G¹, Chodick G², Levy I³. Vaccine. 2018 Mar 21. pii: S0264-410X(18)30373-6. doi: 10.1016/j.vaccine.2018.03.028. [Epub ahead of print]

140.	Hepatitis B vaccine non-responders: possible mechanisms and solutions
	Saco TV¹, Strauss AT¹, Ledford DK¹. Ann Allergy Asthma Immunol. 2018 Mar 19. pii: S1081-1206(18)30215-1. doi: 10.1016/j.anai.2018.03.017. [Epub ahead of print]

141.	When do coinfections matter?
	McArdle AJ¹, Turkova A², Cunnington AJ³. Curr Opin Infect Dis. 2018 Mar 22. doi: 10.1097/QCO.0000000000000447. [Epub ahead of print]

142.	Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures?
	Candotti D¹, Laperche S¹. Front Med (Lausanne). 2018 Feb 21;5:29. doi: 10.3389/fmed.2018.00029. eCollection 2018.

143.

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B

Jourdain G¹, Ngo-Giang-Huong N¹, Harrison L¹, Decker L¹, Khamduang W¹, Tierney C¹, Salvadori N¹, Cressey TR¹, Sirirungsi W¹, Achalapong J¹, Yuthavisuthi P¹, Kanjanavikai P¹, Na Ayudhaya OP¹, Siriwachirachai T¹, Prommas S¹, Sabsanong P¹, Limtrakul A¹, Varadisai S¹, Putiyanun C¹, Suriyachai P¹, Liampongsabuddhi P¹, Sangsawang S¹, Matanasarawut W¹, Buranabanjasatean S¹, Puernngooluerm P¹, Bowonwatanuwong C¹, Puthanakit T¹, Klinbuayaem V¹, Thongsawat S¹, Thanprasertsuk S¹, Siberry GK¹, Watts DH¹, Chakhtoura N¹, Murphy TV¹, Nelson NP¹, Chung RT¹, Pol S¹, Chotivanich N¹. N Engl J Med. 2018 Mar 8;378(10):911-923. doi: 10.1056/NEJMoa1708131.

144.

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

Goossens N¹, de Vito C², Mangia A³, Clément S², Cenderello G⁴, Barrera F⁵, D'Ambrosio R⁶, Coppola N⁷, Zampino R⁸, Stanzione M⁹, Adinolfi LE⁸, Wedemeyer H¹⁰, Semmo N¹¹, Müllhaupt B¹², Semela D¹³, Malinverni R¹⁴, Moradpour D¹⁵, Heim M¹⁶, Trincucci G¹⁷, Rubbia-Brandt L², Negro F¹,²; BOSTIC Study Group. J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891. [Epub ahead of print]

145.	Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies
	Li M¹, Gan Y¹, Fan C², Yuan H¹, Zhang X³, Shen Y⁴, Wang Q¹, Meng Z¹, Xu D¹, Tu H¹. J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12892. [Epub ahead of print]

146.	Vaccination coverage among foreign-born and U.S.-born adolescents in the United States: Successes and gaps - National Immunization Survey-Teen, 2012-2014
	Healy J¹, Rodriguez-Lainz A², Elam-Evans LD³, Hill HA³, Reagan-Steiner S⁴, Yankey D³. Vaccine. 2018 Mar 20;36(13):1743-1750. doi: 10.1016/j.vaccine.2018.02.052. Epub 2018 Feb 23.

147.	HIV/HCV/HBV testing in the emergency department: a feasibility and seroprevalence study
	Bradshaw D¹, Rae C¹, Rayment M¹, Turner N¹, Turner R¹, Pickard G², Pillay K¹, Roberts P¹, Foxton M¹, Sullivan AK¹. HIV Med. 2018 Feb;19 Suppl 1:52-57. doi: 10.1111/hiv.12590.

148.	Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes
	Younossi ZM¹, Stepanova M², Janssen HLA³, Agarwal K⁴, Nguyen MH⁵, Gane E⁶, Tsai N⁷, Younossi I², Racila A². Clin Gastroenterol Hepatol. 2018 Mar 2. pii: S1542-3565(18)30225-8. doi: 10.1016/j.cgh.2018.02.037. [Epub ahead of print]

149.	Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers
	O'Neil CR¹, Congly SE², Rose MS³, Lee SS², Borman MA², Charlton CL⁴, Osiowy C⁵, Swain MG², Burak KW², Coffin CS⁶. Ann Hepatol. 2018 Mar 1;17(2):232-241. doi: 10.5604/01.3001.0010.8640.

150.	Epidemiology and Treatment of Hepatitis B in Prisoners
	Smith JM¹, Uvin AZ¹,², Macmadu A³,⁴, Rich JD¹,³,⁵. Curr Hepatol Rep. 2017 Sep;16(3):178-183. doi: 10.1007/s11901-017-0364-8. Epub 2017 Aug 7.

151.	Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review
	Kinner SA¹, Snow K², Wirtz AL³, Altice FL⁴, Beyrer C³, Dolan K⁵. J Adolesc Health. 2018 Mar;62(3S):S18-S26. doi: 10.1016/j.jadohealth.2017.09.030.

152.	Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
	Hsu CW¹, Su WW², Lee CM³, Peng CY⁴, Chuang WL⁵, Kao JH⁶, Chu HC⁷, Huang YH⁸, Chien RN⁹, Liaw YF¹⁰. J Formos Med Assoc. 2018 Feb 15. pii: S0929-6646(17)30716-7. doi: 10.1016/j.jfma.2017.12.007. [Epub ahead of print]

153.	Improving a process to obtain hepatitis B serology among patients treated with infliximab at a large urban children's hospital
	Jean MR¹, Weaver A¹, Mastin-Diebold T¹, Kissinger K¹, Smitherman EA², Favier L², Danziger-Isakov L³, Williams E¹, Brady RC³, Huggins J², Denson LA¹, Saeed SA¹, Morgan P¹, Dykes DMH¹. BMJ Open Qual. 2017 Oct 18;6(2):e000092. doi: 10.1136/bmjoq-2017-000092. eCollection 2017.

154.	Role of HBx in hepatitis B virus persistence and its therapeutic implications
	Slagle BL¹, Bouchard MJ². Curr Opin Virol. 2018 Feb 15;30:32-38. doi: 10.1016/j.coviro.2018.01.007. [Epub ahead of print]

155.

8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

Papatheodoridis GV¹, Sypsa V², Dalekos G³, Yurdaydin C⁴, Van Boemmel F⁵, Buti M⁶, Goulis J⁷, Luis Calleja J⁸, Chi H⁹, Manolakopoulos S¹⁰, Loglio A¹¹, Siakavellas S¹², Gatselis N³, Kesk?n O⁴, Lehretz M⁵, Savvidou S⁷, de la Revilla J⁸, Hansen BE⁹, Kourikou A¹⁰, Vlachogiannakos I¹², Galanis K³, Idilman R⁴, Colombo M¹³, Esteban R⁶, Janssen HLA¹⁴, Berg T⁵, Lampertico P¹¹. J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30081-3. doi: 10.1016/j.jhep.2018.01.031. [Epub ahead of print]

156.	Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B
	Buti M¹,², Riveiro-Barciela M¹,², Esteban R¹,². Liver Int. 2018 Feb;38 Suppl 1:84-89. doi: 10.1111/liv.13641.

157.	Treatment of hepatitis B: Is there still a role for interferon?
	Viganò M¹, Grossi G², Loglio A², Lampertico P². Liver Int. 2018 Feb;38 Suppl 1:79-83. doi: 10.1111/liv.13635.

158.	Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
	Wong GL¹,²,³. Clin Mol Hepatol. 2018 Jan 22. doi: 10.3350/cmh.2017.0068. [Epub ahead of print]

159.	Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis
	Rinaldi L¹, Ascione A², Messina V³, Rosato V⁴, Valente G⁵, Sangiovanni V⁶, Zampino R⁴, Marrone A⁴, Fontanella L⁴, de Rosa N⁷, Orabona P⁸, Buonomo C⁸, Chirianni A⁶, Adinolfi LE⁴, Piai G⁵. Infection. 2018 Jan 15. doi: 10.1007/s15010-017-1113-1. [Epub ahead of print]

160.	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure
	Gill US¹, Pallett LJ², Kennedy PTF¹, Maini MK². Gut. 2018 Jan 13. pii: gutjnl-2017-314873. doi: 10.1136/gutjnl-2017-314873. [Epub ahead of print]

161.	Factors associated with non-adherence to HBV antiviral therapy
	Sheppard-Law S¹,²,³, Zablotska-Manos I³, Kermeen M⁴, Holdaway S⁵, Lee A⁴, George J⁵,⁶, Zekry A⁷,⁸, Maher L³. Antivir Ther. 2017 Jan 22. doi: 10.3851/IMP3219. [Epub ahead of print]

162.	Using Population Based Hospitalization Data to Monitor Increases in Conditions Causing Morbidity Among Persons Who Inject Drugs
	Collier MG1, Doshani M2, Asher A2. J Community Health. 2018 Jan 5. doi: 10.1007/s10900-017-0458-9. [Epub ahead of print]

163.	Brief report: Prevalence of hepatitis B and C virus infections in U.S. Air Force basic military trainees who donated blood, 2013-2016
	Taylor DF, Cho RS, Okulicz JF, Webber BJ, Gancayco JG. MSMR. 2017 Dec;24(12):20-22.

164.	Influence of birth origin and risk factor profile on hepatitis B mortality: Philadelphia, PA 2003-2013
	Higgins DC1, Kuncio DE2, Johnson CC2, Viner KM2. Ann Epidemiol. 2017 Dec 22. pii: S1047-2797(17)30891-8. doi: 10.1016/j.annepidem.2017.12.006. [Epub ahead of print]

165.	Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012
	Weiser J1, Perez A1, Bradley H1, King H1, Shouse RL1. Ann Intern Med. 2017 Dec 26. doi: 10.7326/M17-1689. [Epub ahead of print]

166.	Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis Bvaccine in adults
	Jackson S1, Lentino J2, Kopp J3, Murray L4, Ellison W5, Rhee M6, Shockey G7, Akella L8, Erby K9, Heyward WL10, Janssen RS11; HBV-23 Study Group. Vaccine. 2017 Dec 27. pii: S0264-410X(17)31791-7. doi: 10.1016/j.vaccine.2017.12.038. [Epub ahead of print]

167.

Impact of Enhanced Health Interventions for United States-Bound Refugees: Evaluating Best Practices in Migration Health

Mitchell T1, Lee D1, Weinberg M1, Phares C1, James N2, Amornpaisarnloet K2, Aumpipat L2, Cooley G3, Davies A2, Tin Shwe VD2, Gajdadziev V2, Gorbacheva O2, Khwan-Niam C2, Klosovsky A4, Madilokkowit W2, Martin D3, Htun Myint NZ2, Yen Nguyen TN2, Nutman TB5, O'Connell EM5, Ortega L1, Prayadsab S2, Srimanee C2, Supakunatom W2, Vesessmith V2, Stauffer WM6,1. Am J Trop Med Hyg. 2017 Dec 18. doi: 10.4269/ajtmh.17-0725. [Epub ahead of print]

168.	Association between virus exposure and depression in US adults
	Gale SD1, Berrett AN2, Erickson LD3, Brown BL2, Hedges DW4. Psychiatry Res. 2017 Dec 20;261:73-79. doi: 10.1016/j.psychres.2017.12.037. [Epub ahead of print]

169.	Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
	Alonso S1, Guerra AR1, Carreira L1, Ferrer JÁ1, Gutiérrez ML1, Fernandez-Rodriguez CM2. BMC Gastroenterol. 2017 Dec 21;17(1):168. doi: 10.1186/s12876-017-0726-2.

170.	Management of Hepatitis B Infection in Pregnancy
	Bartholomew ML1, Lee MJ. Clin Obstet Gynecol. 2017 Dec 15. doi: 10.1097/GRF.0000000000000331. [Epub ahead of print]

171.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop

Block TM1, Alter H2, Brown N3, Brownstein A4, Brosgart C5, Chang KM6, Chen PJ7, Cohen C3, El-Serag H8, Feld J9, Gish R10, Glenn J11, Greten TF12, Guo JT4, Hoshida Y13, Kowdley KV14, Li W15, Lok AS16, McMahon B17, Mehta A18, Perrillo R19, Rice CM20, Rinaudo J12, Schinazi RF21, Shetty K22.Author informationAntiviral Res. 2017 Dec 14;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. [Epub ahead of print]

172.	A Pilot Program Integrating Hepatitis B Virus (HBV) Screening into an Outpatient Endoscopy Unit Improves HBV Screening Among an Ethnically Diverse Safety-Net Hospital
	Campbell B1, Lopez A2, Liu B3, Bhuket T3, Wong RJ4. Dig Dis Sci. 2017 Dec 5. doi: 10.1007/s10620-017-4870-x. [Epub ahead of print]

173.	Unmet Needs in Clinical and Basic Hepatitis B Virus Research
	Su TH1,2, Kao JH1,2,3,4. J Infect Dis. 2017 Nov 16;216(suppl_8):S750-S756. doi: 10.1093/infdis/jix382.

174.	Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network
	Kwak YE1, Stein SM2, Lim JK3. Dig Dis Sci. 2017 Nov 24. doi: 10.1007/s10620-017-4850-1. [Epub ahead of print]

175.	Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016
	Moro PL1, Zheteyeva Y2, Barash F3, Lewis P4, Cano M4. Vaccine. 2017 Nov 23. pii: S0264-410X(17)31603-1. doi: 10.1016/j.vaccine.2017.11.039. [Epub ahead of print]

176.	Antiviral Drugs in Newborn and Children
	Poole CL1, Kimberlin DW2. Pediatr Clin North Am. 2017 Dec;64(6):1403-1415. doi: 10.1016/j.pcl.2017.08.014.

177.	Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES
	Butt AA1,2,3, Yan P1, Shaikh OS1,4, Abou-Samra AB2. Aliment Pharmacol Ther. 2017 Nov 27. doi: 10.1111/apt.14426. [Epub ahead of print]

178.	The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing
	Tucker JD1,2,3, Meyers K4,5, Best J4,6,7, Kaplan K7, Pendse R8, Fenton KA4,9, Andrieux-Meyer I10, Figueroa C11, Goicochea P12, Gore C13,14, Ishizaki A14, Khwairakpam G15, Miller V12, Mozalevskis A16, Ninburg M17, Ocama P18, Peeling R19, Walsh N20, Colombo MG21,22, Easterbrook P11. BMC Infect Dis. 2017 Nov 1;17(Suppl 1):701. doi: 10.1186/s12879-017-2771-4.

179.	Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis
	Amini A1, Varsaneux O1, Kelly H1, Tang W2,3, Chen W4, Boeras DI1, Falconer J1, Tucker JD2,3, Chou R5, Ishizaki A6, Easterbrook P6, Peeling RW7. BMC Infect Dis. 2017 Nov 1;17(Suppl 1):698. doi: 10.1186/s12879-017-2772-3.

180.	Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses
	Lange B1,2, Cohn J3, Roberts T4, Camp J5, Chauffour J6, Gummadi N7, Ishizaki A8, Nagarathnam A9, Tuaillon E10,11, van de Perre P10,11, Pichler C12, Easterbrook P8, Denkinger CM4. BMC Infect Dis. 2017 Nov 1;17(Suppl 1):700. doi: 10.1186/s12879-017-2777-y.

181.	Vaccinations in Older Adults
	Burke M1, Rowe T2. Clin Geriatr Med. 2018 Feb;34(1):131-143. doi: 10.1016/j.cger.2017.08.006. Epub 2017 Oct 14.

182.	Hepatitis B and liver transplantation
	Ferrarese A1, Zanetto A1, Russo FP2. Minerva Gastroenterol Dietol. 2017 Nov 10. doi: 10.23736/S1121-421X.17.02453-9. [Epub ahead of print]

183.	Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B
	Janssen HLA1, Brunetto MR2, Kim YJ3, Ferrari C4, Massetto B5, Nguyen AH5, Joshi A5, Woo J5, Lau AH5, Gaggar A5, Subramanian GM5, Yoshida EM6, Ahn SH7, Tsai NCS8, Fung S9, Gane EJ10. J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408-X. doi: 10.1016/j.jhep.2017.10.027. [Epub ahead of print]

184.	Immunotherapy for Hepatitis B in the Direct Acting Anti-viral Era: Reevaluating the Thymosin ?1 Efficacy Trials in Light of a Combination Therapy Approach
	Naylor PH1, Mutchnick MG1. J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12807. [Epub ahead of print]

185.	Assessment of Adherence to Baseline Quality Measures for Cirrhosis and the Impact of Performance Feedback in a Regional VA Medical Center
	Cahill JA1, Rizvi S1, Saeian K1. Am J Med Qual. 2017 Oct 1:1062860617736805. doi: 10.1177/1062860617736805. [Epub ahead of print]

186.	Viral factors for HBV mother-to-child transmission
	Park JS1, Pan CQ2. Hepatol Int. 2017 Oct 12. doi: 10.1007/s12072-017-9825-y. [Epub ahead of print]

187.	Social Determinants of Health Associated with HBV Testing and Access to Care among Foreign-born Persons Residing in the United States: 2009 - 2012
	Greene KM1, Duffus WA1, Xing J1, King H1. J Health Dispar Res Pract. 2017 Spring;10(2):1-20.

188.

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015

Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T1, Abera S2,3, Ahmed M4, Alam N5,6, Alemayohu MA7, Allen C8, Al-Raddadi R9, Alvis-Guzman N10, Amoako Y11, Artaman A12, Ayele TA13, Barac A14, Bensenor I15, Berhane A16, Bhutta Z17,18, Castillo-Rivas J19, Chitheer A20, Choi JY21, Cowie B22, Dandona L8,23, Dandona R8,23, Dey S24, Dicker D8, Phuc H25, Ekwueme DU26, Zaki MES27, Fischer F28, Fürst T29,30,31, Hancock J8, Hay SI8, Hotez P32,33, Jee SH34, Kasaeian A35, Khader Y36, Khang YH37, Kumar GA38, Kutz M8, Larson H39, Lopez A8,40, Lunevicius R41,42, Malekzadeh R43, McAlinden C44, Meier T45, Mendoza W46, Mokdad A8, Moradi-Lakeh M47,48, Nagel G49, Nguyen Q25, Nguyen G8, Ogbo F50,51, Patton G52, Pereira DM53, Pourmalek F54, Qorbani M55, Radfar A56, Roshandel G57, Salomon JA58, Sanabria J59,60, Sartorius B61, Satpathy M62,63, Sawhney M64, Sepanlou S43, Shackelford K8, Shore H65, Sun J66, Mengistu DT67, Topór-Madry R68,69, Tran B70,71, Ukwaja KN72, Vlassov V73, Vollset SE74,75, Vos T8, Wakayo T76, Weiderpass E77,78,79, Werdecker A80, Yonemoto N81, Younis M82,83, Yu C84, Zaidi Z85,86, Zhu L87, Murray CJL8, Naghavi M8, Fitzmaurice C8,88. JAMA Oncol. 2017 Oct 5. doi: 10.1001/jamaoncol.2017.3055. [Epub ahead of print]

189.	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B
	Seto WK1, Hui RW2, Mak LY2, Fung J3, Cheung KS2, Liu KS2, Wong DK3, Lai CL3, Yuen MF4. Clin Gastroenterol Hepatol. 2017 Sep 29. pii: S1542-3565(17)31186-2. doi: 10.1016/j.cgh.2017.09.044. [Epub ahead of print]

190.	Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection
	Pockros PJ1. Gastroenterol Hepatol (N Y). 2017 Sep;13(9):536-540.

191.	Emerging Trends in Epidemiology of Hepatitis B Virus Infection
	Stasi C1,2, Silvestri C1, Voller F1. J Clin Transl Hepatol. 2017 Sep 28;5(3):272-276. doi: 10.14218/JCTH.2017.00010. Epub 2017 May 30.

192.	Incidence, determinants and outcomes of pregnancy-associated hepatitis Bflares: A regional hospital-based cohort study
	Kushner T1,2,3, Shaw PA3, Kalra A4, Magaldi L5, Monpara P5, Bedi G6, Krok K6, Centkowski S2, Dalldorf K2, D'souza J2, Halegoua-De Marzio D4, Goldberg DS2,3, Trooskin S5, Levine LD7, Srinivas SK7, Lewis JD2,3, Forde KA2,3, Lo Re V 3rd3,8. Liver Int. 2017 Sep 20. doi: 10.1111/liv.13594. [Epub ahead of print]

193.	Hepatitis B, hepatitis C and mortality among HIV-positive individuals
	Thornton AC, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, Main J, Nelson M, Rodger A, Taylor C, Youssef E, Leen C, Gompels M, Kegg S, Schwenk A, Sabin C; UK Collaborative HIV cohort (UK CHIC) steering committee. AIDS. 2017 Sep 18. doi: 10.1097/QAD.0000000000001646. [Epub ahead of print]

194.	Update From the Advisory Committee on Immunization Practices
	O'Leary ST1, Maldonado YA2, Byington CL3. J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):215-218. doi: 10.1093/jpids/pix040.

195.	Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth
	COMMITTEE ON INFECTIOUS DISEASES; COMMITTEE ON FETUS AND NEWBORN.

196.	Perinatal transmission in infants of mothers with chronic hepatitis B in California
	Burgis JC1, Kong D1, Salibay C1, Zipprich J1, Harriman K1, So S1. World J Gastroenterol. 2017 Jul 21;23(27):4942-4949. doi: 10.3748/wjg.v23.i27.4942.

197.	Predictors of positive test results in patients with cancer undergoing hepatitis Bscreening before chemotherapy
	Lok AS1, Cantor SB2, Fisch M2, Barbo AG2, Lin HY2, Suarez-Almazor ME2. J Clin Oncol. 2014 Oct 20;32(30_suppl):143. doi: 10.1200/jco.2014.32.30_suppl.143.

198.	Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure
	Richardson CT1, Hayden MS2, Gilmore ES3, Poligone B4,5. Am J Clin Dermatol. 2017 Aug 11. doi: 10.1007/s40257-017-0312-y. [Epub ahead of print]

199.	Pregnancy outcome in more than 5000 births to women with viral hepatitis: a population-based cohort study in Sweden
	Stokkeland K1,2, Ludvigsson JF3,4,5, Hultcrantz R6,7, Ekbom A8, Höijer J9, Bottai M9, Stephansson O8,10. Eur J Epidemiol. 2017 May 26. doi: 10.1007/s10654-017-0261-z. [Epub ahead of print]

200.	Treatment of chronic hepatitis B infection-2017
	Chen GF1,2, Wang C1,3,4, Lau G1,3,5. Liver Int. 2017 Jan;37 Suppl 1:59-66. doi: 10.1111/liv.13309.

201.	Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience
	Lovett GC1, Nguyen T1, Iser DM1, Holmes JA1, Chen R1, Demediuk B1, Shaw G1, Bell SJ1, Desmond PV1, Thompson AJ1. World J Hepatol. 2017 Jan 8;9(1):48-56. doi: 10.4254/wjh.v9.i1.48.

202.	Occupational Health Update: Focus on Preventing the Acquisition of Infections with Pre-exposure Prophylaxis and Postexposure Prophylaxis
	Weber DJ1, Rutala WA2. Infect Dis Clin North Am. 2016 Sep;30(3):729-57. doi: 10.1016/j.idc.2016.04.008.

203.	Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings
	Spradling PR1, Xing J1, Rupp LB1, Moorman AC1, Gordon SC1, Teshale ET1, Lu M1, Boscarino JA1, Trinacty CM1, Schmidt MA1, Holmberg SD1; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2016 Aug 2. pii: ciw516. [Epub ahead of print]

204.	Factors associated with poor adherence to antiviral treatment for hepatitis B
	Allard N1,2, Dev A2,3,4, Dwyer J5, Srivatsa G6, Thompson A2,7, Cowie B1,2. J Viral Hepat. 2016 Aug 9. doi: 10.1111/jvh.12582. [Epub ahead of print]

205.	Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
	Pan CQ1, Duan Z1, Dai E1, Zhang S1, Han G1, Wang Y1, Zhang H1, Zou H1, Zhu B1, Zhao W1, Jiang H1; China Study Group for the Mother-to-Child Transmission of Hepatitis B. N Engl J Med. 2016 Jun 16;374(24):2324-34. doi: 10.1056/NEJMoa1508660.

206.	Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors
	Villa JA1, Pike DP1, Patel KB1, Lomonosova E1, Lu G2, Abdulqader R1, Tavis JE3. Antiviral Res. 2016 Jun 17;132:186-195. doi: 10.1016/j.antiviral.2016.06.005. [Epub ahead of print]

207.	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study
	Ahn J1, Lim JK2, Lee HM3, Lok AS4, Nguyen M5, Pan CQ6, Mannalithara A5, Te H7, Reddy KR8, Trinh H9, Chu D10, Tran T11, Lau D12, Leduc TS13, Min A14, Trong Le L15, Bae H16, Van Tran S17, Do S18, Hann HL19, Wong C20, Han S21, Pillai A22, Park JS23, Tong M22, Scaglione S24, Woog J25, Kim WR5. Am J Gastroenterol. 2016 Jun 21. doi: 10.1038/ajg.2016.257. [Epub ahead of print]

208.	Noninvasive Tests for Fibrosis Predict 5-Year Mortality and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
	Kim JH1, Kim JW, Seo JW, Choe WH, Kwon SY. J Clin Gastroenterol. 2016 Jun 17. [Epub ahead of print]

209.	International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen
	Wilkinson DE1, Seiz PL2, Schüttler CG2, Gerlich WH2, Glebe D2, Scheiblauer H3, Nick S3, Chudy M3, Dougall T4, Stone L5, Heath AB4; Collaborative Study Group. J Clin Virol. 2016 Jun 6. pii: S1386-6532(16)30135-4. doi: 10.1016/j.jcv.2016.06.003. [Epub ahead of print]

210.	Transmission of blood-borne pathogens in US dental health care settings: 2016 Update
	Cleveland JL, Gray SK, Harte JA, Robison VA, Moorman AC, Gooch BF. J Am Dent Assoc. 2016 May 24. pii: S0002-8177(16)30307-5. doi: 10.1016/j.adaj.2016.03.020. [Epub ahead of print]

211.	Overview of hepatitis B viral replication and genetic variability
	Tong S1, Revill P2. J Hepatol. 2016 Apr;64(1 Suppl):S4-S16. doi: 10.1016/j.jhep.2016.01.027.

212.	Gastroenterologists Have Suboptimal Hepatitis B Virus Screening Rates in Patients Receiving Immunosuppressive Therapy
	Paul S1, Shuja A2, Tam I3, Kim EM3, Kang S4, Kapulsky L4, Viveiros K3, Lee H5. Dig Dis Sci. 2016 Mar 18. [Epub ahead of print]

213.	Are current screening protocols for chronic hepatitis B virus infection adequate?
	Mortensen E1, Kamali A1, Schirmer PL2, Lucero-Obusan C2, Winston CA3, Oda G2, Winters MA1, Durfee J2, Martinello RA4, Davey VJ2, Holodniy M5. Diagn Microbiol Infect Dis. 2015 Dec 17. pii: S0732-8893(15)00442-3. doi: 10.1016/j.diagmicrobio.2015.12.005. [Epub ahead of print]

214.	Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus
	Beck IA1, Payant R1, Ngo-Giang-Huong N2, Khamduang W3, Laomanit L4, Jourdain G2, Frenkel LM5. J Virol Methods. 2016 Mar 26. pii: S0166-0934(16)30049-0. doi: 10.1016/j.jviromet.2016.03.014. [Epub ahead of print]

215.	Hepatitis B virus and hepatitis C virus infection in healthcare workers
	Coppola N1, De Pascalis S1, Onorato L1, Calò F1, Sagnelli C1, Sagnelli E1. World J Hepatol. 2016 Feb 18;8(5):273-81. doi: 10.4254/wjh.v8.i5.273.

216.	Progress with Developing Use of Gene Editing to Cure Chronic Infection with Hepatitis B Virus
	Ely A, Moyo B, Arbuthnot P. Mol Ther. 2016 Feb 26. doi: 10.1038/mt.2016.43. [Epub ahead of print]

217.	Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014
	Williams WW1, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, Rodriguez-Lainz A, Bridges CB. MMWR Surveill Summ. 2016 Feb 5;65(1):1-36. doi: 10.15585/mmwr.ss6501a1.

218.	Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
	Marcellin P1, Zoulim F2, Hézode C3, Causse X4, Roche B5, Truchi R6, Pauwels A7, Ouzan D8, Dumortier J9, Pageaux GP10, Bourlière M11, Riachi G12, Zarski JP13, Cadranel JF14, Tilliet V15, Stern C15, Pétour P16, Libert O15, Consoli SM17, Larrey D18. Dig Dis Sci. 2016 Jan 28. [Epub ahead of print]

219.	Insomnia in Adults With Chronic Hepatitis B, Liver Failure, and Cirrhosis: A Case-
	Guo HM1, Liu M1, Xiang YT2, Zhao J1, Ungvari GS3, Correll CU4, Ng CH5, Chiu HF6, Duan ZP1. Perspect Psychiatr Care. 2015 Dec 3. doi: 10.1111/ppc.12138. [Epub ahead of print]

220.	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis
	Jonas MM1, Lok AS2, McMahon BJ3, Brown RS Jr4, Wong JB5, Ahmed AT6,7, Farah W6,7, Mouchli MA8, Singh S9, Prokop LJ10, Murad MH6,7,11, Mohammed K6,7,11. Hepatology. 2015 Nov 13. doi: 10.1002/hep.28278. [Epub ahead of print]

221.	Role of occult hepatitis B virus infection in chronic hepatitis C
	Coppola N1, Onorato L1, Pisaturo M1, Macera M1, Sagnelli C1, Martini S1, Sagnelli E1. World J Gastroenterol. 2015 Nov 14;21(42):11931-40. doi: 10.3748/wjg.v21.i42.11931.

222.	Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis
	Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Ann Intern Med. 2015 Nov 24. doi: 10.7326/M15-1121. [Epub ahead of print]

223.	Hepatitis delta virus: Making the point from virus isolation up to 2014
	Romeo R1, Perbellini R1. World J Hepatol. 2015 Oct 8;7(22):2389-95. doi: 10.4254/wjh.v7.i22.2389.

224.	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study
	Ahn J1, Lee HM2, Lim JK3, Pan CQ4, Nguyen MH5, Ray Kim W5, Mannalithara A5, Trinh H6, Chu D7, Tran T8, Min A9, Do S10, Te H11, Reddy KR12, Lok AS13. Aliment Pharmacol Ther. 2015 Oct 28. doi: 10.1111/apt.13440. [Epub ahead of print]

225.	Diagnosing and treating hepatic encephalopathy
	Tiberi O1, Tognarelli JM2, Cook NA3, Crossey MM4, Dhanjal NS5, Taylor-Robinson SD6. Br J Hosp Med (Lond). 2015 Nov 2;76(11):646-54. doi: 10.12968/hmed.2015.76.11.646.

226.	Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk
	Huang YT1, Yang HI, Liu J, Lee MH, Freeman JR, Chen CJ. Epidemiology. 2015 Oct 6. [Epub ahead of print]

227.	Society for Maternal-Fetal Medicine (SMFM) Consult Series #38: Hepatitis B in Pregnancy- Screening, Treatment and Prevention of Vertical Transmission
	Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dionne-Odom J, Tita AT, Silverman NS. Am J Obstet Gynecol. 2015 Oct 7. pii: S0002-9378(15)01214-4. doi: 10.1016/j.ajog.2015.09.100. [Epub ahead of print]

228.

Combination of Tenofovir Disoproxil Fumarate and Peginterferon alfa-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B

Marcellin P1, Ahn SH2, Ma X3, Caruntu FA4, Tak WY5, Elkashab M6, Chuang WL7, Lim SG8, Tabak F9, Mehta R10, Petersen J11, Foster GR12, Lou L13, Martins EB14, Dinh P14, Lin L14, Corsa A14, Charuworn P14, Subramanian GM14, Reiser H14, Reesink HW15, Fung S16, Strasser SI17, Trinh H18, Buti M19, Gaeta GB20, Hui AJ21, Papatheodoridis G22, Flisiak R23, Chan HL24; study 149 investigators. Gastroenterology. 2015 Oct 7. pii: S0016-5085(15)01429-8. doi: 10.1053/j.gastro.2015.09.043. [Epub ahead of print]

229.	Invited Commentary: Screening for hepatitis B in the immigrant population and individuals who are in need of immunosuppressive drug therapy
	Perrillo R1. Proc (Bayl Univ Med Cent). 2015 Oct;28(4):443-4.

230.	Determinants of Outcome Among Patients with Acute Liver Failure Listed for Liver Transplantation in the US
	Reddy KR1, Ellerbe C2, Schilsky M3, Stravitz RT4, Fontana RJ5, Durkalski V2, Lee WM6; Acute Liver Failure Study Group. Liver Transpl. 2015 Sep 30. doi: 10.1002/lt.24347. [Epub ahead of print]

231.	A systematic review and meta-analysis of management options for adults who respond poorly to hepatitis B vaccination
	David MC1, Ha SH2, Paynter S3, Lau C4. Vaccine. 2015 Sep 27. pii: S0264-410X(15)01327-4. doi: 10.1016/j.vaccine.2015.09.051. [Epub ahead of print]

232.	Estimated Annual Perinatal Hepatitis B Virus Infections in the United States, 2000-2009
	Ko SC1, Fan L2, Smith EA3, Fenlon N4, Koneru AK2, Murphy TV2. J Pediatric Infect Dis Soc. 2014 Dec 18. pii: piu115. [Epub ahead of print]

233.	Screening for hepatitis B in patients with lymphoma
	Ramirez J1, Duddempudi AT1, Sana MM1, Hasan SS1, de Los Santos M1, Song J1, Fang-Hollingsworth Y1, Gupta SS1, Sears DM1. Proc (Bayl Univ Med Cent). 2015 Oct;28(4):438-42.

234.	Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development
	Clark DN1, Hu J2. Antiviral Res. 2015 Sep 23. pii: S0166-3542(15)00222-3. doi: 10.1016/j.antiviral.2015.09.011. [Epub ahead of print]

235.	Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease
	Mikolajczyk AE1, Aronsohn AI2. Adv Chronic Kidney Dis. 2015 Sep;22(5):352-60. doi: 10.1053/j.ackd.2015.06.008.

236.	Glomerular Diseases Associated With Hepatitis B and C
	Gupta A1, Quigg RJ2. Adv Chronic Kidney Dis. 2015 Sep;22(5):343-51. doi: 10.1053/j.ackd.2015.06.003.

237.	Feasibility, acceptability and safety of a nurse led hepatitis B clinic based in the community
	Pritchard-Jones J, Stevens C, McCaughan G, Strasser S. Collegian. 2015;22(2):233-40.

238.	Hepatocellular Carcinoma in the Setting of Chronic Hepatitis B Virus Infection: Tumor Recurrence and Survival Rates After Liver Transplantation
	Dugum M1, Hanouneh I2, Lopez R3, Aucejo F4, Eghtesad B4, Zein N2. Transplant Proc. 2015 Jul-Aug;47(6):1939-44. doi: 10.1016/j.transproceed.2015.02.021.

239.	Hepatitis B: Working Towards a Cure
	Chang BW1, Kaung A, Robbins L, Tran TT. Curr Gastroenterol Rep. 2015 Sep;17(9):460. doi: 10.1007/s11894-015-0460-2.

240.	Present and future therapies of hepatitis B: From discovery to cure
	Liang TJ1, Block TM2, McMahon BJ3, Ghany MG1, Urban S4, Guo JT2, Locarnini S5, Zoulim F6, Chang KM7, Lok AS8. Hepatology. 2015 Aug 3. doi: 10.1002/hep.28025. [Epub ahead of print]

241.	Randomized Controlled Trial of Entecavir Versus Placebo in Children with HBeAg-positive Chronic Hepatitis B
	Jonas MM1, Chang MH2, Sokal E3, Schwarz KB4, Kelly D5, Mo Kim K6, Ling SC7, Rosenthal P8, Oraseanu D9, Reynolds L10, Thiry A10, Ackerman P10. Hepatology. 2015 Jul 29. doi: 10.1002/hep.28015. [Epub ahead of print]

242.	Comparison of Accelerated and Standard Hepatitis B Vaccination Schedules in High-Risk Healthy Adults: A Meta-Analysis of Randomized Controlled Trials
	Jin H1, Tan Z2, Zhang X2, Wang B1, Zhao Y1, Liu P1. PLoS One. 2015 Jul 21;10(7):e0133464. doi: 10.1371/journal.pone.0133464. eCollection 2015.

243.	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
	Martin P1, Lau DT2, Nguyen MH3, Janssen HL4, Dieterich DT5, Peters MG6, Jacobson IM7. Clin Gastroenterol Hepatol. 2015 Jul 15. pii: S1542-3565(15)00963-5. doi: 10.1016/j.cgh.2015.07.007. [Epub ahead of print]

244.	Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients
	Watanabe T1, Tokumoto Y, Joko K, Michitaka K, Mashiba T, Hiraoka A, Ochi H, Koizumi Y, Tada F, Hirooka M, Yoshida O, Imai Y, Abe M, Hiasa Y. Hepatol Int. 2015 Jul 22. [Epub ahead of print]

245.	Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
	Cui G1, Xu X2, Diao H1. Sci Rep. 2015 Jul 13;5:11854. doi: 10.1038/srep11854.

246.	Noninvasive Assessment of Liver Fibrosis
	Castera L1. Dig Dis. 2015;33(4):498-503. doi: 10.1159/000374097. Epub 2015 Jul 6.

247.	The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma
	Wang Q1, Blank S, Fiel MI, Kadri H, Luan W, Warren L, Zhu A, Deaderick PA, Sarpel U, Labow DM, Hiotis SP. Ann Surg Oncol. 2015 Jul 10. [Epub ahead of print]

248.	Optimal Management of Hepatitis B Virus Infection - EASL Special Conference
	Lampertico P1, Maini M2, Papatheodoridis G3. J Hepatol. 2015 Jul 3. pii: S0168-8278(15)00453-5. doi: 10.1016/j.jhep.2015.06.026. [Epub ahead of print]

249.	Hepatitis B and C virus infection and risk of lymphoid malignancies: A population-based cohort study (JPHC Study)
	Abe SK1, Inoue M2, Sawada N3, Iwasaki M3, Shimazu T3, Yamaji T3, Sasazuki S3, Tanaka Y4, Mizokami M5, Tsugane S6; JPHC Study Group. Cancer Epidemiol. 2015 Jul 3. pii: S1877-7821(15)00130-7. doi: 10.1016/j.canep.2015.06.002. [Epub ahead of print]

250.	Outcomes of Infants Born to Women Infected With Hepatitis B
	Schillie S1, Walker T2, Veselsky S3, Crowley S4, Dusek C5, Lazaroff J6, Morris SA7, Onye K8, Ko S3, Fenlon N9, Nelson NP3, Murphy TV3. Pediatrics. 2015 Apr 20. pii: peds.2014-3213. [Epub ahead of print]

251.	The Epidemiology of Acute Hepatitis B in the United States from Population-Based Surveillance, 2006-2011
	Iqbal K1, Klevens RM1, Kainer MA2, Baumgartner J3, Gerard K4, Poissant T5, Sweet K6, Vonderwahl C7, Knickerbocker T8, Khudyakov Y1, Xia GL1, Roberts H1, Teshale E1. Clin Infect Dis. 2015 Apr 22. pii: civ332. [Epub ahead of print]

252.	Chronic hepatitis B: a wave of new therapies on the horizon
	Block TM1, Rawat S2, Brosgart CL3. Antiviral Res. 2015 Jun 22. pii: S0166-3542(15)00145-X. doi: 10.1016/j.antiviral.2015.06.014. [Epub ahead of print]

253.	Cluster-Randomized Trial to Increase Hepatitis B Testing among Koreans in Los Angeles
	Bastani R1, Glenn BA2, Maxwell AE2, Jo AM3, Herrmann AK2, Crespi CM2, Wong WK2, Chang LC2, Stewart SL4, Nguyen TT5, Chen MS Jr6, Taylor VM7. Cancer Epidemiol Biomarkers Prev. 2015 Jun 23. pii: cebp.1396.2014. [Epub ahead of print]

254.	Role of T-regulatory cells in the response to hepatitis B vaccine in hemodialysis patients
	Mathew RO1,2, Mason DL1,3, Song R4, Tryniszewski T5, Kennedy JS5. Hemodial Int. 2015 Jun 23. doi: 10.1111/hdi.12326. [Epub ahead of print]

255.	A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy
	Chen WC1, Cheng JS2, Chiang PH2, Tsay FW3, Chan HH4, Chang HW5, Yu HC2, Tsai WL4, Lai KH4, Hsu PI4. PLoS One. 2015 Jun 29;10(6):e0131545. doi: 10.1371/journal.pone.0131545. eCollection 2015.

256.	Hepatitis B Reactivation During Successful Treatment of Hepatitis C with Sofosbuvir and Simeprevir
	Collins JM1, Raphael KL2, Terry C2, Cartwright EJ3, Pillai A4, Anania FA5, Farley MM6. Clin Infect Dis. 2015 Jun 16. pii: civ474. [Epub ahead of print]

257.	Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities
	Gish RG1, Given BD2, Lai CL3, Locarnini SA4, Lau JY5, Lewis DL2, Schluep T2. Antiviral Res. 2015 Jun 16. pii: S0166-3542(15)00139-4. doi: 10.1016/j.antiviral.2015.06.008. [Epub ahead of print]

258.	Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment
	Shin SK1, Kim JH2, Park H1, Kwon OS1, Lee HJ3, Yeon JE3, Byun KS3, Suh SJ4, Yim HJ4, Kim YS1, Kim JH1. J Gastroenterol Hepatol. 2015 Jun 11. doi: 10.1111/jgh.13020. [Epub ahead of print]

259.	Hepatitis B screening and prevalence among resettled refugees - United States, 2006-2011
	Scott KC, Taylor EM, Mamo B, Herr ND, Cronkright PJ, Yun K, Altshuler M, Shetty S. MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):570-3.

260.	Medical training fails to prepare providers to care for patients with chronic hepatitis B infection
	Chao SD1, Wang BM1, Chang ET1, Ma L1, So SK1. World J Gastroenterol. 2015 Jun 14;21(22):6914-23. doi: 10.3748/wjg.v21.i22.6914.

261.	Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease
	Russo FP1, Rodríguez-Castro K1, Scribano L1, Gottardo G1, Vanin V1, Farinati F1. World J Hepatol. 2015 May 18;7(8):1097-104. doi: 10.4254/wjh.v7.i8.1097.

262.	Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B
	Pan CQ1, Chan S1, Trinh H1, Yao A1, Bae H1, Lou L1. World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524.

263.	Long-term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B - a cohort study of 53,500 subjects
	Wong GL1,2,3, Tse YK1,2, Wong VW1,2,3, Fung TY4, Choi KK5, Chan HL1,2,3. Hepatology. 2015 May 14. doi: 10.1002/hep.27894. [Epub ahead of print]

264.	Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B infected subjects
	Ding WJ1, Wang MM2, Wang GS1, Fen S1, Qin JJ1, Fan JG1. J Gastroenterol Hepatol. 2015 May 14. doi: 10.1111/jgh.12998. [Epub ahead of print]

265.	Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir
	Kim BG1, Jung SW1, Kim EH1, Kim JH1, Park JH1, Sung SJ1, Park BR2, Kim MH2, Kim CJ2, Lee BU1, Park JH1, Jeong ID1, Bang SJ1, Shin JW1, Park NH1,2. J Gastroenterol Hepatol. 2015 May 14. doi: 10.1111/jgh.12993. [Epub ahead of print]

266.	Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update
	Hwang JP1, Somerfield MR1, Alston-Johnson DE1, Cryer DR1, Feld JJ1, Kramer BS1, Sabichi AL1, Wong SL1, Artz AS1. J Clin Oncol. 2015 May 11. pii: JCO.2015.61.3745. [Epub ahead of print]

267.	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia
	Chen CY1, Huang SY1, Cheng A2, Chou WC3, Yao M1, Tang JL4, Tsay W1, Sheng WH2, Tien HF1. PLoS One. 2015 May 14;10(5):e0126037. doi: 10.1371/journal.pone.0126037. eCollection 2015.

268.	Screening for human immunodeficiency virus and other sexually transmitted diseases among u.s. Women with prenatal care
	Ross CE1, Tao G, Patton M, Hoover KW. Obstet Gynecol. 2015 May;125(5):1211-6. doi: 10.1097/AOG.0000000000000756.

269.	Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure
	Pattullo V1. World J Hepatol. 2015 May 8;7(7):954-67. doi: 10.4254/wjh.v7.i7.954.

270.	Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load
	Sinn DH1, Lee J1, Goo J2, Kim K2, Gwak GY1, Paik YH1, Choi MS1, Lee JH1, Koh KC1, Yoo BC1, Paik SW1. Hepatology. 2015 May 11. doi: 10.1002/hep.27889. [Epub ahead of print]

271.	Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs
	Locarnini S1, Hatzakis A2, Chen DS3, Lok A4. J Hepatol. 2015 Apr;62(1S):S76-S86. doi: 10.1016/j.jhep.2015.01.018.

272.	Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy
	Kim LH1, Chaung KT, Ha NB, Kin KC, Vu VD, Trinh HN, Nguyen HA, Nguyen MH. Eur J Gastroenterol Hepatol. 2015 Apr 21. [Epub ahead of print]

273.	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine
	Bowden S1, Locarnini S1, Chang TT1, Chao YC1, Han KH1, Gish RG1, de Man RA1, Yu M1, Llamoso C1, Tang H1. World J Gastroenterol. 2015 Apr 21;21(15):4644-51. doi: 10.3748/wjg.v21.i15.4644.

274.	Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis
	Arroyo V1, Moreau R2, Jalan R3, Ginès P4; EASL-CLIF Consortium CANONIC Study. J Hepatol. 2015 Apr;62(1S):S131-S143. doi: 10.1016/j.jhep.2014.11.045.

275.	Outcomes of Infants Born to Women Infected With Hepatitis B
	Schillie S1, Walker T2, Veselsky S3, Crowley S4, Dusek C5, Lazaroff J6, Morris SA7, Onye K8, Ko S3, Fenlon N9, Nelson NP3, Murphy TV3. Pediatrics. 2015 Apr 20. pii: peds.2014-3213. [Epub ahead of print]

276.	The Epidemiology of Acute Hepatitis B in the United States from Population-Based Surveillance, 2006-2011
	Iqbal K1, Klevens RM1, Kainer MA2, Baumgartner J3, Gerard K4, Poissant T5, Sweet K6, Vonderwahl C7, Knickerbocker T8, Khudyakov Y1, Xia GL1, Roberts H1, Teshale E1. Clin Infect Dis. 2015 Apr 22. pii: civ332. [Epub ahead of print]

277.	Poor Recognition of Risk Factors for Hepatitis B by Physicians Prescribing Immunosuppressive Therapy: A Call for Universal Rather than Risk-Based Screening
	Visram A1, Chan KK2, McGee P3, Boro J2, Hicks LK4, Feld JJ1. PLoS One. 2015 Apr 15;10(4):e0120749. doi: 10.1371/journal.pone.0120749.

278.	Intended and unintended effects of large-scale adverse event disclosure: a controlled before-after analysis of five large-scale notifications
	Wagner TH1, Taylor T2, Cowgill E2, Asch SM3, Su P2, Bokhour B4, Durfee J5, Martinello RA6, Maguire E7, Elwy AR4. BMJ Qual Saf. 2015 May;24(5):295-302. doi: 10.1136/bmjqs-2014-003800.

279.	A retrospective study of administration of vaccination for hepatitis B among newborn infants prior to hospital discharge at a midwestern tertiary care center
	Myers HI1, Spracklen CN2, Ryckman KK3, Murray JC4. Vaccine. 2015 Mar 31. pii: S0264-410X(15)00361-8. doi: 10.1016/j.vaccine.2015.03.053. [Epub ahead of print]

280.	A Comparison of Patients With Hepatitis B- or Hepatitis C-Based Advanced-Stage Hepatocellular Carcinoma
	Carr BI1, Guerra V2, Steel JL3, Lu SN4. Semin Oncol. 2015 Apr;42(2):309-315. doi: 10.1053/j.seminoncol.2014.12.019. Epub 2015 Jan 28.

281.	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs
	Nard FD1, Todoerti M1, Grosso V1, Monti S1, Breda S1, Rossi S1, Montecucco C1, Caporali R1. World J Hepatol. 2015 Mar 27;7(3):344-61. doi: 10.4254/wjh.v7.i3.344.

282.	Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance
	Croagh CM1, Desmond PV1, Bell SJ1. World J Hepatol. 2015 Mar 27;7(3):289-303. doi: 10.4254/wjh.v7.i3.289.

283.	Personalized treatment of hepatitis B
	Lok AS1. Clin Mol Hepatol. 2015 Mar;21(1):1-6. Epub 2015 Mar 25.

284.	New insights in the management of chronic hepatitis B
	Gill US1, Kennedy PT2. Clin Med. 2015 Apr;15(2):191-6. doi: 10.7861/clinmedicine.15-2-191.

285.	Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis
	Yang Q1, Shi YU2, Yang Y2, Lou G2, Lv F1. Biomed Rep. 2015 Mar;3(2):269-275. Epub 2015 Jan 7.

286.	Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials
	Tran TT1, Gordon SC2, Fung S3, Dinh P4, Yee L4, Martins EB4, Buti M5, Marcellin P6. PLoS One. 2015 Mar 19;10(3):e0121632. doi: 10.1371/journal.pone.0121632. eCollection 2015.

287.	T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance
	Ye B1, Liu X1, Li X1, Kong H1, Tian L1, Chen Y1. Cell Death Dis. 2015 Mar 19;6:e1694. doi: 10.1038/cddis.2015.42.

288.	Recent advances in use of gene therapy to treat hepatitis B virus infection
	Bloom K1, Ely A, Arbuthnot P. Adv Exp Med Biol. 2015;848:31-49. doi: 10.1007/978-1-4939-2432-5_2.

289.	Prospective study of hepatitis B virus reactivation in patients with hematological malignancies
	Pompili M1, Basso M1, Hohaus S2, Bosco G1, Nosotti L3, D'Andrea M3, Fenu S4, Grieco A1, Laure Ann Hepatol. 2015 Mar-Apr;14(2):168-74.

290.	Sharp truth: health care workers remain at risk of bloodborne infection
	Rice BD1, Tomkins SE2, Ncube FM2. Occup Med (Lond). 2015 Feb 6. pii: kqu206. [Epub ahead of print]

291.	Prognosis in liver transplantation recipients after hepatitis B virus recurrence
	Sun LY, Zhu ZJ, Qu W, Sun XY, Rao W, Liu Y. Hepatogastroenterology. 2014 Oct;61(135):2047-51.

292.	Prospective study of hepatitis B virus reactivation in patients with hematological malignancies
	Linke R1, Ulrich F1, Bechstein WO1, Schnitzbauer AA1. Ann Hepatol. 2015 Mar-Apr;14(2):161-7.

293.	Comparison of the efficacies of entecavir 0.5 and 1.0?mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments
	Cho Y1, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ. J Med Virol. 2015 Feb 24. doi: 10.1002/jmv.24150. [Epub ahead of print]

294.	Sharp truth: health care workers remain at risk of bloodborne infection
	Rice BD1, Tomkins SE2, Ncube FM2. Occup Med (Lond). 2015 Feb 6. pii: kqu206. [Epub ahead of print]

295.	Effect of Entecavir and Tenofovir Treatment on Noninvasive Fibrosis Scores: Which One Is Better?
	Koksal AR1, Alkim H, Boga S, Ergun M, Bayram M, Ozguven BY, Alkim C. Am J Ther. 2015 Feb 2. [Epub ahead of print]

296.	Cancer risk in HBV patients with statin and metformin use: a population-based cohort study
	Chen CI1, Kuan CF, Fang YA, Liu SH, Liu JC, Wu LL, Chang CJ, Yang HC, Hwang J, Miser JS, Wu SY. Medicine (Baltimore). 2015 Feb;94(6):e462. doi: 10.1097/MD.0000000000000462.

297.	Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis
	Xia BW1, Zhang YC1, Wang J2, Ding FH2, He XD3.

298.	Acoustic radiation force impulse elastography, FibroScan®, Forns' index and their combination in the assessment of liver fibrosis in patients with chronic hepatitis B, and the impact of inflammatory activity and steatosis on these diagnostic methods
	Dong DR1, Hao MN2, Li C2, Peng Z3, Liu X4, Wang GP1, Ma AL1. Mol Med Rep. 2015 Feb 4. doi: 10.3892/mmr.2015.3299. [Epub ahead of print]

299.	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection
	Song LW1, Liu PG2, Liu CJ3, Zhang TY1, Cheng XD4, Wu HL3, Yang HC3, Hao XK4, Yuan Q5, Zhang J6, Kao JH3, Chen DS3, Chen PJ7, Xia NS8. Clin Microbiol Infect. 2014 Oct 29. pii: S1198-743X(14)00063-9. doi: 10.1016/j.cmi.2014.10.002. [Epub ahead of print]

300.	The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system
	Sun WC1, Hsu PI1, Yu HC2, Lin KH1, Tsay FW1, Wang HM1, Tsai TJ1, Chen WC1, Lai KH1, Cheng JS1. PLoS One. 2015 Feb 6;10(2):e0116978. doi: 10.1371/journal.pone.0116978. eCollection 2015.

301.	The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis
	Zhang X1, Liu L2, Zhang M1, Gao S1, Du Y1, An Y3, Chen S1. Ann Hepatol. 2015 Mar-Apr;14(2):150-60.

302.	Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure
	Zeisel MB1, Lucifora J2, Mason WS3, Sureau C4, Beck J5, Levrero M6, Kann M7, Knolle PA8, Benkirane M9, Durantel D2, Michel ML10, Autran B11, Cosset FL12, Strick-Marchand H13, Trépo C14, Kao JH15, Carrat F16, Lacombe K16, Schinazi RF17, Barré-Sinoussi F18, Delfraissy JF19, Zoulim F14. Gut. 2015 Feb 10. pii: gutjnl-2014-308943. doi: 10.1136/gutjnl-2014-308943. [Epub ahead of print]

303.	Vaccination coverage among adults, excluding influenza vaccination - United States, 2013
	Williams WW, Lu PJ, O'Halloran A, Bridges CB, Kim DK, Pilishvili T, Hales CM, Markowitz LE. MMWR Morb Mortal Wkly Rep. 2015 Feb 6;64(4):95-102.

304.	Hepatitis B virus infection status and risk of type 2 diabetes mellitus: A meta-analysis
	Zhang J1, Shen Y, Cai H, Liu YM, Qin G. Hepatol Res. 2015 Jan 19. doi: 10.1111/hepr.12481. [Epub ahead of print]

305.	Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European liver transplant registry
	Adam R1, Delvart V, Karam V, Ducerf C, Navarro F, Letoublon C, Belghiti J, Pezet D, Castaing D, Le Treut YP, Gugenheim J, Bachellier P, Pirenne J, Muiesan P; all the ELTR contributing centres, the European Liver, Intestine Transplant Association (ELITA). Am J Transplant. 2015 Feb;15(2):395-406. doi: 10.1111/ajt.13060.

306.	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
	Fan R1, Sun J1, Yuan Q2, Xie Q3, Bai X4, Ning Q5, Cheng J6, Yu Y7, Niu J8, Shi G9, Wang H10, Tan D11, Wan M12, Chen S13, Xu M14, Chen X15, Tang H16, Sheng J17, Lu F18, Jia J19, Zhuang H18, Xia N2, Hou J20; Chronic Hepatitis B Study Consortium; Chronic Hepatitis B Study Consortium. Gut. 2015 Jan 13. pii: gutjnl-2014-308546. doi: 10.1136/gutjnl-2014-308546. [Epub ahead of print]

307.	Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial
	Qu C1, Chen T2, Fan C2, Zhan Q1, Wang Y1, Lu J2, Lu LL2, Ni Z2, Huang F2, Yao H2, Zhu J2, Fan J2, Zhu Y2, Wu Z1, Liu G1, Gao W1, Zang M1, Wang D1, Dai M3, Hsia CC1, Zhang Y4, Sun Z1. PLoS Med. 2014 Dec 30;11(12):e1001774. doi: 10.1371/journal.pmed.1001774. eCollection 2014.

308.	Antiviral Treatment among Pregnant Women with Chronic Hepatitis B
	Fan L1, Owusu-Edusei K Jr1, Schillie SF1, Murphy TV1. Infect Dis Obstet Gynecol. 2014;2014:546165. doi: 10.1155/2014/546165. Epub 2014 Dec 7.

309.	Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease
	Kennedy EM1, Bassit LC2, Mueller H3, Kornepati AV1, Bogerd HP1, Nie T2, Chatterjee P2, Javanbakht H3, Schinazi RF4, Cullen BR5. Virology. 2014 Dec 29;476C:196-205. doi: 10.1016/j.virol.2014.12.001. [Epub ahead of print]

310.	Natural history of chronic hepatitis B virus infection
	Busch K1, Thimme R. Med Microbiol Immunol. 2014 Dec 25. [Epub ahead of print]

311.	Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice
	Mo Y, Liang A, Ma J, Chen L, Zheng D, Schumacher HR, Dai L. BMC Musculoskelet Disord. 2014 Dec 22;15(1):449. [Epub ahead of print]

312.	Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients with E Antigen-positive Chronic Hepatitis B
	Marcellin P1, Martinot-Peignoux M2, Asselah T2, Batrla R3, Messinger D4, Rothe V4, Lau G5, Liaw Y6. Clin Gastroenterol Hepatol. 2014 Dec 23. pii: S1542-3565(14)01829-1. doi: 10.1016/j.cgh.2014.12.017. [Epub ahead of print]

313.	Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
	Viganò M1, Invernizzi F, Lampertico P. Liver Int. 2015 Jan;35 Suppl 1:107-13. doi: 10.1111/liv.12717.

314.	Early to Phase II drugs currently under investigation for the treatment of liver fibrosis
	Hauff P1, Gottwald U, Ocker M. Expert Opin Investig Drugs. 2014 Dec 30:1-19. [Epub ahead of print]

315.	Recent FDA warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just the tip of the iceberg?
	Di Bisceglie AM1, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Hepatology. 2014 Nov 21. doi: 10.1002/hep.27609. [Epub ahead of print]

316.	Incidence of Hepatocellular Carcinoma after HBsAg Seroclearance in Chronic Hepatitis B Patients: a Need for Surveillance
	Kim GA1, Lee HC2, Kim MJ3, Ha Y1, Park EJ1, An J1, Lee D1, Shim JH1, Kim KM1, Lim YS1. J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00880-0. doi: 10.1016/j.jhep.2014.11.031. [Epub ahead of print]

317.	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
	Wong GL1, Wong VW, Chan HL. J Viral Hepat. 2014 Dec;21(12):825-34. doi: 10.1111/jvh.12341.

318.	Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach
	Bertacchi D1, Zucca F2, Foresti S3, Mangioni D3, Gori A3. Math Med Biol. 2014 Nov 13. pii: dqu022. [Epub ahead of print]

319.	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
	Wong GL1, Wong VW, Chan HL. J Viral Hepat. 2014 Dec;21(12):825-34. doi: 10.1111/jvh.12341.

320.	Non-invasive assessment of liver fibrosis in chronic hepatitis B
	Branchi F, Conti CB, Baccarin A, Lampertico P, Conte D, Fraquelli M. World J Gastroenterol. 2014 Oct 28;20(40):14568-14580.

321.	Hepatitis A and B immunity and vaccination in chronic hepatitis B and C patients in a large United States cohort
	Henkle E, Lu M, Rupp LB, Boscarino JA, Vijayadeva V, Schmidt MA, Gordon SC; for the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2014 Nov 3. pii: ciu879. [Epub ahead of print]

322.	Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy
	Tada T1, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabtake S, Ito T. J Gastroenterol. 2014 Nov 7. [Epub ahead of print]

323.	Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort
	Sinn DH1, Gwak GY1, Cho J2, Paik SW1, Yoo BC1. PLoS One. 2014 Nov 5;9(11):e112184. doi: 10.1371/journal.pone.0112184. eCollection 2014.

324.	Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013
	Kim HY, Kim W. World J Gastroenterol. 2014 Oct 28;20(40):14581-14588.

325.	Community-based hepatitis B screening: what works?
	Robotin MC1, George J2. Hepatol Int. 2014 Aug 1;8(4):478-492. eCollection 2014.

326.	Tenofovir Disoproxil Fumarate in Asian or Pacific Islander Chronic Hepatitis B Patients With High Viral Load (? 9 log10 copies/mL)
	Fung S1, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, Buti M, Marcellin P. Liver Int. 2014 Oct 2. doi: 10.1111/liv.12694. [Epub ahead of print]

327.	The global burden of liver disease: a challenge for methods and for public health
	Byass P. BMC Med. 2014 Sep 18;12:159. doi: 10.1186/s12916-014-0159-5.

328.	Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine
	Zhang L1, Gui XE2, Teter C3, Zhong H4, Pang Z5, Ding L6, Li F7, Zhou Y8, Zhang L9. Vaccine. 2014 Sep 18. pii: S0264-410X(14)01242-0. doi: 10.1016/j.vaccine.2014.08.078. [Epub ahead of print]

329.	Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients
	Hsiang JC1, Gane EJ, Bai WW, Gerred SJ. J Gastroenterol Hepatol. 2014 Sep 22. doi: 10.1111/jgh.12790. [Epub ahead of print]

330.	Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women
	Lu LL1, Chen BX2, Wang J3, Wang D4, Ji Y4, Yi HG4, Chen T4, Zhang Y5, Petersen E6, Li Q7, Qu C8. Int J Infect Dis. 2014 Sep 19. pii: S1201-9712(14)01613-0. doi: 10.1016/j.ijid.2014.07.028. [Epub ahead of print]

331.	Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial
	Hou JL1, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, Chen CW, Mao Q, Zhao W, Ren H, Tan DM, Niu JQ, Chen SJ, Pan C, Tang H, Wang H, Mao YM, Jia JD, Ning Q, Xu M, Wu SM, Li J, Zhang XX, Ji Y, Dong J, Li J. J Viral Hepat. 2014 Sep 22. doi: 10.1111/jvh.12313. [Epub ahead of print]

332.	Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases
	Hwang JP1, Barbo AG, Perrillo RP. J Viral Hepat. 2014 Sep 15. doi: 10.1111/jvh.12305. [Epub ahead of print]

333.	Risk for hepatitis B and C virus transmission in nail salons and barbershops and state regulatory requirements to prevent such transmission in the United States
	Yang J1, Hall K, Nuriddin A, Woolard D. J Public Health Manag Pract. 2014 Nov-Dec;20(6):E20-30. doi: 10.1097/PHH.0000000000000042.

334.	Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
	Mokdad AA1, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M. BMC Med. 2014 Sep 18;12(1):145. [Epub ahead of print]

335.	Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy
	Wen Z1, Zhang H1, Zhang M2, Tan D3, Li Q4, Zhang H1, Wu P1, Deng L1. Hepat Mon. 2014 Aug 17;14(8):e10813. doi: 10.5812/hepatmon.10813. eCollection 2014.

336.	Hepatitis B and C in pregnancy: a review and recommendations for care
	Dunkelberg JC1, Berkley EM2, Thiel KW3, Leslie KK3. J Perinatol. 2014 Sep 18. doi: 10.1038/jp.2014.167. [Epub ahead of print]

337.	Scoring systems for predicting mortality after liver transplantation
	Pan HC1, Jenq CC2, Lee WC3, Tsai MH4, Fan PC1, Chang CH1, Chang MY2, Tian YC2, Hung CC2, Fang JT2, Yang CW2, Chen YC2. PLoS One. 2014 Sep 12;9(9):e107138. doi: 10.1371/journal.pone.0107138. eCollection 2014.

338.	Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate Handling
	Tien C1, Xu JJ, Chan LS, Chang M, Lim C, Lee S, Huh B, Shinada S, Bae HS, Fong TL. Dig Dis Sci. 2014 Sep 20. [Epub ahead of print]

339.	Individualized management of pregnant women with high hepatitis B virus DNA levels
	Zhang Z, Chen C, Li Z, Wu YH, Xiao XM. World J Gastroenterol. 2014 Sep 14;20(34):12056-12061.

340.	Hepatitis B viral load affects prognosis of hepatocellular carcinoma
	Yu SJ, Kim YJ. World J Gastroenterol. 2014 Sep 14;20(34):12039-12044.

341.	Interleukin 28B genetic polymorphism and hepatitis B virus infection
	Takahashi T. World J Gastroenterol. 2014 Sep 14;20(34):12026-12030.

342.	Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B
	Enomoto M, Morikawa H, Tamori A, Kawada N. World J Gastroenterol. 2014 Sep 14;20(34):12031-12038.

343.	A Randomized, Open-Label Clinical Study of Combined Peginterferon Alfa-2a (40KD) and Entecavir Treatment for HBeAg-Positive Chronic Hepatitis B
	Xie Q1, Zhou H1, Bai X2, Wu S3, Chen JJ4, Sheng J5, Xie Y6, Chen C7, Chan HL8, Zhao M9. Clin Infect Dis. 2014 Sep 4. pii: ciu702. [Epub ahead of print]

344.	Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single north american center
	Franssen B1, Alshebeeb K, Tabrizian P, Marti J, Pierobon ES, Lubezky N, Roayaie S, Florman S, Schwartz ME. Ann Surg. 2014 Oct;260(4):650-8. doi: 10.1097/SLA.0000000000000917.

345.	Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit
	Niederau C. World J Gastroenterol. 2014 Sep 7;20(33):11595-11617.

346.	Association between maternal HBsAg carrier status and neonatal adverse outcomes: meta-analysis
	Luo L1, Wu J, Qu Y, Li J, Pan L, Li D, Wang H, Mu D. J Matern Fetal Neonatal Med. 2014 Sep 18:1-10. [Epub ahead of print]

347.	Caesarean section to prevent transmission of hepatitis B: A meta-analysis
	Chang MS, Gavini S, Andrade PC, McNabb-Baltar J. Can J Gastroenterol Hepatol. 2014 Sep;28(8):439-44.

348.	Recent Population Expansions of Hepatitis B Virus in the United States
	Ramachandran S1, Purdy MA2, Xia GL2, Campo DS2, Dimitrova ZE2, Teshale EH2, Teo CG2, Khudyakov YE2. J Virol. 2014 Sep 3. pii: JVI.01594-14. [Epub ahead of print]

349.	Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
	Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Hepatology. 2014 Aug;60(2):468-76.

350.	Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course and management
	Chang ML1, Liaw YF2. J Hepatol. 2014 Aug 29. pii: S0168-8278(14)00620-5. doi: 10.1016/j.jhep.2014.08.033. [Epub ahead of print]

351.	Prognostic value of the combined use of transient elastography and FibroTest in patients with chronic hepatitis B
	Park MS1, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Shin SH, Kang W, Moon C, Han KH. Liver Int. 2014 Sep 2. doi: 10.1111/liv.12678. [Epub ahead of print]

352.	The immune tolerant phase of chronic HBV infection: new perspectives on an old concept
	Bertoletti A1, Kennedy PT2. Cell Mol Immunol. 2014 Sep 1. doi: 10.1038/cmi.2014.79. [Epub ahead of print]

353.	Diagnostic usefulness of real-time elastography for liver fibrosis in chronic viral hepatitis B and C
	Kim YW1, Kwon JH1, Jang JW2, Kim MJ1, Oh BS1, Chung KW1, Park ES3, Nam SW1. Gastroenterol Res Pract. 2014;2014:210407. doi: 10.1155/2014/210407. Epub 2014 Aug 10.

354.	Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains
	Lee YB1, Lee JH2, Lee DH1, Cho H1, Ahn H1, Choi WM1, Cho YY1, Lee M1, Yoo JJ1, Cho Y1, Cho EJ1, Yu SJ1, Kim YJ1, Yoon JH1, Kim CY1, Lee HS1. Antimicrob Agents Chemother. 2014 Aug 25. pii: AAC.03845-14. [Epub ahead of print]

355.	Entecavir Is Safe and Effective in Patients Previously Treated with Adefovir, including Those with Adefovir-Resistance
	Nguyen NH1, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. J Gastroenterol Hepatol. 2014 Aug 28. doi: 10.1111/jgh.12728. [Epub ahead of print]

356.	Assessment of Bone Mineral Density in Tenofovir treated Chronic Hepatitis B patients: Can FRAX identify those at greatest risk?
	Gill US1, Zissimopoulos A2, Al-Shamma S2, Burke K2, McPhail MJ3, Barr DA4, Kallis YN2, Marley RT2, Kooner P2, Foster GR1, Kennedy PT1. J Infect Dis. 2014 Aug 25. pii: jiu471. [Epub ahead of print]

357.	Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination
	Yolima CG1, Xavier MG, Magda CM, José Ángel RP, Natalia BS, Francisco RF, Francesc CJ. J Gastroenterol Hepatol. 2014 Aug 26. doi: 10.1111/jgh.12712. [Epub ahead of print]

358.	Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
	Zoulim F1, Carosi G2, Greenbloom S3, Mazur W4, Nguyen T5, Jeffers L6, Brunetto M7, Yu S8, Llamoso C8. J Hepatol. 2014 Aug 28. pii: S0168-8278(14)00618-7. doi: 10.1016/j.jhep.2014.08.031. [Epub ahead of print]

359.	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B was associated with unexpected high rate of peripheral neuropathy
	Marcellin P1, Wursthorn K2, Wedemeyer H2, Chuang WL3, Lau G4, Avila C5, Peng CY6, Gane E7, Gee Lim S8, Fainboim H9, Foster GR10, Safadi R11, Rizzetto M12, Manns M2, Bao W13, Naoumov N5. J Hepatol. 2014 Aug 21. pii: S0168-8278(14)00607-2. doi: 10.1016/j.jhep.2014.08.021. [Epub ahead of print]

360.	Survey of health status, nutrition and geography of food selection of chronic liver disease patients
	Leslie T1, Pawloski L2, Kallman-Price J3, Escheik C4, Hossain N3, Fang Y3, Gerber LH5, Younossi ZM3. Ann Hepatol. 2014 Sep-Oct;13(5):533-40.

361.	Human Immunodeficiency Virus and Coinfection with Hepatitis B and C
	Petty LA1, Steinbeck JL2, Pursell K2, Jensen DM3. Infect Dis Clin North Am. 2014 Sep;28(3):477-499. doi: 10.1016/j.idc.2014.05.005.

362.	Knowledge, Awareness and Medical Practice of Asian Americans/Pacific Islanders on Chronic Hepatitis B Infection: Review of Current Psychosocial Evidence
	Do TN, Nam SG. Pogon Sahoe Yongu. 2011;31(3):341-364.

363.	Temporal Trends of Non-alcoholic Fatty Liver Disease-related Hepatocellular Carcinoma in the Veteran Affairs Population
	Mittal S1, Sada YH2, El-Serag HB3, Kanwal F3, Duan Z2, Temple S2, May SB2, Kramer JR2, Richardson PA2, Davila JA2. Clin Gastroenterol Hepatol. 2014 Aug 19. pii: S1542-3565(14)01228-2. doi: 10.1016/j.cgh.2014.08.013. [Epub ahead of print]

364.	Risk assessment of clinical outcomes in asian patients with chronic hepatitis B using enhanced liver fibrosis test
	Kim BK1, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim DY, Ahn SH, Han KH, Kim SU, Park YN. Hepatology. 2014 Aug 20. doi: 10.1002/hep.27389. [Epub ahead of print]

365.	Antenatal hepatitis B in a large teaching NHS Trust - Implications for future care
	White HA1, Wiselka MJ2, Wilson DJ3. J Infect. 2014 Aug 16. pii: S0163-4453(14)00245-X. doi: 10.1016/j.jinf.2014.07.028. [Epub ahead of print]

366.	Hepatitis B vaccine by intradermal route in non responder patients: An update
	Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, La Rosa M, Leonardi S. World J Gastroenterol. 2014 Aug 14;20(30):10383-10394.

367.	Natural history of chronic hepatitis B: Phases in a complex relationship
	Croagh CM, Lubel JS. World J Gastroenterol. 2014 Aug 14;20(30):10395-10404.

368.	APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS)
	Teshale E1, Lu M, Rupp LB, Holmberg SD, Moorman AC, Spradling P, Vijayadeva V, Boscarino JA, Schmidt MA, Gordon SC; the CHeCS Investigators. J Viral Hepat. 2014 Aug 1. doi: 10.1111/jvh.12279. [Epub ahead of print]

369.	Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience
	Zhang D, Jiao Z, Han J, Cao H. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4057-66. eCollection 2014.

370.	Comparison of Diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis
	Xiao G1, Yang J, Yan L. Hepatology. 2014 Aug 18. doi: 10.1002/hep.27382. [Epub ahead of print]

371.	Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
	Liu YR, Lin BB, Zeng DW, Zhu YY, Chen J, Zheng Q, Dong J1, Jiang JJ. BMC Gastroenterol. 2014 Aug 16;14:145. doi: 10.1186/1471-230X-14-145.

372.	Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B
	Brouwer WP1, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL. Aliment Pharmacol Ther. 2014 Aug 11. doi: 10.1111/apt.12910. [Epub ahead of print]

373.	Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma
	Wang L, Wu-Xiao ZJ, Chen XQ, Zhang YJ, Lu Y, Xia ZJ. Leuk Lymphoma. 2014 Aug 11:1-20. [Epub ahead of print]

374.	Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides
	Patwardhan VR1, Sengupta N, Bonder A, Lau D, Afdhal NH. Aliment Pharmacol Ther. 2014 Aug 11. doi: 10.1111/apt.12908. [Epub ahead of print]

375.	A new model for predicting liver cirrhosis in chronic hepatitis B virus carriers with low serum alanine transaminase activity
	Zeng DW1, Zhang JM2, Liu YR1, Dong J1, Wu YL1, Lin S1, Jiang JJ1, Zhu YY3. Clin Res Hepatol Gastroenterol. 2014 Jul 18. pii: S2210-7401(14)00152-1. doi: 10.1016/j.clinre.2014.06.007. [Epub ahead of print]

376.	Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B
	Bessone F. Liver Int. 2014 Aug;34(7):991-1000. doi: 10.1111/liv.12499. Epub 2014 Mar 12.

377.	Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling
	Guedj J1, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang JT, Hoofnagle JH, Heller T, Dahari H. Hepatology. 2014 Aug 7. doi: 10.1002/hep.27357. [Epub ahead of print]

378.	A Randomized Study to Evaluate the Immunogenicity and Safety of a Heptavalent Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus influenzae b, and Meningococcal Serogroup C Combination Vaccine Administered to Infants at 2, 4, and 12 Months of Age
	Thollot F1, Scheifele D, Pankow-Culot H, Cheuvart B, Leyssen M, Ulianov L, Miller JM. Pediatr Infect Dis J. 2014 Jul 16. [Epub ahead of print]

379.	Outcomes of Patients with Chronic Hepatitis B Who do not Meet Criteria for Antiviral Treatment at Presentation
	Yapali S1, Talaat N1, Fontana RJ1, Oberhelman K1, Lok AS2. Clin Gastroenterol Hepatol. 2014 Jul 17. pii: S1542-3565(14)01048-9. doi: 10.1016/j.cgh.2014.07.019. [Epub ahead of print]

380.	Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate
	Marcellin P1, Buti M2, Krastev Z3, de Man RA4, Zeuzem S5, Lou L6, Gaggar A6, Flaherty JF6, Massetto B6, Lin L6, Dinh P6, Mani Subramanian G6, McHutchison JG6, Flisiak R7, Gurel S8, Dusheiko GM9, Jenny Heathcote E10. J Hepatol. 2014 Jul 18. pii: S0168-8278(14)00518-2. doi: 10.1016/j.jhep.2014.07.019. [Epub ahead of print]

381.	Platelets promote liver immunopathology contributing to hepatitis B virus-mediated hepatocarcinogenesis
	Sitia G. Semin Oncol. 2014 Jun;41(3):402-5. doi: 10.1053/j.seminoncol.2014.04.013. Epub 2014 Apr 24.

382.	A new model for predicting liver cirrhosis in chronic hepatitis B virus carriers with low serum alanine transaminase activity
	Zeng DW1, Zhang JM2, Liu YR1, Dong J1, Wu YL1, Lin S1, Jiang JJ1, Zhu YY3. Clin Res Hepatol Gastroenterol. 2014 Jul 18. pii: S2210-7401(14)00152-1. doi: 10.1016/j.clinre.2014.06.007. [Epub ahead of print]

383.	Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections
	Rehermann B1, Bertoletti A. Hepatology. 2014 Jul 21. doi: 10.1002/hep.27323. [Epub ahead of print]

384.	Prevention of hepatitis B virus reinfection in liver transplant recipients
	Roche B1, Samuel D. Intervirology. 2014;57(3-4):196-201. doi: 10.1159/000360944. Epub 2014 Jul 15.

385.	Chronic hepatitis B virus in young adults: the need for new approaches to management
	Gill US1, Kennedy PT. Expert Rev Anti Infect Ther. 2014 Jul 23:1-9. [Epub ahead of print]

386.	Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
	Institute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis Infection; Colvin HM, Mitchell AE, editors.

387.	The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US
	Younossi ZM1, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, Hunt S. Aliment Pharmacol Ther. 2014 Jul 16. doi: 10.1111/apt.12881. [Epub ahead of print]

388.	Therapy of acute and fulminant hepatitis B
	Tillmann HL1, Patel K. Intervirology. 2014;57(3-4):181-8. doi: 10.1159/000360939. Epub 2014 Jul 15.

389.	Chronic Hepatitis B Treatment Eligibility and Actual Treatment Rates in Patients in Community Gastroenterology and Primary Care Settings
	Nguyen VG1, Wan K, Trinh HN, Li J, Zhang JQ, Nguyen MH. J Clin Gastroenterol. 2014 Jul 10. [Epub ahead of print]

390.	Hepatitis Viruses and Liver Transplantation: Evolving Trends in Antiviral Management
	Verna EC. Clin Liver Dis. 2014 Aug;18(3):575-601. doi: 10.1016/j.cld.2014.05.002.

391.	Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients with Cirrhosis
	Dalton-Fitzgerald E1, Tiro J2, Kandunoori P1, Halm EA3, Yopp A4, Singal AG5. Clin Gastroenterol Hepatol. 2014 Jul 11. pii: S1542-3565(14)00987-2. doi: 10.1016/j.cgh.2014.06.031. [Epub ahead of print]

392.	Residual Amount of HBV DNA in Serum is Related to Relapse in Chronic Hepatitis B Patients After Cessation of Nucleos(t)ide Analogs
	Jiang JN1, Huang ZL, He LX, Huang YH, Su MH, Xie R, Liang YX, Fu WD, Huang XH, Guo WW, Zhong SH, Liu ZH, Li SH, Zhu TF, Gao ZL. J Clin Gastroenterol. 2014 Jul 10. [Epub ahead of print]

393.	Clinical impact of occult hepatitis B virus infection in immunosuppressed patients
	Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. World J Hepatol. 2014 Jun 27;6(6):384-93. doi: 10.4254/wjh.v6.i6.384.

394.	Effect of Menarche Onset on the Clinical Course in Females with Chronic Hepatitis B Virus Infection
	Wu JF1, Tsai WY1, Tung YC1, Chen HL2, Ni YH3, Hsu HY1, Chang MH4. J Pediatr. 2014 Jun 24. pii: S0022-3476(14)00499-5. doi: 10.1016/j.jpeds.2014.05.049. [Epub ahead of print]

395.	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest) and elastography (FibroScan)
	Poynard T1, Vergniol J2, Ngo Y3, Foucher J2, Thibault V4, Munteanu M3, Merrouche W2, Lebray P5, Rudler M5, Deckmyn O3, Perazzo H5, Thabut D5, Ratziu V5, de Ledinghen V2. J Hepatol. 2014 Jul 9. pii: S0168-8278(14)00457-7. doi: 10.1016/j.jhep.2014.06.027. [Epub ahead of print]

396.	Chronic hepatitis B infection and risk of preterm labor: A meta-analysis of observational studies
	Huang QT1, Wei SS2, Zhong M3, Hang LL2, Xu YY2, Cai GX2, Liu Q4, Yu YH2. J Clin Virol. 2014 Jun 16. pii: S1386-6532(14)00222-4. doi: 10.1016/j.jcv.2014.06.006. [Epub ahead of print]

397.	Association between infection of hepatitis B virus and onset risk of B-cell non-Hodgkin's lymphoma: a systematic review and a meta-analysis
	Yi HZ1, Chen JJ, Cen H, Yan W, Tan XH. Med Oncol. 2014 Aug;31(8):84. doi: 10.1007/s12032-014-0084-7. Epub 2014 Jun 28.

398.

Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians

Arends P1, Sonneveld MJ1, Zoutendijk R1, Carey I2, Brown A3, Fasano M4, Mutimer D5, Deterding K6, Reijnders JG1, Oo Y5, Petersen J7, van Bömmel F8, de Knegt RJ1, Santantonio T4, Berg T8, Welzel TM9, Wedemeyer H6, Buti M10, Pradat P11, Zoulim F11, Hansen B1, Janssen HL12; for the VIRGIL Surveillance Study Group. Gut. 2014 Jul 10. pii: gutjnl-2014-307023. doi: 10.1136/gutjnl-2014-307023. [Epub ahead of print]

399.	Vertical transmission of hepatitis B virus: challenges and solutions
	Gentile I, Borgia G. Int J Womens Health. 2014 Jun 10;6:605-11. doi: 10.2147/IJWH.S51138. eCollection 2014.

400.	The bloodborne pathogen standard in private practice
	Davis D1, Carlton A, Wisch JS. Community Support Oncol. 2014 Mar;12(3):82-3.

401.	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy
	Lee HW1, Yoo EJ1, Kim BK2, Kim SU2, Park JY2, Kim DY2, Ahn SH3, Han KH3. Am J Gastroenterol. 2014 Jun 24. doi: 10.1038/ajg.2014.157. [Epub ahead of print]

402.	The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis
	Ow MM1, de Zoysa JR, Gane EJ. N Z Med J. 2014 Jun 20;127(1396):34-42.

403.	Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy
	Jang JW. World J Gastroenterol. 2014 Jun 28;20(24):7675-7685.

404.	Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer
	Levaggi A1, DE Maria A2, Dozin B3, Iacono G4, Bighin C5, Giraudi S4, Lambertini M5, D'Alonzo A4, Poggio F5, Pronzato P5, Del Mastro L4. Anticancer Res. 2014 Jul;34(7):3715-20.

405.	Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: A pilot project undertaken at the Vancouver General Hospital
	Kapeluto J, Kadatz M, Wormsbecker A, Sidhu K, Yoshida EM. Can J Gastroenterol Hepatol. 2014 Jun;28(6):315-8.

406.	Hepatitis B in Pregnancy
	Whittaker G, Herrera JL. South Med J. 2014 Mar;107(3):195-200.

407.	Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement
	LeFevre ML. Ann Intern Med. 2014 May 27. doi: 10.7326/M14-1018. [Epub ahead of print]

408.	Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples
	Taranta A1, Tien Sy B2, Zacher BJ1, Rogalska-Taranta M3, Manns MP1, Bock CT4, Wursthorn K5. J Clin Virol. 2014 May 2. pii: S1386-6532(14)00148-6. doi: 10.1016/j.jcv.2014.04.015. [Epub ahead of print]

409.	Management of chronic hepatitis B in children: an unresolved issue
	Della Corte C1, Nobili V, Comparcola D, Cainelli F, Vento S. J Gastroenterol Hepatol. 2014 May;29(5):912-9. doi: 10.1111/jgh.12550.

410.	Current recommendations of managing HBV infection in preconception or pregnancy
	Park JS1, Pan C. Front Med. 2014 Jun;8(2):158-65. doi: 10.1007/s11684-014-0340-4. Epub 2014 May 29.

411.	Cirrhosis Regression in Patients With Viral Hepatitis B and C: A Systematic Review
	Manne V1, Akhtar E, Saab S. J Clin Gastroenterol. 2014 Jun 11. [Epub ahead of print]

412.	Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection
	Spradling PR1, Bulkow L2, Teshale EH3, Negus S4, Homan C4, Simons B4, McMahon BJ5. J Hepatol. 2014 Jun 6. pii: S0168-8278(14)00393-6. doi: 10.1016/j.jhep.2014.05.045. [Epub ahead of print]

413.	Bridging Basic Science and Clinical Research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis
	Boettler T1, Moradpour D2, Thimme R1, Zoulim F3. J Hepatol. 2014 May 15. pii: S0168-8278(14)00357-2. doi: 10.1016/j.jhep.2014.05.016. [Epub ahead of print]

414.	Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors
	Wang MM1, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Dig Dis Sci. 2014 May 18. [Epub ahead of print]

415.	Current Treatment Guidelines for Chronic Hepatitis B and Their Application.
	Uribe LA1, O'Brien CG, Wong RJ, Gish RR, Tsai N, Nguyen MH. J Clin Gastroenterol. 2014 May 22. [Epub ahead of print]

416.	Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study
	Yang F1, Zhu HL2, He C2, Li JJ2, Xiang B2, Cui X2, Huang J2, Ji J2, Ma HB2, Liu T2. Indian J Hematol Blood Transfus. 2014 Jun;30(2):97-104. doi: 10.1007/s12288-012-0195-2. Epub 2012 Oct 30.

417.	Prevention of Liver Cancer Through the Early Detection of Risk-Related Behavior Among Hepatitis B or C Carriers
	Fan JY1, Huang TJ, Jane SW, Chen MY. Cancer Nurs. 2014 May 15. [Epub ahead of print]

418.	Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation
	Manne V, Allen RM, Saab S. Gastroenterol Hepatol (N Y). 2014 Mar;10(3):175-9.

419.	Hepatitis B virus genotypes: Global distribution and clinical importance
	Sunbul M. World J Gastroenterol. 2014 May 14;20(18):5427-5434.

420.	A drug safety evaluation of rituximab and risk of hepatitis B
	Riedell P1, Carson KR. Expert Opin Drug Saf. 2014 May 12:1-11. [Epub ahead of print]

421.	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
	Seto WK1, Hui AJ2, Wong VW3, Wong GL3, Liu KS1, Lai CL1, Yuen MF1, Chan HL3. Gut. 2014 May 15. pii: gutjnl-2014-307237. doi: 10.1136/gutjnl-2014-307237. [Epub ahead of print]

422.	Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of Hepatitis B Virus
	Greenup AJ1, Tan PK1, Nguyen V1, Glass A1, Davison S1, Chatterjee U2, Holdaway S3, Samarasinghe D3, Jackson K4, Locarnini S4, Levy MT5. J Hepatol. 2014 May 3. pii: S0168-8278(14)00301-8. doi: 10.1016/j.jhep.2014.04.038. [Epub ahead of print]

423.	Impact of Viral Hepatitis on Outcomes after Liver Resection for Hepatocellular Carcinoma: Results from a North American Center
	Lee JJ1, Kim PT, Fischer S, Fung S, Gallinger S, McGilvray I, Moulton CA, Wei AC, Greig PD, Cleary SP. Ann Surg Oncol. 2014 May 8. [Epub ahead of print]

424.	Early identification and linkage to care of persons with chronic hepatitis B virus infection - three u.s. Sites, 2012-2014
	Beckett GA, Ramirez G, Vanderhoff A, Nichols K, Chute SM, Wyles DL, Schoenbachler BT, Bedell DT, Cabra R, Ward JW; Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):399-401.

425.	Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis
	Lu YP, Liang XJ, Xiao XM, Huang SM, Liu ZW, Li J, Hocher B, Chen YP. Clin Lab. 2014;60(4):571-86.

426.	Cost-Effectiveness of Testing Hepatitis B-Positive Pregnant Women for Hepatitis B e Antigen or Viral Load
	Fan L1, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Obstet Gynecol. 2014 May;123(5):929-37. doi: 10.1097/AOG.0000000000000124.

427.	Notes from the field: investigation of infectious disease risks associated with a nontransplant anatomical donation center - Arizona, 2014
	de Perio MA, Bernard BP, Delaney LJ, Pesik N, Cohen NJ; National Institute for Occupational Safety and Health, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 2;63(17):384-5.

428.	Prognostic Evaluation of Patients Undergoing Living-Donor Liver Transplant By APACHE II and MELD Scores
	Zhang ZY1, Chen R, Zhou ZQ, Peng CH, Zhou GW. Exp Clin Transplant. 2014 Apr 28. doi: 10.6002/ect.2013.0289. [Epub ahead of print]

429.	A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation
	Gish RG1, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, Locarnini S, Hammond R, Bowden S. J Viral Hepat. 2014 Apr 30. doi: 10.1111/jvh.12257. [Epub ahead of print]

430.	Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection
	Sagnelli E1, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N.

431.	Strategies to Inhibit Entry of HBV and HDV into Hepatocytes
	Urban S1, Bartenschlager R2, Kubitz R3, Zoulim F4. Gastroenterology. 2014 Apr 24. pii: S0016-5085(14)00556-3. doi: 10.1053/j.gastro.2014.04.030. [Epub ahead of print]

432.	Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease
	Pang JX1, Zimmer S2, Niu S2, Crotty P3, Tracey J3, Pradhan F3, Shaheen AA3, Coffin CS3, Heitman SJ1, Kaplan GG1, Swain MG3, Myers RP1. PLoS One. 2014 Apr 22;9(4):e95776. doi: 10.1371/journal.pone.0095776. eCollection 2014.

433.	Scoring systems predict the prognosis of acute-on-chronic hepatitis B liver failure: an evidence-based review
	Wu FL1, Shi KQ, Chen YP, Braddock M, Zou H, Zheng MH. Expert Rev Gastroenterol Hepatol. 2014 Apr 24. [Epub ahead of print]

434.	Viral infections in pregnancy: advice for healthcare workers
	Chin TL1, Macgowan AP2, Jacobson SK2, Donati M3. J Hosp Infect. 2014 Mar 12. pii: S0195-6701(14)00066-8. doi: 10.1016/j.jhin.2013.12.011. [Epub ahead of print]

435.	The impact of hepatitis B on heart transplantation: 19 years of national experience in Korea
	Shin HS1, Cho HJ1, Jeon ES2, Hwang HY3, Kim JJ4, Kim KB3, Oh BH1, Lee HY1. Ann Transplant. 2014 Apr 23;19:182-7. doi: 10.12659/AOT.889680.

436.	Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection
	Trembling PM1, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. J Viral Hepat. 2013 Aug 15. doi: 10.1111/jvh.12161. [Epub ahead of print]

437.	Hepatitis B vaccination and screening awareness in primary care practitioners
	Said A1, Jou JH2. Hepat Res Treat2014;2014:373212. doi: 10.1155/2014/373212. Epub. 2014 Mar 6.

438.	Characteristics and Management of Patients with Chronic Hepatitis B in an Integrated Care Setting
	Sarkar M1, Shvachko VA, Ready JB, Pauly MP, Terrault NA, Peters MG, Manos MM. Dig Dis Sci. 2014 Apr 12. [Epub ahead of print]

439.	The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis
	Conway R1, Doran MF, O'Shea FD, Crowley B, Cunnane G. Clin Rheumatol. 2014 Apr 13. [Epub ahead of print]

440.	The clinical significance of occult HBV infection
	Squadrito G, Spinella R, Raimondo G. Ann Gastroenterol. 2014;27(1):15-19.

441.	A prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy
	Tamori A1, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, Enomoto M, Murakami Y, Kawada N. J Gastroenterol Hepatol. 2014 Apr 14. doi: 10.1111/jgh.12604. [Epub ahead of print]

442.	Characterization of Chronic Hepatitis B Cases Among Foreign-Born Persons in Six Population-Based Surveillance Sites, United States 2001-2010
	Liu SJ1, Iqbal K, Shallow S, Speers S, Rizzo E, Gerard K, Poissant T, Klevens RM. J Immigr Minor Health. 2014 Apr 5. [Epub ahead of print]

443.	Distinct Seromarkers Predict Different Milestones of Chronic Hepatitis B Progression
	Liu J1, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Hsiao CK, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Hepatology. 2014 Feb 20. doi: 10.1002/hep.27083. [Epub ahead of print]

444.	Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007
	Byrne DD1, Newcomb CW2, Carbonari DM3, Nezamzadeh MS3, Leidl KB2, Herlim M2, Yang YX4, Hennessy S3, Kostman JR5, Leonard MB6, Localio R2, Lo Re V 3rd7. Ann Epidemiol. 2014 Mar 5. pii: S1047-2797(14)00075-1. doi: 10.1016/j.annepidem.2014.02.013. [Epub ahead of print]

445.	Risk of Hip Fracture Associated with Untreated and Treated Chronic Hepatitis B Virus Infection
	Byrne DD1, Newcomb CW2, Carbonari DM3, Nezamzadeh MS3, Leidl KB2, Herlim M2, Yang YX1, Hennessy S3, Kostman JR4, Leonard MB5, Russell Localio A2, Lo Re V 3rd6. J Hepatol. 2014 Apr 5. pii: S0168-8278(14)00218-9. doi: 10.1016/j.jhep.2014.04.001. [Epub ahead of print]

446.	Association of Nucleos(t)ide Analogue Therapy with Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B-a Nationwide Cohort Study
	Wu CY1, Lin JT2, Ho HJ3, Su CW4, Lee TY5, Wang SY6, Wu C6, Wu JC7. Gastroenterology. 2014 Apr 1. pii: S0016-5085(14)00445-4. doi: 10.1053/j.gastro.2014.03.048. [Epub ahead of print]

447.	Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis
	Singal AG1, Pillai A2, Tiro J3. PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624. eCollection 2014.

448.	Hepatitis B in pregnancy
	Dyson JK1, Waller J2, Turley A3, Michael E3, Moses S4, Valappil M4, Hudson M5, Bassendine M5, McPherson S5. Frontline Gastroenterol. 2014 Apr;5(2):111-117. Epub 2013 Oct 17.

449.	Management of hepatitis B during pregnancy
	Patton H1, Tran TT2. Nat Rev Gastroenterol Hepatol. 2014 Apr 1. doi: 10.1038/nrgastro.2014.30. [Epub ahead of print]

450.	Prevention of Neonatal Hepatitis B Virus Transmission
	Bleich LM1, Swenson ES. J Clin Gastroenterol. 2014 Mar 24. [Epub ahead of print]

451.	Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis
	Liu F, Wang X, Wei F, Hu H, Zhang D, Hu P1, Ren H. Virol J. 2014 Mar 28;11(1):59. doi: 10.1186/1743-422X-11-59.

452.	Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region
	Bottero J1, Boyd A2, Lemoine M3, Carrat F4, Gozlan J5, Collignon A6, Boo N7, Dhotte P8, Varsat B9, Muller G10, Cha O11, Valin N12, Nau J13, Campa P12, Silbermann B14, Bary M15, Girard PM1, Lacombe K1. PLoS One. 2014 Mar 24;9(3):e92266. doi: 10.1371/journal.pone.0092266. eCollection 2014.

453.	Immune response to hepatitis B vaccination in drug using populations: A systematic review and meta-regression analysis
	Kamath G1, Shah DP1, Hwang LY2. Vaccine. 2014 Mar 11. pii: S0264-410X(14)00299-0. doi: 10.1016/j.vaccine.2014.02.072. [Epub ahead of print]

454.	The importance of baseline viral load when assessing relative efficacy in treatment-naive HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis
	Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. Syst Rev. 2014 Mar 7;3(1):21. [Epub ahead of print]

455.	Student vaccination requirements of u.s. Health professional schools: a national survey
	Libby TE1, Lindley MC, Ahmed F, Stevenson J, Grabowsky M, Strikas RA. J Allied Health. 2014 Spring;43(1):12-21.

456.	Efficacy and safety of tenofovir disoproxil fumarate in asian-americans with chronic hepatitis B in community settings
	Pan CQ1, Trinh H2, Yao A3, Bae H4, Lou L5, Chan S6; Study 123 Group. PLoS One. 2014 Mar 4;9(3):e89789. doi: 10.1371/journal.pone.0089789. eCollection 2014.

457.	Hepatitis B Reactivation and Rituximab: A New Boxed Warning and Considerations for Solid Organ Transplantation
	Martin ST1, Cardwell SM, Nailor MD, Gabardi S. Am J Transplant. 2014 Mar 4. doi: 10.1111/ajt.12649. [Epub ahead of print]

458.	Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009
	Zhou F1, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy TV, Cortese M, Rodewald L. Pediatrics. 2014 Mar 3. [Epub ahead of print]

459.	Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study
	Tseng KC, Chen CY, Tsai HW, Chang TT, Chuang WL, Hsu PI, Liu WC, Cheng PN. Antivir Ther. 2014 Feb 28. doi: 10.3851/IMP2754. [Epub ahead of print]

460.	Reported reasons for testing among hepatitis B virus infected patients, - Chronic Hepatitis Cohort Study (CHeCS), United States, 2006-2010
	Gerbi GB1, Rupp LB, Ko SC, Moorman A, Holmberg SD, Xu F; The CHeCS Investigators. Liver Int. 2014 Mar 3. doi: 10.1111/liv.12509. [Epub ahead of print]

461.	An update on hepatitis B, d, and e viruses
	Price J. Top Antivir Med. 2013 Dec;21(5):157-63.

462.	The pharmaceuticalization of sexual risk: Vaccine development and the new politics of cancer prevention
	Mamo L1, Epstein S2. Soc Sci Med. 2014 Jan;101:155-65. doi: 10.1016/j.socscimed.2013.11.028. Epub 2013 Nov 21.

463.	WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs
	Walsh N1, Verster A2, Rodolph M2, Akl EA3. Int J Drug Policy. 2014 Jan 26. pii: S0955-3959(14)00012-7. doi: 10.1016/j.drugpo.2014.01.009. [Epub ahead of print]

464.	Prognostic Benefit of the Addition of a Quantitative Index of Hepatic Encephalopathy to the MELD score: the MELD-EEG
	Montagnese S, De Rui M, Schiff S, Ceranto E, Valenti P, Angeli P, Cillo U, Zanus G, Gatta A, Amodio P, Merkel C. Liver Int. 2014 Feb 12. doi: 10.1111/liv.12490. [Epub ahead of print]

465.	Incomplete Hepatitis B Immunization, Maternal Carrier Status and Increased Risk of Liver Diseases: A 20-year Cohort Study of 3.8 Million Vaccinees
	Chien YC, Jan CF, Chiang CJ, Kuo HS, You SL, Chen CJ. Hepatology. 2014 Feb 4. doi: 10.1002/hep.27048. [Epub ahead of print]

466.	Effect of a liver cancer education program on hepatitis B screening among asian americans in the Baltimore-washington metropolitan area, 2009-2010
	Juon HS1, Lee S2, Strong C3, Rimal R4, Kirk GD5, Bowie J5. Prev Chronic Dis. 2014 Feb 6;11:E18. doi: 10.5888/pcd11.130258.

467.	Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients with Normal Levels of Alanine Aminotransferase and High Levels of HBV DNA
	Chan HL1, Chan CK2, Hui AJ3, Chan S4, Poordad F5, Chang TT6, Mathurin P7, Flaherty JF8, Lin L8, Corsa A8, Gaggar A8, Subramanian GM8, McHutchison JG8, Lee S9, Gane EJ10. Gastroenterology. 2014 Jan 23. pii: S0016-5085(14)00103-6. doi: 10.1053/j.gastro.2014.01.044. [Epub ahead of print]

468.	The validity of serum markers for fibrosis staging in chronic hepatitis B and C
	Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, Schmidt MA, Lu M; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. J Viral Hepat. 2014 Jan 29. doi: 10.1111/jvh.12224. [Epub ahead of print]

469.	Lamivudine Compared With Newer Antivirals for Prophylaxis of Hepatitis B Core Antibody Positive Livers: A Cost-Effectiveness Analysis
	Wright AJ, Fishman JA, Chung RT. Am J Transplant. 2014 Jan 24. doi: 10.1111/ajt.12598. [Epub ahead of print]

470.	Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy
	Lee M, Oh S, Lee HJ, Yeum TS, Lee JH, Yu SJ, Kim HY, Yoon JH, Lee HS, Kim YJ. J Viral Hepat. 2013 Dec 18. doi: 10.1111/jvh.12217. [Epub ahead of print]

471.	Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C
	Reddy A, May E, Ehrinpreis M, Mutchnick M. World J Gastroenterol. 2013 Dec 28;19(48):9328-33. doi: 10.3748/wjg.v19.i48.9328.

472.	Risk of Hepatobiliary Cancer After Solid Organ Transplant in the United States
	Koshiol J1, Pawlish K2, Goodman MT3, McGlynn KA4, Engels EA5. Clin Gastroenterol Hepatol. 2013 Dec 19. pii: S1542-3565(13)01964-2. doi: 10.1016/j.cgh.2013.12.018. [Epub ahead of print]

473.	Extra-hepatic Effects of Nucleoside and Nucleotide Analogues in Chronic Hepatitis B Treatment
	Fung J, Seto WK, Lai CL, Yuen MF. J Gastroenterol Hepatol. 2013 Dec 27. doi: 10.1111/jgh.12499. [Epub ahead of print]

474.	Biomarkers of liver cell deat.
	Eguchi A1, Wree A2, Feldstein AE2. J Hepatol. 2014 Jan 8. pii: S0168-8278(14)00006-3. doi: 10.1016/j.jhep.2013.12.026. [Epub ahead of print]

475.	Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients
	Chen DB1, Chen YM1, Liu J1, Xie DY1, Lu CR1, Huang ZL1, Zhu RH1, Gao ZL2. J Clin Virol. 2014 Jan;59(1):50-4. doi: 10.1016/j.jcv.2013.11.002. Epub 2013 Nov 13.

476.	Sexual transmission of viral hepatitis
	Gorgos L. Infect Dis Clin North Am. 2013 Dec;27(4):811-36. doi: 10.1016/j.idc.2013.08.002. Epub 2013 Oct 31.

477.	Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants
	Solmone M, Giombini E, Vincenti D, Rozera G, Testa A, Moscetti A, Catalano M, Abbate I, Capobianchi MR, Menzo S. Antivir Ther. 2013 Nov 25. doi: 10.3851/IMP2700. [Epub ahead of print]

478.	A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B
	Cox NR, Patel K, Tillmann HL. Mol Diagn Ther. 2013 Dec 3. [Epub ahead of print]

479.	Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals
	Godbole G, Irish D, Basarab M, Mahungu T, Fox-Lewis A, Thorne C, Jacobs M, Dusheiko G, Rosenberg WM, Suri D, Millar AD, Nastouli E. BMC Pregnancy Childbirth. 2013 Dec 1;13:222. doi: 10.1186/1471-2393-13-222.

480.	The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease
	Pais R, Rusu E, Ratziu V. Clin Liver Dis. 2014 Feb;18(1):165-78. doi: 10.1016/j.cld.2013.09.015.

481.	Hepatitis B Virus (HBV) Infection, Immunity and Susceptibility Among Men Who Have Sex with Men (MSM), Los Angeles County, USA
	Pitasi MA, Bingham TA, Sey EK, Smith AJ, Teshale EH. AIDS Behav. 2013 Nov 26. [Epub ahead of print]

482.	Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B
	Arends P, van der Eijk AA, Sonneveld MJ, Hansen BE, Janssen HL, Haagmans BL. Antivir Ther. 2013 Dec 3. doi: 10.3851/IMP2711. [Epub ahead of print]

483.	Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients
	Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty Jr JF, McHutchison JG, Manns M. J Hepatol. 2013 Nov 29. pii: S0168-8278(13)00826-X. doi: 10.1016/j.jhep.2013.11.024. [Epub ahead of print]

484.	Non-invasive assessment of liver fibrosis using real-time tissue elastography in patients with chronic hepatitis B
	Hu Q1, Zhu SY2, Kang LK1, Wang XY1, Lun HM3, Xu CM1. Clin Radiol. 2014 Feb;69(2):194-9. doi: 10.1016/j.crad.2013.10.003. Epub 2013 Nov 26.

485.	Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study
	Ha NB, Ha NB, Chaung KT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Dig Dis Sci. 2013 Nov 19. [Epub ahead of print]

486.	Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis
	Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. World J Gastroenterol. 2013 Oct 28;19(40):6849-56. doi: 10.3748/wjg.v19.i40.6849.

487.	Hepatitis B vaccination coverage among health-care personnel in the United States
	Byrd KK, Lu PJ, Murphy TV. Public Health Rep. 2013 Nov-Dec;128(6):498-509.

488.	The ratios of Treg/Th17 and TGF-?1/IL-17 are associated with the development of HBV-associated liver cirrhosis
	Yu X, Guo R, Ming D, Su M, Lin C, Deng Y, Lin Z, Su Z. J Gastroenterol Hepatol. 2013 Nov 15. doi: 10.1111/jgh.12459. [Epub ahead of print]

489.	HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
	Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. Gut. 2013 Oct 25. doi: 10.1136/gutjnl-2013-305517. [Epub ahead of print]

490.	Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
	Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Gut. 2013 Nov 13. doi: 10.1136/gutjnl-2013-305785. [Epub ahead of print]

491.	Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B
	Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. World J Gastroenterol. 2013 Oct 28;19(40):6834-41. doi: 10.3748/wjg.v19.i40.6834.

492.	HBV- and HCV-related infections and risk of pancreatic cancer
	Fiorino S, Cuppini A, Castellani G, Bacchi-Reggiani ML, Jovine E. JOP. 2013 Nov 10;14(6):603-9. doi: 10.6092/1590-8577/1948.

493.	Measures to Reduce Mother-to-Child Transmission of Hepatitis B Virus in China: A Meta-Analysis
	Xu H, Zeng T, Liu JY, Lei Y, Zhong S, Sheng YJ, Zhou Z, Ren H. Dig Dis Sci. 2013 Nov 6. [Epub ahead of print]

494.	Efficient identification of low-income Asian American women at high risk for hepatitis B
	Joseph G, Nguyen K, Nguyen T, Stewart S, Davis S, Kevany S, Marquez T, Pasick R. J Health Care Poor Underserved. 2013 Nov;24(4):1701-16. doi: 10.1353/hpu.2013.0159.

495.	Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues
	Liu CJ. J Gastroenterol Hepatol. 2014 Jan;29(1):26-30. doi: 10.1111/jgh.12421

496.	Entecavir-associated myopathy: a case report and literature review
	Yuan K, Wang G, Huang Z, Lin B, Zhou H, Lu X. Muscle Nerve. 2013 Nov 12. doi: 10.1002/mus.24118. [Epub ahead of print]

497.	Antiviral efficacy of entecavir in nucleos(t)ide-naïve patients of Black/African descent with chronic hepatitis B
	Jeffers L, Van Rensburg CJ, Banks A, Schechter M, Schmidt SJ, Hu W, Llamoso C, Parana R. J Viral Hepat. 2014 Jan;21(1):74-6. doi: 10.1111/jvh.12144. Epub 2013 Sep 24.

498.	Hepatitis B: global scientific development from a critical point of view
	Schmidt S, Bundschuh M, Scutaru C, Klingelhoefer D, Groneberg DA, Gerber A. J Viral Hepat. 2013 Nov 10. doi: 10.1111/jvh.12205. [Epub ahead of print]

499.	Chronic hepatitis B virus infection
	McMahon BJ. Med Clin North Am. 2014 Jan;98(1):39-54. doi: 10.1016/j.mcna.2013.08.004. Epub 2013 Oct 20.

500.	Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers
	Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, Liang D. J Hepatol. 2013 Nov 19. pii: S0168-8278(13)00801-5. doi: 10.1016/j.jhep.2013.11.008. [Epub ahead of print]

501.	Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio
	Harimoto N, Shirabe K, Nakagawara H, Toshima T, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y. Transplantation. 2013 Dec 15;96(11):1008-12. doi: 10.1097/TP.0b013e3182a53f2b.

502.	Knowledge of HBV and HCV and individuals' attitudes toward HBV- and HCV-infected colleagues: a national cross-sectional study among a working population in Japan
	Eguchi H, Wada K. PLoS One. 2013 Sep 26;8(9):e76921. doi: 10.1371/journal.pone.0076921.

503.	Hepatitis B virus gene mutations and hepatocarcinogenesis
	Liang T, Chen EQ, Tang H. Asian Pac J Cancer Prev. 2013;14(8):4509-13.

504.	Trends in the knowledge, attitudes and practices of travel risk groups toward prevention of hepatitis B: Results from the repeated cross-sectional Dutch Schiphol Airport Survey 2002-2009
	van Genderen PJ, van Thiel PP, Mulder PG, Overbosch D; Dutch Schiphol Airport Study Group. Travel Med Infect Dis. 2013 Sep 29. pii: S1477-8939(13)00140-3. doi: 10.1016/j.tmaid.2013.09.002. [Epub ahead of print]

505.	Anti-TNF therapy in patients with HBV infection-analysis of 87 patients with inflammatory arthritis
	Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ, Pang XF, Li ZG. Clin Rheumatol. 2013 Sep 29. [Epub ahead of print]

506.	Quality of life, depression, and anxiety among hepatitis B patients
	Keskin G, Gümüs AB, Orgun F. Gastroenterol Nurs. 2013 Sep-Oct;36(5):346-56. doi: 10.1097/SGA.0b013e3182a788cc.

507.	Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria
	Jiang L, Yan LN, Wen TF, Li B, Yang JY. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):494-9.

508.	Prevention of recurrent hepatitis B infection after liver transplantation
	Wong TC, Fung JY, Lo CM. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):465-72.

509.	Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis
	Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H. J Clin Pharmacol. 2013 Sep 16. doi: 10.1002/jcph.181. [Epub ahead of print]

510.	High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients
	Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, Kuo HT, Huang JF, Chang JM, Chen HC, Juo SH, Hwang SJ, Chuang WL; FORMOSA-LIKE group. J Hepatol. 2013 Oct 2. pii: S0168-8278(13)00683-1. doi: 10.1016/j.jhep.2013.09.023. [Epub ahead of print]

511.	Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection
	Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Eur J Clin Microbiol Infect Dis. 2013 Oct 1. [Epub ahead of print]

512.	Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population
	Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; Checs Investigators. Clin Gastroenterol Hepatol. 2013 Oct 6. pii: S1542-3565(13)01511-5. doi: 10.1016/j.cgh.2013.09.062. [Epub ahead of print]

513.	Hepatitis B virus gene mutations and hepatocarcinogenesis
	Liang T, Chen EQ, Tang H. Asian Pac J Cancer Prev. 2013;14(8):4509-13.

514.	Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection
	Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Antimicrob Agents Chemother. 2013 Dec;57(12):6325-32. doi: 10.1128/AAC.01742-13. Epub 2013 Oct 7.

515.	Hepatitis B and C in the armed forces
	Freshwater DA. J R Army Med Corps. 2013 Sep;159(3):169-74. doi: 10.1136/jramc-2013-000096. Epub 2013 Jun 3.

516.	Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial
	Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, Bhutia K, Gupta E, Mukhopadhyay CK, Dutta AK, Trivedi SS. J Viral Hepat. 2013 Nov;20(11):801-10. doi: 10.1111/jvh.12102. Epub 2013 Apr 23.

517.	Analysis of rheumatoid factor according to various hepatitis B virus infectious statuses
	Choi ST, Lee HW, Song JS, Lee SK, Park YB.

518.	Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade
	Yim HJ, Hwang SG. Clin Mol Hepatol. 2013 Sep;19(3):195-209. doi: 10.3350/cmh.2013.19.3.195. Epub 2013 Sep 30.

519.	De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B Before Pregnancy
	Li-Na M, Xiang-Chun D, Xiao-Yan L, Chun-Qiong X, Liu SW, Yan X. J Med Virol. 2013 Oct 25. doi: 10.1002/jmv.23828. [Epub ahead of print]

520.	Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis
	Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, Markova A, Bremer B, Schlaphoff V, Cornberg M, Manns MP, Sandberg JK, Ljunggren HG, Björkström NK, Wedemeyer H. J Infect Dis. 2013 Nov 1. [Epub ahead of print]

521.	Hepatitis viruses and non-Hodgkin's lymphoma: A review
	Datta S, Chatterjee S, Policegoudra RS, Gogoi HK, Singh L. World J Virol. 2012 Dec 12;1(6):162-173.

522.	Prevalence of Hepatitis-B Viral Markers in Patients With Inflammatory Bowel Disease in a Hepatitis-B-Endemic Area: Inadequate Protective Antibody Levels in Young Patients
	Kim ES, Cho KB, Park KS, Jang BI, Kim KO, Jeon SW, Kim EY, Yang CH, Kim WJ; Daegugyeongbuk Gastrointestinal Study Group (DGSG). J Clin Gastroenterol. 2013 Oct 24. [Epub ahead of print]

523.	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy
	Wong GL, Wong VW. World J Gastroenterol. 2013 Oct 21;19(39):6515-22. doi: 10.3748/wjg.v19.i39.6515.

524.	Differences Between Hepatocellular Carcinoma and Hepatitis B Virus Infection in Patients With and Without Cirrhosis
	Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Ann Surg Oncol. 2013 Oct 17. [Epub ahead of print]

525.	HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
	Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. Gut. 2013 Oct 25. doi: 10.1136/gutjnl-2013-305517. [Epub ahead of print]

526.	Analysis of S gene mutation of the hepatitis B virus in adult liver transplant recipients showing resistance to hepatitis B immunoglobulin therapy
	Park GC, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Shin YW, Kim SH, Chang KH, Namgoong JM, Park CS, Park HW, Park YH, Kang SH, Jung BH, Lee SG. Transplant Proc. 2013 Oct;45(8):3047-51. doi: 10.1016/j.transproceed.2013.08.055.

527.	Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus
	Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T. Liver Cancer. 2013 Jan;2(1):40-46.

528.	Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis
	Ye XG, Su QM. World J Gastroenterol. 2013 Oct 21;19(39):6665-78. doi: 10.3748/wjg.v19.i39.6665.

529.	Assessment of current criteria for primary non-response in chronic hepatitis B patients receiving entecavir therapy
	Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Hepatology. 2013 Oct 29. doi: 10.1002/hep.26910. [Epub ahead of print]

530.	Clinical outcomes and risk factors of hepatitis B virus recurrence in patients who received prophylaxis with entecavir and hepatitis B immunoglobulin following liver transplantation
	Kim YK, Kim SH, Lee SD, Park SJ. Transplant Proc. 2013 Oct;45(8):3052-6. doi: 10.1016/j.transproceed.2013.08.065.

531.	Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
	Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW. Clin Mol Hepatol. 2013 Sep;19(3):300-4. doi: 10.3350/cmh.2013.19.3.300. Epub 2013 Sep 30.

532.	Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs
	Lee YH, Bae SC, Song GG. Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.

533.	Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population
	Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; Checs Investigators. Clin Gastroenterol Hepatol. 2013 Oct 6. pii: S1542-3565(13)01511-5. doi: 10.1016/j.cgh.2013.09.062. [Epub ahead of print]

534.	Prevention and Risk Factors of Hepatitis B Recurrence after Living Donor Liver Transplantation
	Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK, Choi JY. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12403. [Epub ahead of print]

535.	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously
	Cheng HR, Kao JH, Wu HL, Chen TC, Tseng TC, Liu CH, Su TH, Chen PJ, Chen DS, Liu CJ. Liver Int. 2013 Sep 11. doi: 10.1111/liv.12324. [Epub ahead of print]

536.	Clinical implications of the titer of serum hepatitis B surface antigen during the natural history of hepatitis B virus infection
	Suh SJ, Bae SI, Kim JH, Kang K, Yeon JE, Byun KS. J Med Virol. 2014 Jan;86(1):117-23. doi: 10.1002/jmv.23767. Epub 2013 Sep 30.

537.	Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors
	Qiu LP, Chen L, Chen KP. Fundam Clin Pharmacol. 2013 Oct 4. doi: 10.1111/fcp.12053. [Epub ahead of print]

538.	Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts
	Leong J, Coty P, Fiel MI, Chang C, Florman S, Schiano T. Hepatol Res. 2013 Sep 25. doi: 10.1111/hepr.12249. [Epub ahead of print]

539.	IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients
	Zhang Q, Lapalus M, Asselah T, Laouénan C, Moucari R, Martinot-Peignoux M, Bieche I, Estrabaud E, De Muynck S, Boyer N, Bedossa P, Vidaud M, Marcellin P, Lada O. J Viral Hepat. 2013 Oct 10. doi: 10.1111/jvh.12177. [Epub ahead of print]

540.	Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?
	Yu LH, Li N, Shi J, Guo WX, Wu MC, Cheng SQ. Ann Surg Oncol. 2013 Oct 12. [Epub ahead of print]

541.	Chronic Hepatitis B Management Based on Standard Guidelines in Community Primary Care and Specialty Clinics
	Ku KC, Li J, Ha NB, Martin M, Nguyen VG, Nguyen MH. Dig Dis Sci. 2013 Oct 13. [Epub ahead of print]

542.	Association between Mannose-binding lectin gene polymorphisms and hepatitis B virus infection: a meta-analysis
	Xu HD, Zhao MF, Wan TH, Song GZ, He JL, Chen Z. PLoS One. 2013 Oct 8;8(10):e75371. doi: 10.1371/journal.pone.0075371.

543.	HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers
	Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, Lindh M. Liver Int. 2013 Oct 1. doi: 10.1111/liv.12345. [Epub ahead of print]

544.	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir
	Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. Hepatology. 2013 Oct 1. doi: 10.1002/hep.26739. [Epub ahead of print]

545.	Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis
	Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. J Med Virol. 2014 Jan;86(1):131-8. doi: 10.1002/jmv.23790. Epub 2013 Oct 12.

546.	De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis
	Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. World J Gastroenterol. 2013 Oct 7;19(37):6278-83. doi: 10.3748/wjg.v19.i37.6278.

547.	De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis
	Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. World J Gastroenterol. 2013 Oct 7;19(37):6278-83. doi: 10.3748/wjg.v19.i37.6278.

548.	Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus Infection
	Abe H, Seki N, Sugita T, Aida Y, Ishiguro H, Miyazaki T, Itagaki M, Sutoh S, Aizawa Y. Hepat Res Treat. 2013;2013:739247. doi: 10.1155/2013/739247. Epub 2013 Sep 9.

549.	Adjuvant therapy for hepatocellular carcinoma: Current situation and prospect
	Wang ZG, Zhang GF, Wu JC, Jia MK. Drug Discov Ther. 2013 Aug;7(4):137-143.

550.	Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies
	Qin Q, Zhang C, Zhu H, Yang X, Xu L, Liu J, Lu J, Zhan L, Cheng H, Sun X. J Cancer Res Clin Oncol. 2013 Sep 28. [Epub ahead of print]

551.	The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities
	Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G. Curr Opin HIV AIDS. 2013 Nov;8(6):528-34. doi: 10.1097/COH.0000000000000008.

552.	Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China
	Chao J, Song L, Zhang H, Zhu L, Tian L, Jin H, Liu P. BMC Health Serv Res. 2013 Oct 4;13:386. doi: 10.1186/1472-6963-13-386.

553.	Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria
	Jiang L, Yan LN, Wen TF, Li B, Yang JY. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):494-9.

554.	Pathogenesis of viruses-associated human cancers: Epstein-Barr virus and hepatitis B virus as two examples
	Chang KC, Chang Y, Wang LH, Tsai HW, Huang W, Su IJ. J Formos Med Assoc. 2013 Oct 2. pii: S0929-6646(13)00300-8. doi: 10.1016/j.jfma.2013.09.001. [Epub ahead of print]

555.	Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis
	Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H. J Clin Pharmacol. 2013 Sep 16. doi: 10.1002/jcph.181. [Epub ahead of print]

556.	Prevention of recurrent hepatitis B infection after liver transplantation
	Wong TC, Fung JY, Lo CM. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):465-72.

557.	Why does living donor liver transplantation flourish in Asia?
	Chen CL, Kabiling CS, Concejero AM. Nat Rev Gastroenterol Hepatol. 2013 Dec;10(12):746-51. doi: 10.1038/nrgastro.2013.194. Epub 2013 Oct 8.

558.	Developing an evidence-based guideline for the management of exposure to hepatitis B at a Victorian tertiary hospital
	Pierce AB, Armishaw J, Aitchison S. Aust N Z J Public Health. 2013 Oct;37(5):411-5. doi: 10.1111/1753-6405.12107.

559.	Molecular Epidemiology and Clinical Characteristics of Hepatitis B Identified through the French Mandatory Notification System
	Thibault V, Laperche S, Thiers V, Sayon S, Letort MJ, Delarocque-Astagneau E, Antona D. PLoS One. 2013 Sep 25;8(9):e75267. doi: 10.1371/journal.pone.0075267.

560.	A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses
	Moudgil V, Redhu D, Dhanda S, Singh J. J Environ Pathol Toxicol Oncol. 2013;32(2):165-75.

561.	Anti-TNF therapy in patients with HBV infection-analysis of 87 patients with inflammatory arthritis
	Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ, Pang XF, Li ZG. Clin Rheumatol. 2013 Sep 29. [Epub ahead of print]

562.	Comparison of tenofovir and entecavir in patients with chronic HBV infection
	Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, Akkoyunlu Y. Eur Rev Med Pharmacol Sci. 2013 Sep;17(18):2467-73.

563.	Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy
	Yu HC, Lin KH, Hsu PI, Tsay FW, Wang HM, Tsai TJ, Lai KH. Clin Ther. 2013 Sep;35(9):1386-99. doi: 10.1016/j.clinthera.2013.07.329.

564.	Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B
	Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papaptheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A. Gastroenterology. 2013 Sep 22. pii: S0016-5085(13)01359-0. doi: 10.1053/j.gastro.2013.09.031. [Epub ahead of print]

565.	Antiviral treatment for hepatitis B virus recurrence following liver transplantation
	Lee S, Kwon CH, Moon HH, Kim TS, Roh Y, Song S, Shin M, Kim JM, Park JB, Kim SJ, Joh JW, Lee SK. Clin Transplant. 2013 Sep-Oct;27(5):E597-604. doi: 10.1111/ctr.12212.

566.	Quality of life, depression, and anxiety among hepatitis B patients
	Keskin G, Gümüs AB, Orgun F. Gastroenterol Nurs. 2013 Sep-Oct;36(5):346-56. doi: 10.1097/SGA.0b013e3182a788cc.

567.	Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
	Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Oncology. 2013;85(4):197-203. doi: 10.1159/000354698. Epub 2013 Sep 19.

568.	Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
	Zhu XJ, Sun XH, Zhou ZH, Liu SQ, Lv H, Li M, Li L, Gao YQ. Evid Based Complement Alternat Med. 2013;2013:620230. doi: 10.1155/2013/620230. Epub 2013 Aug 24.

569.	Kinetics of Hepatitis B Virus Load During Haemodialysis Sessions and ?-Interferon: A Prospective Study
	Fabrizi F, Lunghi G, Alongi G, Aucella F, Barbisoni F, Bisegna S, Mangano S, Romei-Longhena G, Artoni A, Bettoni G, Messa P, Martin P. Kidney Blood Press Res. 2013 Sep 4;37(4-5):286-294. [Epub ahead of print]

570.	Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants
	Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z. Virol J. 2013 Sep 22;10:292. doi: 10.1186/1743-422X-10-292.

571.	Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative
	He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M, Zhu P, Huang H, Wang Y. BMC Infect Dis. 2013 Oct 3;13:458. doi: 10.1186/1471-2334-13-458.

572.	Predictors of Significant Fibrosis in Chronic Hepatitis B Patients With Low Viremia
	Abdo AA, Bzeizi KI, Babatin MA, Alsohaibani F, Almana H, Alsaad KO, Alghamdi H, Al-Hamoudi W, Alswat K, Alfaleh FZ, Myers RP, Sanai FM. J Clin Gastroenterol. 2013 Sep 25. [Epub ahead of print]

573.	Thrombocytopenia in patients with hepatitis B virus-related chronic hepatitis: Evaluation of the immature platelet fraction
	Dou J, Lou Y, Wu J, Lu Y, Jin Y. Platelets. 2013 Sep 18. [Epub ahead of print]

574.	Safety of tenofovir during pregnancy for the mother and fetus: a systematic review
	Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Clin Infect Dis. 2013 Dec;57(12):1773-81. doi: 10.1093/cid/cit601. Epub 2013 Sep 17.

575.	Does prolidase indicate worsening of hepatitis B infection?
	Duygu F, Aksoy N, Cicek AC, Butun I, Unlu S. J Clin Lab Anal. 2013 Sep;27(5):398-401. doi: 10.1002/jcla.21617.

576.	Association between viral hepatitis B infection and halitosis
	Han DH, Lee SM, Lee JG, Kim YJ, Kim JB. Acta Odontol Scand. 2013 Sep 23. [Epub ahead of print]

577.	Role of Hepatitis B Surface Antigen (HBsAg) in Identifying True Inactive HBsAg Carriers Infected With Genotype C Hepatitis B Virus
	Yim SY, Um SH, Jung JY, Seo YS, Yim HJ, Ryu HS, Chun HJ, Jeen YT, Kim CD, Keum B, Lee HS. J Clin Gastroenterol. 2013 Sep 16. [Epub ahead of print]

578.	Hepatitis B Management in Vulnerable Populations: Gaps in Disease Monitoring and Opportunities for Improved Care
	Burman BE, Mukhtar NA, Toy BC, Nguyen TT, Chen AH, Yu A, Berman P, Hammer H, Chan D, McCulloch CE, Khalili M. Dig Dis Sci. 2013 Sep 20. [Epub ahead of print]

579.	Effect of a carbohydrate-containing late-evening snack on energy metabolism and fasting substrate utilization in adults with acute-on-chronic liver failure due to Hepatitis B
	Hou W, Li J, Lu J, Wang JH, Zhang FY, Yu HW, Zhang J, Yao QW, Wu J, Shi SY, Mager DR, Meng QH. Eur J Clin Nutr. 2013 Sep 18. doi: 10.1038/ejcn.2013.163. [Epub ahead of print]

580.	Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study
	Huang YW, Wang TC, Lin SC, Chang HY, Chen DS, Hu JT, Yang SS, Kao JH. Clin Infect Dis. 2013 Dec;57(12):1695-702. doi: 10.1093/cid/cit603. Epub 2013 Sep 18.

581.	The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis
	Zhang M, Wu R, Jiang J, Minuk GY, Niu J. Alcohol. 2013 Nov;47(7):553-8. doi: 10.1016/j.alcohol.2013.07.003. Epub 2013 Sep 13.

582.	Plasma Levels of Adiponectin and Primary Liver Cancer Risk in Middle-Aged Japanese Adults with Hepatitis Virus Infection: A Nested Case-Control Study
	Michikawa T, Inoue M, Sawada N, Sasazuki S, Tanaka Y, Iwasaki M, Shimazu T, Yamaji T, Mizokami M, Tsugane S; for the Japan Public Health Center?based Prospective Study Group. Cancer Epidemiol Biomarkers Prev. 2013 Nov 19. [Epub ahead of print]

583.	National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2012
	Centers for Disease Control and Prevention (CDC).

584.	Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study
	Liang J, Jiang MJ, Deng X, Xiao Zhou X. Hepat Mon. 2013 May 23;13(6):e7862. doi: 10.5812/hepatmon.7862.

585.	Lactic acidosis during telbivudine treatment for HBV: a case report and literature review
	Jin JL, Hu P, Lu JH, Luo SS, Huang XY, Weng XH, Zhang JM. World J Gastroenterol. 2013 Sep 7;19(33):5575-80. doi: 10.3748/wjg.v19.i33.5575.

586.	Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy
	Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, Peng BG. Med Oncol. 2013 Dec;30(4):721. doi: 10.1007/s12032-013-0721-6. Epub 2013 Sep 13.

587.	Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis
	Xia P, Zhou M, Dong DS, Xing YN, Bai Y. Tumour Biol. 2013 Sep 12. [Epub ahead of print]

588.	Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B
	Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F. Eur J Gastroenterol Hepatol. 2013 Sep 9. [Epub ahead of print]

589.	Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: An Indian perspective
	Srivastava M, Rungta S, Dixit VK, Shukla SK, Singh TB, Jain AK. Antiviral Res. 2013 Nov;100(2):300-5. doi: 10.1016/j.antiviral.2013.08.020. Epub 2013 Sep 5.

590.	Effects of hepatitis B virus X protein on human T cell cytokines
	Lou X, Hou Y, Liang D. Can J Microbiol. 2013 Sep;59(9):620-6. doi: 10.1139/cjm-2013-0259. Epub 2013 Jul 12.

591.	Hepatitis B antivirals and resistance
	Devi U, Locarnini S. Curr Opin Virol. 2013 Oct;3(5):495-500. doi: 10.1016/j.coviro.2013.08.006. Epub 2013 Sep 7.

592.	Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure
	Weng M, Zeng WZ, Wu XL, Zhang Y, Jiang MD, Wang Z, Zhou DJ, He X. Virol J. 2013 Sep 6;10(1):277. [Epub ahead of print]

593.	Possible origins and evolution of the hepatitis B virus (HBV)
	Locarnini S, Littlejohn M, Aziz MN, Yuen L. Semin Cancer Biol. 2013 Sep 3. pii: S1044-579X(13)00082-5. doi: 10.1016/j.semcancer.2013.08.006. [Epub ahead of print]

594.	An Overview of Hepatitis B Virus Surface Antigen Mutant in the Asia Pacific
	Hudu SA, Malik YA, Niazlin MT, Harmal NS, Sekawi Z. Curr Issues Mol Biol. 2013 Sep 6;16(2):69-78. [Epub ahead of print]

595.	Chronic hepatitis D at a standstill: where do we go from here?
	Ciancio A, Rizzetto M. Nat Rev Gastroenterol Hepatol. 2013 Sep 10. doi: 10.1038/nrgastro.2013.164. [Epub ahead of print]

596.	Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy
	Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E. J Hepatol. 2013 Sep 6. pii: S0168-8278(13)00646-6. doi: 10.1016/j.jhep.2013.08.023. [Epub ahead of print]

597.	Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study
	Du QW, Ding JG, Sun QF, Hong L, Cai FJ, Zhou QQ, Wu YH, Fu RQ. Med Sci Monit. 2013 Sep 9;19:751-6. doi: 10.12659/MSM.889443.

598.	Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA
	Martinot-Peignoux M, Lapalus M, Laouénan C, Lada O, Netto-Cardoso AC, Boyer N, Ripault MP, Carvalho-Filho R, Asselah T, Marcellin P. J Clin Virol. 2013 Oct;58(2):401-7. doi: 10.1016/j.jcv.2013.08.010. Epub 2013 Aug 16.

599.	Racial disparities in hepatitis B infection in Ohio: screening and immunization are critical for early clinical management
	Misra R, Jiobu K, Zhang J, Liu Q, Li F, Kirkpatrick R, Ho J. J Investig Med. 2013 Oct;61(7):1121-8. doi: 10.231/JIM.0b013e3182a70f10.

600.	On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study
	Chen YC, Hsu CW, Chang MY, Yeh CT.

601.	Current role of Lamivudine regarding therapeutic response and resistance in children with chronic hepatitis B
	Hong SJ, Kim YH, Choe BH, Park HJ, Tak WY, Kweon YO. Pediatr Gastroenterol Hepatol Nutr. 2013 Jun;16(2):80-8. doi: 10.5223/pghn.2013.16.2.80. Epub 2013 Jun 30.

602.	Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants
	Tong HV, Toan NL, Song LH, Bock CT, Kremsner PG, Velavan TP. J Viral Hepat. 2013 Oct;20(10):687-98. doi: 10.1111/jvh.12089. Epub 2013 May 7.

603.	The oncogenic role of hepatitis B virus
	Rivière L, Ducroux A, Buendia MA. Recent Results Cancer Res. 2014;193:59-74. doi: 10.1007/978-3-642-38965-8_4.

604.	Prevention of hepatitis B virus infection and liver cancer
	Chang MH. Recent Results Cancer Res. 2014;193:75-95. doi: 10.1007/978-3-642-38965-8_5.

605.	Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in china
	Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, Zhang S, Zhang Y, Bi S. J Virol. 2013 Nov;87(22):12196-206. doi: 10.1128/JVI.02127-13. Epub 2013 Sep 4.

606.	Safety and Efficacy of Protease Inhibitors to Treat Hepatitis C After Liver Transplantation, a Multicenter Experience
	Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haim-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallee JC. J Hepatol. 2013 Aug 29. pii: S0168-8278(13)00613-2. doi: 10.1016/j.jhep.2013.08.018. [Epub ahead of print]

607.	Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B
	Chao DC, Hu KQ. Drug Des Devel Ther. 2013 Aug 20;7:777-88. doi: 10.2147/DDDT.S33947.

608.	Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010
	Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. J Clin Virol. 2013 Oct;58(2):396-400. doi: 10.1016/j.jcv.2013.08.012. Epub 2013 Aug 16.

609.	Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up
	Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, Lan KH, Su CW, Chan WL, Lin HC, Lee FY, Wu JC. PLoS One. 2013 Aug 22;8(8):e72049. doi: 10.1371/journal.pone.0072049.

610.	Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus
	Zhang X, Zhang F, Wu D, Bao C, Zhu P, Zhang X, Huang C, He D, Tao Y, Fang Y, Gu J, Wu H, Sun L, Yang X, Huang F, Xu H, Zhao D, Zhang M, Zheng Y, Li Z. Int J Rheum Dis. 2013 Aug;16(4):408-12. doi: 10.1111/1756-185X.12125. Epub 2013 Jul 2.

611.	Hepatitis B virus-induced hepatocellular carcinoma
	Xu C, Zhou W, Wang Y, Qiao L. Cancer Lett. 2013 Aug 25. pii: S0304-3835(13)00610-1. doi: 10.1016/j.canlet.2013.08.035. [Epub ahead of print]

612.	Effect of occult hepatitis B virus infection on the early-onset of hepatocellular carcinoma in patients with hepatitis C virus infection
	Nakano M, Kawaguchi T, Nakamoto S, Kawaguchi A, Kanda T, Imazeki F, Kuromatsu R, Sumie S, Satani M, Yamada S, Torimura T, Kakuma T, Yokosuka O, Sata M. Oncol Rep. 2013 Nov;30(5):2049-55. doi: 10.3892/or.2013.2700. Epub 2013 Aug 27.

613.	HBV induced HCC: major risk factors from genetic to molecular level
	Ayub A, Ashfaq UA, Haque A. Biomed Res Int. 2013;2013:810461. doi: 10.1155/2013/810461. Epub 2013 Aug 7.

614.	Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance
	Seo SY, Kim IH, Sohn JY, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG. Intervirology. 2013 Aug 24. [Epub ahead of print]

615.	Effect of Tenofovir With and Without Interferon on Hepatitis D Virus Replication in HIV-Hepatitis B Virus-Hepatitis D Virus-Infected Patients
	Boyd A, Miailhes P, Brichler S, Scholtès C, Maylin S, Delaugerre C, Chevallier-Queyron P, Gordien E, Girard PM, Lacombe K. AIDS Res Hum Retroviruses. 2013 Sep 24. [Epub ahead of print]

616.	An assessment of the performance of self-reported vaccination status for hepatitis B, National Health and Nutrition Examination Survey 1999-2008
	Denniston MM, Byrd KK, Klevens RM, Drobeniuc J, Kamili S, Jiles RB. Am J Public Health. 2013 Oct;103(10):1865-73. doi: 10.2105/AJPH.2013.301313. Epub 2013 Aug 15.

617.	Screening for hepatitis B virus and hepatitis C virus at a community fair: a single-center experience
	Woo GA, Hill MA, de Medina MD, Schiff ER. Gastroenterol Hepatol (N Y). 2013 May;9(5):293-9.

618.	MicroRNAs may solve the mystery of chronic hepatitis B virus infection
	Wei YF, Cui GY, Ye P, Chen JN, Diao HY. World J Gastroenterol. 2013 Aug 14;19(30):4867-76. doi: 10.3748/wjg.v19.i30.4867.

619.	Expert recommendations on application of interferon for chronic hepatitis B
	Wan MB, Weng XH. J Dig Dis. 2013 Aug 23. doi: 10.1111/1751-2980.12096. [Epub ahead of print]

620.	Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
	Thiele M, Gluud LL, Dahl EK, Krag A. BMJ Open. 2013 Aug 14;3(8). pii: e003265. doi: 10.1136/bmjopen-2013-003265.

621.	Is HBsAg quantification ready, for prime time?
	Chevaliez S. Clin Res Hepatol Gastroenterol. 2013 Aug 7. pii: S2210-7401(13)00147-2. doi: 10.1016/j.clinre.2013.07.004. [Epub ahead of print]

622.	Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma
	Matsui T, Kang JH, Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Andoh S, Andoh S, Sakai H, Maemori M, Maguchi H, Tanaka Y. J Med Virol. 2013 Nov;85(11):1900-6. doi: 10.1002/jmv.23694. Epub 2013 Aug 7.

623.	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B
	Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Gut. 2013 Aug 31. doi: 10.1136/gutjnl-2013-305138. [Epub ahead of print]

624.	The Hepatitis B Vaccine Protects Re-Exposed Health Care Workers, But Does Not Provide Sterilizing Immunity
	Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. Gastroenterology. 2013 Jul 31. pii: S0016-5085(13)01134-7. doi: 10.1053/j.gastro.2013.07.044. [Epub ahead of print]

625.	Physicians infrequently adhere to hepatitis vaccination guidelines for chronic liver disease
	Thudi K, Yadav D, Sweeney K, Behari J. PLoS One. 2013 Jul 26;8(7):e71124. doi: 10.1371/journal.pone.0071124. Print 2013.

626.	Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England
	McPherson S, Valappil M, Moses SE, Eltringham G, Miller C, Baxter K, Chan A, Shafiq K, Saeed A, Qureshi R, Hudson M, Bassendine MF. J Viral Hepat. 2013 Sep;20(9):638-44. doi: 10.1111/jvh.12084. Epub 2013 Mar 12.

627.	Hepatitis B virus reverse transcriptase mutations in treatment Naïve chronic hepatitis B patients
	Singla B, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. J Med Virol. 2013 Jul;85(7):1155-62. doi: 10.1002/jmv.23608.

628.	Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
	Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Eur J Cancer. 2013 Nov;49(16):3486-3496. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.

629.	Nanoparticles encapsulating HBV-CpG induce therapeutic immunity against hepatitis B virus infection
	Lv S, Wang J, Dou S, Yang X, Ni X, Sun R, Tian Z, Wei H. Hepatology. 2013 Aug 1. doi: 10.1002/hep.26654. [Epub ahead of print]

630.	Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B
	Venkatesh SK, Wang G, Lim SG, Wee A. Eur Radiol. 2013 Aug 9. [Epub ahead of print]

631.	Hospitalizations due to hepatitis C in Los Angeles County, 2007-2009: case characteristics and factors associated with mortality
	Sie L, Gatto NM, Bancroft E. J Viral Hepat. 2013 Sep;20(9):628-37. doi: 10.1111/jvh.12086. Epub 2013 Mar 20.

632.	Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients
	Wang CC, Tseng TC, Wang PC, Lin HH, Kao JH. J Formos Med Assoc. 2013 Aug 1. pii: S0929-6646(13)00205-2. doi: 10.1016/j.jfma.2013.06.003. [Epub ahead of print]

633.	Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: A clinical study
	Ruan P, Xu SY, Zhou BP, Huang J, Gong ZJ. J Int Med Res. 2013 Oct;41(5):1732-1739. Epub 2013 Aug 1.

634.	Survey of Asian Patients with Hepatitis B Infection: Limited Knowledge of Transmission and Screening of Family Members
	Vijayan T, Zheng P, Nguyen C, Brown AM, Chen YW, Peters MG. J Immigr Minor Health. 2013 Aug 3. [Epub ahead of print]

635.	Why isn't evidence based practice improving health care for minorities in the United States?
	Lee H, Fitzpatrick JJ, Baik SY. Appl Nurs Res. 2013 Aug 5. pii: S0897-1897(13)00041-4. doi: 10.1016/j.apnr.2013.05.004. [Epub ahead of print]

636.	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation
	Leung VY, Shen J, Wong VW, Abrigo J, Wong GL, Chim AM, Chu SH, Chan AW, Choi PC, Ahuja AT, Chan HL, Chu WC. Radiology. 2013 Aug 2. [Epub ahead of print]

637.	Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B
	Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL. J Clin Invest. 2013 Sep 3;123(9):3728-39. doi: 10.1172/JCI68182. Epub 2013 Aug 8.

638.	Prognostic impact of telomere maintenance gene polymorphisms in hepatocellular carcinoma patients with chronic Hepatitis B
	Jung SW, Park NH, Shin JW, Park BR, Kim CJ, Lee JE, Shin ES, Kim JA, Chung YH. Hepatology. 2013 Aug 1. doi: 10.1002/hep.26655. [Epub ahead of print]

639.	Results of treatment of chronic hepatitis B with pegylated interferon
	Viganò M, Mangia G, Lampertico P. Clin Liver Dis. 2013 Aug;17(3):425-43. doi: 10.1016/j.cld.2013.05.004. Epub 2013 Jul 3.

640.	Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B
	Asselah T, Marcellin P. Clin Liver Dis. 2013 Aug;17(3):445-50. doi: 10.1016/j.cld.2013.05.001. Epub 2013 Jul 3.

641.	Impact of therapy on the long-term outcome of chronic hepatitis B
	Liaw YF. Clin Liver Dis. 2013 Aug;17(3):413-23. doi: 10.1016/j.cld.2013.05.005. Epub 2013 Jun 21.

642.	Hepatitis B in HIV-infected patients
	Soriano V, Poveda E, Vispo E, Barreiro P. Clin Liver Dis. 2013 Aug;17(3):489-501. doi: 10.1016/j.cld.2013.05.008. Epub 2013 Jul 8

643.	The importance of hemovigilance in the transmission of infectious diseases
	Martins PR, Martins RA, Barbosa Vde F, Pereira Gde A, Moraes-Souza H, Silva SS. Rev Bras Hematol Hemoter. 2013;35(3):180-4. doi: 10.5581/1516-8484.20130040.

644.	HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients
	Martinot-Peignoux M, Asselah T, Marcellin P. Clin Liver Dis. 2013 Aug;17(3):399-412. doi: 10.1016/j.cld.2013.05.006. Epub 2013 Jun 27.

645.	Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan
	Chen CT, Chen JY, Wang JH, Chang KC, Tseng PL, Kee KM, Chen PF, Tsai LS, Chen SC, Lin SC, Lu SN. Kaohsiung J Med Sci. 2013 Aug;29(8):451-9. doi: 10.1016/j.kjms.2012.12.006. Epub 2013 Feb 9.

646.	Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients
	Roche B, Samuel D. Clin Liver Dis. 2013 Aug;17(3):451-73. doi: 10.1016/j.cld.2013.05.003. Epub 2013 Jun 27.

647.	Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China
	Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, Tang X, Tan DM, Ren H, Tang H, Cohen D, Llamoso C. J Viral Hepat. 2013 May 29. doi: 10.1111/jvh.12115. [Epub ahead of print]

648.	Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
	Rongrui L, Na H, Zongfang L, Fanpu J, Shiwen J. Curr Pharm Des. 2013 Jul 19. [Epub ahead of print]

649.	Cost-effectiveness of questionnaires in preventing transfusion-transmitted infections
	de Kort W, van den Burg P, Geerligs H, Pasker-de Jong P, Marijt-van der Kreek T. Transfusion. 2013 Jul 25. doi: 10.1111/trf.12349. [Epub ahead of print]

650.	The current status of combination therapy of Chronic Hepatitis B
	Chen EQ, Tang H. Eur Rev Med Pharmacol Sci. 2013 Aug;17(15):2023-31.

651.	Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations
	Fuchs I, Abu-Shakra M, Sikuler E. Isr Med Assoc J. 2013 Jun;15(6):303-7.

652.	The natural course of chronic hepatitis B virus infection and its management
	Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. Adv Pharmacol. 2013;67:247-91. doi: 10.1016/B978-0-12-405880-4.00007-X.

653.	Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective
	Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B. J Clin Virol. 2013 Sep;58(1):67-73. doi: 10.1016/j.jcv.2013.06.035. Epub 2013 Jul 20.

654.	Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis
	Feuth T, Arends JE, Lieveld FI, Mundt MW, Hoepelman AI, Siersema PD, van Erpecum KJ. Scand J Gastroenterol. 2013 Sep;48(9):1074-81. doi: 10.3109/00365521.2013.819441. Epub 2013 Jul 25.

655.	Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
	Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F. J Hepatol. 2013 Jul 18. pii: S0168-8278(13)00528-X. doi: 10.1016/j.jhep.2013.07.017. [Epub ahead of print]

656.	Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis
	Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R. PLoS One. 2013 Jul 10;8(7):e68152. doi: 10.1371/journal.pone.0068152. Print 2013.

657.	Association of treatment and outcomes of doctor-shopping behavior in patients with hepatocellular carcinoma
	Hsieh CI, Chung KP, Yang MC, Li TC. Patient Prefer Adherence. 2013 Jul 11;7:693-701. doi: 10.2147/PPA.S43631. Print 2013.

658.	RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B
	Chen B, Ye B, Zhang J, Ying L, Chen Y.

659.	Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies
	Xu JH, Fu JJ, Wang XL, Zhu JY, Ye XH, Chen SD.

660.	Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection
	Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH. PLoS One. 2013 Jul 17;8(7):e69166. doi: 10.1371/journal.pone.0069166. Print 2013.

661.	Imbalance between circulating CD4+ regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure
	Dong X, Gong Y, Zeng H, Hao Y, Wang X, Hou J, Wang J, Li J, Zhu Y, Liu H, Han J, Zhou H, Shen L, Gao T, Zhou T, Yang S, Li S, Chen Y, Meng Q, Li H. Liver Int. 2013 Jun 19. doi: 10.1111/liv.12248. [Epub ahead of print]

662.	A Chinese Medicine, Kuan-Sin-Yin Decoction, Improves Liver Function in Hepatitis B Virus Carriers: A Randomized, Controlled Study
	Lee CJ, Cheng CH, Li YH, Liu CY, Hsu CH. J Altern Complement Med. 2013 Jul 17. [Epub ahead of print]

663.	Too much of a good thing? When to stop catch-up vaccination
	Hutton DW, Brandeau ML. Med Decis Making. 2013 Oct;33(7):920-36. doi: 10.1177/0272989X13493142. Epub 2013 Jul 15.

664.	Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection
	Wang L, Chen H, Fan C, Gong Z. J Med Virol. 2013 Nov;85(11):1907-12. doi: 10.1002/jmv.23689. Epub 2013 Jul 12.

665.	Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome
	Aung MN, Leowattana W, Win KN, Tangpukdee N, Muangnoicharoen S. J Infect Dev Ctries. 2013 Jul 15;7(7):541-9. doi: 10.3855/jidc.2759.

666.	Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B
	Morita S, Matsumoto A, Umemura T, Shibata S, Kamijo N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Yoshizawa K, Tanaka E. Hepatol Res. 2013 Jul 16. doi: 10.1111/hepr.12208. [Epub ahead of print]

667.	Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach
	Schiffer JT, Swan DA, Stone D, Jerome KR. PLoS Comput Biol. 2013 Jul;9(7):e1003131. doi: 10.1371/journal.pcbi.1003131. Epub 2013 Jul 4.

668.	A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection
	Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozgune? N, Colak O, Gunduz A, Senates E, Ozaras R, Inci A, Tabak F. Wien Klin Wochenschr. 2013 Aug;125(15-16):453-460. Epub 2013 Jul 17.

669.	Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
	Lin MT, Chou YP, Hu TH, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW. Arch Virol. 2013 Jul 16. [Epub ahead of print]

670.	Safety and efficacy of hepatitis B vaccination in cirrhosis of liver
	Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Adv Virol. 2013;2013:196704. doi: 10.1155/2013/196704. Epub 2013 Jun 6.

671.	Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients
	Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G, Xu Q. PLoS One. 2013 Jul 3;8(7):e68568. doi: 10.1371/journal.pone.0068568. Print 2013.

672.	Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues
	Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G. Liver Transpl. 2013 Jul 15. doi: 10.1002/lt.23703. [Epub ahead of print]

673.	Impact of HBV Integration Into Liver Tissue on the Efficacy of Peginterferon and Ribavirin Therapy in Hepatitis B Virus-negative Chronic Hepatitis C Patients
	Toyoda H, Kumada T, Tada T, Murakami Y. J Clin Gastroenterol. 2013 Jul 8. [Epub ahead of print]

674.	Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma
	Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME, Hiotis SP. Br J Cancer. 2013 Aug 6;109(3):573-81. doi: 10.1038/bjc.2013.352. Epub 2013 Jul 11.

675.	Frequent Emergency Department Visits are More Prevalent in Psychiatric, Alcohol Abuse, and Dual Diagnosis Conditions than in Chronic Viral Illnesses Such as Hepatitis and Human Immunodeficiency Virus
	Minassian A, Vilke GM, Wilson MP. J Emerg Med. 2013 Jul 8. pii: S0736-4679(13)00467-8. doi: 10.1016/j.jemermed.2013.05.007. [Epub ahead of print]

676.	Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1)
	Zhang X, Xing H, Feng X, Zhang H, Wang Y, Yan H. Virol J. 2013 Jul 12;10(1):232. [Epub ahead of print]

677.	The reliability of HBV core antibody in serological screening for hepatitis B virus
	Ba Alawi F, Robertson PW, LePage AK, Jayamaha J, Baleriola C, Rawlinson WD. Pathology. 2013 Aug;45(5):501-5. doi: 10.1097/PAT.0b013e3283631cf9.

678.	Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations
	Yang JH, Zhang H, Chen XB, Chen G, Wang X. World J Gastroenterol. 2013 Jun 28;19(24):3861-5. doi: 10.3748/wjg.v19.i24.3861.

679.	Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
	Rehermann B. Nat Med. 2013 Jul;19(7):859-68. doi: 10.1038/nm.3251.

680.	Gaps in Pre-rituximab Hepatitis B Screening: An Institutional Experience
	Abbi KK, Gorris M, Skeel RT. Am J Ther. 2013 Jun 28. [Epub ahead of print]

681.	Chronic hepatitis B--what's new?
	MacLachlan J, Cowie B. Aust Fam Physician. 2013 Jul;42(7):448-51.

682.	Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B
	Maier M, Liebert UG, Wittekind C, Kaiser T, Berg T, Wiegand J. PLoS One. 2013 Jun 27;8(6):e67481. Print 2013.

683.	Role of viral genotypes and hepatitis B viral mutants in the risk of hepatocellular carcinoma associated with hepatitis B and C dual infection
	Hung CH, Chen CH, Lee CM, Hu TH, Lu SN, Wang JH, Huang CM. Intervirology. 2013;56(5):316-24. doi: 10.1159/000350738. Epub 2013 Jul 2.

684.	Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
	Jun DW, Kim BI, Cho YK, Kim HJ, Kwon YO, Park SY, Han SY, Baek YH, Jung YJ, Kim HY, Kim W, Heo J, Woo HY, Hwang SG, Rim KS, Choi JY, Bae SH, Lee YS, Lim YS, Cheong JY, Cho SW, Lee BS, Kim SH, Sohn JH, Kim TY, Paik YH, Kim JK, Lee KS. Clin Mol Hepatol. 2013 Jun;19(2):165-72. doi: 10.3350/cmh.2013.19.2.165. Epub 2013 Jun 27.

685.	Therapeutic advances in the management of chronic hepatitis B infection
	Brooks J, Gelson W, Rushbrook SM. Ther Adv Chronic Dis. 2013 Jul;4(4):157-66. doi: 10.1177/2040622313484647.

686.	Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years
	Liu B, Wen X, Huang C, Wei Y. Int J Biochem Cell Biol. 2013 Sep;45(9):1987-96. doi: 10.1016/j.biocel.2013.06.017. Epub 2013 Jun 29.

687.	Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns
	Shrivastava S, TrehanPati N, Patra S, Kottilil S, Pande C, Trivedi SS, Sarin SK. J Viral Hepat. 2013 Aug;20(8):582-91. doi: 10.1111/jvh.12078. Epub 2013 Feb 14.

688.	Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma
	Bayliss J, Lim L, Thompson AJ, Desmond P, Angus P, Locarnini S, Revill PA. J Hepatol. 2013 Jun 25. pii: S0168-8278(13)00434-0. doi: 10.1016/j.jhep.2013.06.018. [Epub ahead of print]

689.	Prophylaxis of hepatitis B infection in solid organ transplant recipients
	John S, Andersson KL, Kotton CN, Hertl M, Markmann JF, Cosimi AB, Chung RT. Therap Adv Gastroenterol. 2013 Jul;6(4):309-19. doi: 10.1177/1756283X13487942.

690.	Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies
	Dalia S, Chavez J, Castillo JJ, Sokol L. Leuk Res. 2013 Sep;37(9):1107-15. doi: 10.1016/j.leukres.2013.06.007. Epub 2013 Jun 26.

691.	Identification of ?-taxilin as an essential factor for the life cycle of hepatitis B virus
	Hoffmann J, Boehm C, Himmelsbach K, Donnerhak C, Roettger H, Weiss TS, Ploen D, Hildt E. J Hepatol. 2013 Jun 28. pii: S0168-8278(13)00437-6. doi: 10.1016/j.jhep.2013.06.020. [Epub ahead of print]

692.	Occult hepatitis B in patients on hemodialysis: a review
	Fontenele AM, Filho NS, Ferreira AS. Ann Hepatol. 2013 Jul-Aug;12(4):527-31.

693.	Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen-negative Patients With Chronic Hepatitis
	Sanai FM, Babatin MA, Bzeizi KI, Alsuhaibani F, Al-Hamoudi W, Alsaad KS, Almana H, Handoo FA, Al-Ashgar H, Alghamdi H, Ibrahim A, Aljumah A, Alalwan A, Altraif IH, Al-Hussaini H, Myers RP, Abdo AA. Clin Gastroenterol Hepatol. 2013 Jun 28. pii: S1542-3565(13)00876-8. doi: 10.1016/j.cgh.2013.05.038. [Epub ahead of print]

694.	As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3? pathway
	Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y, Wu D. Oncogene. 2013 Jul 1. doi: 10.1038/onc.2013.236. [Epub ahead of print]

695.	Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir
	Kim MN, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Ahn SH. J Clin Gastroenterol. 2013 Jun 26. [Epub ahead of print]

696.	Demographic and serological characteristics of Asian Americans with hepatitis B infection diagnosed at community screenings
	Xu JJ, Tien C, Chang M, Rhee J, Tien A, Bae HS, Ho FC, Chan LS, Fong TL. J Viral Hepat. 2013 Aug;20(8):575-81. doi: 10.1111/jvh.12073. Epub 2013 Mar 25.

697.	Normal vitamin D levels are associated with spontaneous hepatitis B surface antigen seroclearance
	Mahamid M, Nseir W, Abu Elhija O, Shteingart S, Mahamid A, Smamra M, Koslowsky B. World J Hepatol. 2013 Jun 27;5(6):328-31. doi: 10.4254/wjh.v5.i6.328.

698.	The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy
	Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC. PLoS One. 2013 Jun 21;8(6):e66457. Print 2013.

699.	Ultrasensitive Amplification Refractory Mutation System Real-Time PCR (ARMS RT-PCR) Assay for Detection of Minority Hepatitis B Virus-Resistant Strains in the Era of Personalized Medicine
	Ntziora F, Paraskevis D, Haida C, Manesis E, Papatheodoridis G, Manolakopoulos S, Elefsiniotis I, Karamitros T, Vassilakis A, Hatzakis A. J Clin Microbiol. 2013 Sep;51(9):2893-900. doi: 10.1128/JCM.00936-13. Epub 2013 Jun 26.

700.	Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection
	Chen F, He JL, Zheng M, Zhu HH, Li SP, Wang K, Zhang XX, Zhao YR, Wu SS, Chen Z. J Viral Hepat. 2013 Aug;20(8):566-74. doi: 10.1111/jvh.12067. Epub 2013 Feb 6.

701.	Correlation between interleukin?23 receptor gene polymorphisms and risk of hepatitis B virus infection in patients
	Peng Q, Qin Y, Chen Z, Deng Y, Xu J, Li S, Qin X. Mol Med Rep. 2013 Aug;8(2):613-20. doi: 10.3892/mmr.2013.1558. Epub 2013 Jun 26.

702.	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen - a prospective cohort study with paired transient elastography examination
	Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12312. [Epub ahead of print]

703.	Fibroscan can avoid liver biopsy in Indian patients with Chronic Hepatitis B
	Goyal R, Mallick SR, Mahanta M, Kedia S, Shalimar, Dhingra R, Sharma H, Das P, Gupta SD, Panda S, Acharya SK. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12318. [Epub ahead of print]

704.	Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients
	Kim BK, Ko SY, Kwon SY, Park E, Kim JH, Choe WH, Lee CH. Hepat Mon. 2013 Apr 1;13(4):e6056. doi: 10.5812/hepatmon.6056. Print 2013 Apr.

705.	Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis
	Zheng Y, Zhang S, Tan Grahn HM, Ye C, Gong Z, Zhang Q. Hepat Mon. 2013 Apr 1;13(4):e6496. doi: 10.5812/hepatmon.6496. Print 2013 Apr.

706.	Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress
	Peng G. Scand J Immunol. 2013 Jun 24. doi: 10.1111/sji.12086. [Epub ahead of print]

707.	Living related liver Transplant in hepatitis B related liver disease without Hepatitis B Immunoglobulin prophylaxis
	Wadhawan M, Goyal S, Goyal N, Taneja S, Kumar A. Liver Transpl. 2013 Jun 21. doi: 10.1002/lt.23692. [Epub ahead of print]

708.	Serum HBsAg Quantification as a useful assessment for significant fibrosis in HBeAg positive hepatitis B virus carriers
	Xun YH, Zang GQ, Guo JC, Yu XL, Liu H, Xiang J, Liu J, Shi JP. J Gastroenterol Hepatol. 2013 Jun 25. doi: 10.1111/jgh.12304. [Epub ahead of print]

709.	HBV genotype F: natural history and treatment
	Marciano S, Galdame OA, Gadano AC. Antivir Ther. 2013;18(3 Pt B):485-8. doi: 10.3851/IMP2604. Epub 2013 Jun 21.

710.	Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
	Chen GY, Su TH, Kao JH. J Formos Med Assoc. 2013 Jun 20. pii: S0929-6646(13)00178-2. doi: 10.1016/j.jfma.2013.05.011. [Epub ahead of print]

711.	Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy
	Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY. BMC Cancer. 2013 Jun 24;13:306. doi: 10.1186/1471-2407-13-306.

712.	Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis
	Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. World J Gastroenterol. 2013 Jun 14;19(22):3481-6. doi: 10.3748/wjg.v19.i22.3481.

713.	Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development
	Ringelhan M, Heikenwalder M, Protzer U. Dig Dis. 2013;31(1):138-51. doi: 10.1159/000347209. Epub 2013 Jun 17.

714.	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment
	Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. J Hepatol. 2013 Jun 17. pii: S0168-8278(13)00417-0. doi: 10.1016/j.jhep.2013.06.007. [Epub ahead of print]

715.	Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma
	Wei Q, Xu X, Ling Q, Zhou B, Zheng SS. Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):251-5.

716.	Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients
	Lü W, Yang HH, Fan YM, Li T, Zhang LF, Mui C, Fan HW, Zhou BT, Liu ZY, Ng H, Liu XQ. Chin Med J (Engl). 2013 Jun;126(12):2333-6.

717.	Hepatitis B viral factors and treatment responses in chronic hepatitis B
	Lin CL, Kao JH. J Formos Med Assoc. 2013 Jun;112(6):302-11. doi: 10.1016/j.jfma.2013.02.001. Epub 2013 Mar 17.

718.	Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing
	Han Y, Zhang Y, Mei Y, Wang Y, Liu T, Guan Y, Tan D, Liang Y, Yang L, Yi X. J Virol Methods. 2013 Jun 14;193(2):341-347. doi: 10.1016/j.jviromet.2013.06.015. [Epub ahead of print]

719.	Association between the hepatitis B and C viruses and metabolic diseases in patients stratified by age
	Li WC, Lee YY, Chen IC, Sun C, Chiu FH, Chuang CH. Liver Int. 2013 May 20. doi: 10.1111/liv.12224. [Epub ahead of print]

720.	Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection
	Perrakis A, Förtsch T, Del Medico A, Croner RS, Vassos N, Yedibela S, Lohmüller C, Zopf S, Hohenberger W, Müller V. Transplant Proc. 2013 Jun;45(5):1953-6. doi: 10.1016/j.transproceed.2012.11.020.

721.	Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou Criteria
	Gao T, Xia Q, Qiu DK, Feng YY, Chi JC, Wang SY, Xi ZF, Zhang JJ, Xu N, Chen SY, Qiu YL, Shen LW, Zhou TT, Dong XJ, Li QG, Li H. J Dig Dis. 2013 Jun 19. doi: 10.1111/1751-2980.12083. [Epub ahead of print]

722.	Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival
	Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CH, Gamblin TC. HPB (Oxford). 2013 Jun 19. doi: 10.1111/hpb.12134. [Epub ahead of print]

723.	Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B
	Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC, Llamoso C. Liver Transpl. 2013 Aug;19(8):887-95. doi: 10.1002/lt.23690.

724.	Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B
	Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. J Clin Oncol. 2013 Aug 1;31(22):2765-72. doi: 10.1200/JCO.2012.48.5938. Epub 2013 Jun 17.

725.	The Efficacy and Safety of Nucleos(t)ide Analogues in Patients with Spontaneous Acute Exacerbation of Chronic Hepatitis B: A Systematic Review and Meta-Analysis
	Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. PLoS One. 2013 Jun 11;8(6):e65952. doi: 10.1371/journal.pone.0065952. Print 2013.

726.	Molecular mechanisms of HBV-associated hepatocarcinogenesis
	Guerrieri F, Belloni L, Pediconi N, Levrero M. Semin Liver Dis. 2013 May;33(2):147-56. doi: 10.1055/s-0033-1345721. Epub 2013 Jun 8.

727.	Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels
	Loggi E, Bihl FK, Cursaro C, Granieri C, Galli S, Brodosi L, Furlini G, Bernardi M, Brander C, Andreone P. PLoS One. 2013 Jun 4;8(6):e65327. doi: 10.1371/journal.pone.0065327. Print 2013.

728.	Topographical Impact of Hepatitis B-related Hepatocellular Carcinoma on Local Recurrence After Radiofrequency Ablation
	Kim JS, Kim W, So YH, Yu SJ, Kim BG. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]

729.	Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
	Abu-Amara M, Feld JJ. Semin Liver Dis. 2013 May;33(2):157-66. doi: 10.1055/s-0033-1345719. Epub 2013 Jun 8.

730.	Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study
	Fang J, Li W, Tan Z, Li D. Int Urol Nephrol. 2013 Jun 12. [Epub ahead of print]

731.	Immunosuppression and HBV reactivation
	Shouval D, Shibolet O. Semin Liver Dis. 2013 May;33(2):167-77. doi: 10.1055/s-0033-1345722. Epub 2013 Jun 8.

732.	Antiviral therapy for chronic hepatitis B in pregnancy
	Pan CQ, Lee HM. Semin Liver Dis. 2013 May;33(2):138-46. doi: 10.1055/s-0033-1345718. Epub 2013 Jun 8.

733.	Past Exposure to Hepatitis B: A Risk Factor for Increase in Mortality?
	Jinjuvadia R, Liangpunsakul S, Antaki F. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]

734.	Resolving ambiguity in the phylogenetic relationship of genotypes A, B, and C of hepatitis B virus
	Jiang Y, Wang M, Zheng H, Wang WR, Jin L, He Y. BMC Evol Biol. 2013 Jun 11;13:120. doi: 10.1186/1471-2148-13-120.

735.	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B
	Kim YJ, Young Kim H, Lee JH, Jong Yu S, Yoon JH, Lee HS, Yong Kim C, Youn Cheong J, Won Cho S, Hwa Park N, Lae Park B, Namgoong S, Hyo Kim L, Sub Cheong H, Doo Shin H. Hum Mol Genet. 2013 Jun 26. [Epub ahead of print]

736.	Chronic hepatitis B: a treatment update
	Wong V, Chan H. Semin Liver Dis. 2013 May;33(2):122-9. doi: 10.1055/s-0033-1345715. Epub 2013 Jun 8.

737.	Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B
	Su ZJ, Yu XP, Guo RY, Ming DS, Huang LY, Su ML, Deng Y, Lin ZZ. Diagn Microbiol Infect Dis. 2013 Aug;76(4):437-44. doi: 10.1016/j.diagmicrobio.2013.04.026. Epub 2013 Jun 7.

738.	A trivial role of STAT4 variant in chronic hepatitis B induced hepatocellular carcinoma
	Clark A, Gerlach F, Tong HV, Hoan NX, Song LH, Toan NL, Bock CT, Kremsner PG, Velavan TP. Infect Genet Evol. 2013 Jun 6;18C:257-261. doi: 10.1016/j.meegid.2013.05.025. [Epub ahead of print]

739.	Reduced Toll-like receptor-3 expression in chronic hepatitis B patients and its restoration by interferon therapy
	Huang YW, Lin SC, Wei SC, Hu JT, Chang HY, Huang SH, Chen DS, Chen PJ, Hsu PN, Yang SS, Kao JH. Antivir Ther. 2013 Jun 6. doi: 10.3851/IMP2630. [Epub ahead of print]

740.	Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine
	Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M. Hum Vaccin Immunother. 2013 Jun 6;9(8). [Epub ahead of print]

741.	Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma
	Sitia G, Iannacone M, Guidotti LG. J Hepatol. 2013 Jun 3. pii: S0168-8278(13)00373-5. doi: 10.1016/j.jhep.2013.05.040. [Epub ahead of print]

742.	New therapeutic targets and drugs for the treatment of chronic hepatitis B
	Fletcher SP, Delaney WE 4th. Semin Liver Dis. 2013 May;33(2):130-7. doi: 10.1055/s-0033-1345713. Epub 2013 Jun 8.

743.	The molecular virology of hepatitis B virus
	Glebe D, Bremer CM. Semin Liver Dis. 2013 May;33(2):103-12. doi: 10.1055/s-0033-1345717. Epub 2013 Jun 8.

744.	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues
	Wong GL, Chan HL, Lo AO, Chan HY, Tse CH, Chim AM, Wong VW. Antivir Ther. 2013 Jun 5. doi: 10.3851/IMP2615. [Epub ahead of print]

745.	Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes a to j
	Liu CJ, Kao JH. Semin Liver Dis. 2013 May;33(2):97-102. doi: 10.1055/s-0033-1345716. Epub 2013 Jun 8.

746.	Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients
	Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. Hepatology. 2013 Jun 6. doi: 10.1002/hep.26549. [Epub ahead of print]

747.	Similar evolution of Hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy
	Lavocat F, Dény P, Pichoud C, Hawajri NA, Kitrinos K, Borroto-Esoda K, Zoulim F. J Hepatol. 2013 Jun 3. pii: S0168-8278(13)00371-1. doi: 10.1016/j.jhep.2013.05.038. [Epub ahead of print]

748.	Albumin Fusion of Interleukin-28B: Production and Characterization of Its Biological Activities and Protein Stability
	Zhao J, Si Y, Cheng M, Yang Y, Niu Y, Li X, Liu X, Yang W. PLoS One. 2013 May 31;8(5):e64301. doi: 10.1371/journal.pone.0064301. Print 2013.

749.	Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents
	Wu TW, Chu CC, Ho TY, Chang Liao HW, Lin SK, Lin M, Lin HH, Wang LY. Hum Genet. 2013 Jun 6. [Epub ahead of print]

750.	Editorial: Prophylaxis in HBV-Infected Liver Transplant Patients: End of the HBIG Era?
	Terrault N. Am J Gastroenterol. 2013 Jun;108(6):949-51. doi: 10.1038/ajg.2013.122.

751.	Acute hepatitis B outbreaks in 2 skilled nursing facilities and possible sources of transmission: north Carolina, 2009-2010
	Seña AC, Moorman A, Njord L, Williams RE, Colborn J, Khudyakov Y, Drobenuic J, Xia GL, Wood H, Moore Z. Infect Control Hosp Epidemiol. 2013 Jul;34(7):709-16. doi: 10.1086/670996. Epub 2013 May 16.

752.	The potential of 1018 ISS adjuvant in hepatitis B vaccines: Introduction
	Eng NF, Bhardwaj N, Mulligan R, Diaz-Mitoma F. Hum Vaccin Immunother. 2013 May 31;9(8). [Epub ahead of print]

753.	Trends in Utilization of Transarterial Treatments for Hepatocellular Carcinoma: Results of a Survey by the Italian Society of Interventional Radiology
	Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Cardiovasc Intervent Radiol. 2013 May 30. [Epub ahead of print]

754.	Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues
	Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A. J Viral Hepat. 2013 Jul;20(7):502-9. doi: 10.1111/jvh.12054. Epub 2013 Feb 6.

755.	The Metabolomic Window into Hepatobiliary Disease
	Beyo?lu D, Idle JR. J Hepatol. 2013 May 25. pii: S0168-8278(13)00362-0. doi: 10.1016/j.jhep.2013.05.030. [Epub ahead of print]

756.	Hepatitis B Knowledge, Screening, and Vaccination among Hmong Americans
	Kue J, Thorburn S. J Health Care Poor Underserved. 2013;24(2):566-78. doi: 10.1353/hpu.2013.0081.

757.	Differential roles of serum HBV DNA and HBsAg level in predicting virological breakthrough in patients receiving lamivudine therapy
	Su CW, Wu CY, Hung HH, Wu CH, Sheen IJ, Wu JC. J Gastroenterol Hepatol. 2013 Jun 4. doi: 10.1111/jgh.12283. [Epub ahead of print]

758.	Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B
	Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. J Clin Virol. 2013 Aug;57(4):323-30. doi: 10.1016/j.jcv.2013.04.012. Epub 2013 Jun 2.

759.	Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection
	Spradling PR, Simons B, Narayanan M, Xing J, Homan C, Bulkow L, Cagle H, Schraer CD, McMahon BJ. J Viral Hepat. 2013 Jul;20(7):510-3. doi: 10.1111/jvh.12071. Epub 2013 Mar 25.

760.	Role of serum dehydroepiandrosterone sulfate level on the clearance of chronic hepatitis B virus infection
	Wu JF, Tsai WY, Tung YC, Chen HL, Ni YH, Hsu HY, Chang MH. J Gastroenterol. 2013 Jun 1. [Epub ahead of print]

761.	Hepatitis B virus reactivation associated with atorvastatin
	Wu DC. Int J Infect Dis. 2013 May 29. pii: S1201-9712(13)00169-0. doi: 10.1016/j.ijid.2013.04.001. [Epub ahead of print]

762.	Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: A 20-year follow-up study in Thailand
	Poovorawan Y, Chongsrisawat V, Theamboonlers A, Crasta PD, Messier M, Hardt K. Hum Vaccin Immunother. 2013 May 31;9(8). [Epub ahead of print]

763.	Deceased Organ Donor Screening for HIV, Hepatitis B, and Hepatitis C Viruses: A Survey of Organ Procurement Organization Practices
	Theodoropoulos N, Jaramillo A, Ladner DP, Ison MG. Am J Transplant. 2013 May 24. doi: 10.1111/ajt.12260. [Epub ahead of print]

764.	Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice
	Xu XH, Li GL, Qin Y, Li Q, He FQ, Li JY, Pan QR, Deng JY. Virol J. 2013 May 25;10(1):162. [Epub ahead of print]

765.	Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: A meta-analysis
	Qu LS, Liu JX, Kuai XL, Xu ZF, Jin F, Zhou GX. Hepatol Res. 2013 May 27. doi: 10.1111/hepr.12172. [Epub ahead of print]

766.	Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B
	Kim do Y, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Gut Liver. 2013 May;7(3):329-34. doi: 10.5009/gnl.2013.7.3.329. Epub 2013 Apr 9.

767.	Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association
	Hope VD, Eramova I, Capurro D, Donoghoe MC. Epidemiol Infect. 2013 May 29:1-17. [Epub ahead of print]

768.	Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
	Singal AK, Salameh H, Kuo YF, Fontana RJ. Aliment Pharmacol Ther. 2013 Jul;38(2):98-106. doi: 10.1111/apt.12344. Epub 2013 May 28.

769.	Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores
	Hsu CW, Liang KH, Huang SF, Tsao KC, Yeh CT. BMC Res Notes. 2013 May 27;6:212. doi: 10.1186/1756-0500-6-212.

770.	Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus
	Hu Y, Chen J, Wen J, Xu C, Zhang S, Xu B, Zhou YH. BMC Pregnancy Childbirth. 2013 May 24;13(1):119. [Epub ahead of print]

771.	Challenges in Cancer Vaccine Development for Hepatocellular Carcinoma
	Buonaguro L, Petrizzo A, Tagliamonte M, Lina Tornesello M, Buonaguro FM. J Hepatol. 2013 May 25. pii: S0168-8278(13)00363-2. doi: 10.1016/j.jhep.2013.05.031. [Epub ahead of print]

772.	Differences in metabolites of different tongue coatings in patients with chronic hepatitis B
	Zhao Y, Gou XJ, Dai JY, Peng JH, Feng Q, Sun SJ, Cao HJ, Zheng NN, Fang JW, Jiang J, Su SB, Liu P, Hu YY, Zhang YY. Evid Based Complement Alternat Med. 2013;2013:204908. doi: 10.1155/2013/204908. Epub 2013 Apr 17.

773.	Progression from Excessive to Deficient Syndromes in Chronic Hepatitis B: A Dynamical Network Analysis of miRNA Array Data
	Chen QL, Lu YY, Zhang GB, Song YN, Zhou QM, Zhang H, Zhang W, Su SB. Evid Based Complement Alternat Med. 2013;2013:945245. doi: 10.1155/2013/945245. Epub 2013 Apr 16.

774.	Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus
	Zhang L, Gui X, Fan J, Wang B, Ji H, Yisilafu R, Li F, Zhou Y, Tong Y, Kong X, Ye P, Zong L. J Matern Fetal Neonatal Med. 2013 Jun 20. [Epub ahead of print]

775.	Comparison of the AdvanSure HBV Real-time PCR Test with Three Other HBV DNA Quantification Assays
	Kim H, Shin S, Oh EJ, Kahng J, Kim Y, Lee HK, Kwon HJ. Ann Clin Lab Sci. 2013 Spring;43(2):230-7.

776.	Partial virological response to adefovir add-on Lamivudine rescue therapy in patients with Lamivudine-resistant chronic hepatitis B
	Chon YE, Park JY, Ahn SH, Kim do Y, Han KH, Chon CY, Choi A, Kim SU. Digestion. 2013;87(3):196-203. doi: 10.1159/000348853. Epub 2013 May 9.

777.	High Levels of HBV after the Onset Lead to Chronic Infection in Patients with Acute Hepatitis B
	Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, Mizokami M, Miyakawa Y, Koike K. Clin Infect Dis. 2013 May 23. [Epub ahead of print]

778.	Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings
	Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Xu J, Yuan ZH, Wang B, Zhao K, Wen YM; for the YIC Efficacy Trial Study Team. J Hepatol. 2013 May 11. pii: S0168-8278(13)00295-X. doi: 10.1016/j.jhep.2013.05.003. [Epub ahead of print]

779.	Treatment of patients with dual hepatitis C and B by peginterferon ? and ribavirin reduced risk of hepatocellular carcinoma and mortality
	Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Gut. 2013 May 15. [Epub ahead of print]

780.	Association between cytotoxic T-lymphocyte associated protein 4 gene +49 A/G polymorphism and chronic infection with hepatitis B virus: A meta-analysis
	Xu H, Zhao M, He J, Chen Z. J Int Med Res. 2013 Jun;41(3):559-67. doi: 10.1177/0300060513483387. Epub 2013 May 13.

781.	Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy
	Liaw YF. J Hepatol. 2013 May 11. pii: S0168-8278(13)00333-4. doi: 10.1016/j.jhep.2013.05.007. [Epub ahead of print]

782.	Notes from the field: transmission of HBV among assisted-living-facility residents - virginia, 2012
	Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 May 17;62(19):389.

783.	A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study
	Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH. Clin Microbiol Infect. 2013 May 10. doi: 10.1111/1469-0691.12220. [Epub ahead of print]

784.	Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours
	Ling WH, Soe PP, Pang AS, Lee SC. Br J Cancer. 2013 May 28;108(10):1931-5. doi: 10.1038/bjc.2013.225. Epub 2013 May 7.

785.	Association of polymorphisms in the interleukin-4 gene with response to hepatitis B vaccine and susceptibility to hepatitis B virus infection: A meta-analysis
	Cui W, Sun CM, Deng BC, Liu P. Gene. 2013 Aug 1;525(1):35-40. doi: 10.1016/j.gene.2013.04.065. Epub 2013 May 4.

786.	The comparison of the efficacy of pegylated interferon ?-2a and ?-2b in chronic hepatitis B patients
	Dogan UB, Golge N, Akin MS. Eur J Gastroenterol Hepatol. 2013 May 4. [Epub ahead of print]

787.	Treatment and non-treatment related ocular manifestations in patients with chronic hepatitis B or C
	Tsoumani A, Theopistos V, Katsanos K, Asproudis I, Tsianos EV. Eur Rev Med Pharmacol Sci. 2013 Apr;17(8):1123-31.

788.	Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection
	Biswas S, Candotti D, Allain JP. J Virol. 2013 May 8. [Epub ahead of print]

789.	Management of Hepatitis B: My Practice and how it relates to the Guidelines
	Yapali S, Talaat N, Lok AS. Clin Gastroenterol Hepatol. 2013 May 6. pii: S1542-3565(13)00606-X. doi: 10.1016/j.cgh.2013.04.036. [Epub ahead of print]

790.	Antiviral activity of Bifidobacterium adolescentis SPM0212 against Hepatitis B virus
	Lee DK, Kang JY, Shin HS, Park IH, Ha NJ. Arch Pharm Res. 2013 May 9. [Epub ahead of print]

791.	Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B
	Zhu X, Gong Q, Yu D, Zhang D, Gu L, Han Y, Chen J, Zhang Y, Zhang X. J Clin Virol. 2013 Apr 29. pii: S1386-6532(13)00123-6. doi: 10.1016/j.jcv.2013.04.003. [Epub ahead of print]

792.	Cesarean Section Reduces Perinatal Transmission of HBV Infection from Hepatitis B Surface Antigen-Positive Women to Their Infants
	Pan CQ, Zou HB, Chen Y, Zhang X, Zhang H, Li J, Duan Z. Clin Gastroenterol Hepatol. 2013 Apr 29. pii: S1542-3565(13)00586-7. doi: 10.1016/j.cgh.2013.04.026. [Epub ahead of print]

793.	High Prevalence of Occult Hepatitis C Virus Infection in Patients with Chronic Hepatitis B Virus Infection
	Castillo I, Bartolomé J, Quiroga JA, Carreño V. J Med Microbiol. 2013 May 2. [Epub ahead of print]

794.	Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B
	Zhang L, Hao CQ, Liu JF, Wang M. Virol J. 2013 Apr 29;10:134. doi: 10.1186/1743-422X-10-134.

795.	Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir
	Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW. Antivir Ther. 2013 May 2. doi: 10.3851/IMP2580. [Epub ahead of print]

796.	Education Provides Significant Benefits to Patients with Hepatitis B Virus or Hepatitis C Virus Infection: A Systematic Review
	Shah HA, Abu-Amara M. Clin Gastroenterol Hepatol. 2013 Apr 29. pii: S1542-3565(13)00584-3. doi: 10.1016/j.cgh.2013.04.024. [Epub ahead of print]

797.	Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma
	Nishikawa H, Osaki Y, Arimoto A, Kita R, Kimura T. Anticancer Res. 2013 May;33(5):2211-9.

798.	Virologic response during up to 2 years of entecavir plus adefovir combination therapy in multiple drug-refractory chronic hepatitis B patients: A Randomized Trial.
	Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Antimicrob Agents Chemother. 2013 May 6. [Epub ahead of print]

799.	The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area
	Jang ES, Jeong SH, Lee SH, Hwang SH, Ahn SY, Lee J, Park YS, Hwang JH, Kim JW, Kim N, Lee DH, Kim HY. Liver Int. 2013 Apr 4. doi: 10.1111/liv.12186. [Epub ahead of print]

800.	Prevalence of occult hepatitis B virus infection in hemodialysis patients
	Yoo JH, Hwang SG, Yang DH, Son MS, Kwon CI, Ko KH, Hong SP, Park PW, Rim KS. Korean J Gastroenterol. 2013 Apr 25;61(4):209-14.

801.	Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections
	Vermeulen M, Coleman C, Mitchel J, Reddy R, van Drimmelen H, Ficket T, Lelie N. Transfusion. 2013 Apr 29. doi: 10.1111/trf.12218. [Epub ahead of print]

802.	Excellent liver transplantation survival and prevention of hepatitis B recurrence using hepatitis B immunoglobulin and nucleoside or nucleotide analogue along with treating physician adherence to treatment protocol
	Lindenger C, Castedal M, Cahlin C, Friman S. Transplant Proc. 2013 Apr;45(3):1188-92. doi: 10.1016/j.transproceed.2012.10.007.

803.	Are liver transplant recipients protected against hepatitis a and B?
	Andersson D, Castedal M, Friman V. Transplant Proc. 2013 Apr;45(3):1193-7. doi: 10.1016/j.transproceed.2012.10.012.

804.	Country of birth and other factors associated with hepatitis B prevalence in a population with high levels of immigration
	Reekie J, Gidding HF, Kaldor JM, Liu B. J Gastroenterol Hepatol. 2013 Apr 26. doi: 10.1111/jgh.12245. [Epub ahead of print]

805.	Contributing factors to colorectal cancer and hepatitis B screening among vietnamese americans
	Nguyen-Truong CK, Lee-Lin F, Gedaly-Duff V. Oncol Nurs Forum. 2013 May 1;40(3):238-51. doi: 10.1188/13.ONF.238-251.

806.	Extended treatment with peginterferon ?-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion
	Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. J Dig Dis. 2013 Apr 25. doi: 10.1111/1751-2980.12065. [Epub ahead of print]

807.	The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis
	Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J. Ann Hepatol. 2013 May-Jun;12(3):364-72.

808.	Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants
	Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH. J Antimicrob Chemother. 2013 Apr 25. [Epub ahead of print]

809.	Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy
	Deng XL, Li QL, Guo JJ. Virus Genes. 2013 Apr 25. [Epub ahead of print]

810.	Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma
	Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Oncol Rep. 2013 Apr 24. doi: 10.3892/or.2013.2422. [Epub ahead of print]

811.	Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
	Lieveld FI, van Vlerken LG, Siersema PD, van Erpecum KJ. Ann Hepatol. 2013 May-Jun;12(3):380-91.

812.	Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients
	Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ. PLoS One. 2013 Apr 17;8(4):e61448. doi: 10.1371/journal.pone.0061448. Print 2013.

813.	Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study
	Chen MS Jr, Fang DM, Stewart SL, Ly MY, Lee S, Dang JH, Nguyen TT, Maxwell AE, Bowlus CL, Bastani R, Nguyen TT. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):782-91. doi: 10.1158/1055-9965.EPI-12-1399. Epub 2013 Apr 23.

814.	Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the chinese experience from 1999 to 2010
	Hu Z, Zhou J, Wang H, Zhang M, Li S, Huang Y, Wu J, Li Z, Zhou L, Zheng S. PLoS One. 2013 Apr 16;8(4):e61620. doi: 10.1371/journal.pone.0061620. Print 2013.

815.	Association between Interferon-Inducible Protein 6 (IFI6) Polymorphisms and Hepatitis B Virus Clearance
	Park GH, Kim KY, Cho SW, Cheong JY, Yu GI, Shin DH, Kwack KB. Genomics Inform. 2013 Mar;11(1):15-23. doi: 10.5808/GI.2013.11.1.15. Epub 2013 Mar 31.

816.	Dried blood spot sampling for hepatitis B virus serology and molecular testing
	Mohamed S, Raimondo A, Pénaranda G, Camus C, Ouzan D, Ravet S, Bourlière M, Khiri H, Dukan P, Olive D, Halfon P. PLoS One. 2013 Apr 16;8(4):e61077. doi: 10.1371/journal.pone.0061077. Print 2013.

817.	Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials.
	Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Hepatol Res. 2013 Apr 2. doi: 10.1111/hepr.12115. [Epub ahead of print]

818.	Advance in molecular diagnostic tools for hepatitis B virus detection
	Pazienza V, Niro GA, Fontana R, Vinciguerra M, Andriulli A. Clin Chem Lab Med. 2013 Apr 6:1-11. doi: 10.1515/cclm-2013-0136. [Epub ahead of print]

819.	Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer
	Müller T, Mehrle S, Schieck A, Haberkorn U, Urban S, Mier W. Mol Pharm. 2013 May 3. [Epub ahead of print]

820.	Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
	Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Liver Int. 2013 Apr 2. doi: 10.1111/liv.12168. [Epub ahead of print]

821.	Optimal Testing of the Live Organ Donor for Blood-Borne Viral Pathogens: The Report of a Consensus Conference
	Blumberg EA, Ison MG, Pruett TL, Segev DL; on behalf of the Optimal Testing of the Live Organ Donor Consensus Conference Participants. Am J Transplant. 2013 Apr 19. doi: 10.1111/ajt.12205. [Epub ahead of print]

822.	Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B
	Li X, Wang Y, Han D, Zhang W, Zhang Z, Ye X, Tian L, Dong Y, Zhu Q, Chen Y. Hepatol Res. 2013 Mar 4. doi: 10.1111/hepr.12105. [Epub ahead of print]

823.	Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome
	Delaney WE 4th. Antiviral Res. 2013 Apr 18. pii: S0166-3542(13)00096-X. doi: 10.1016/j.antiviral.2013.04.010. [Epub ahead of print]

824.	Association of the rs3077 and rs9277535 polymorphisms in HLA-DP with hepatitis B virus infection and spontaneous clearance: A meta-analysis
	Zhang XL, Ni XC, Jia JH, Dong JH, Yu FX, Ma N, Liu XH, Li M, Liu DW. Scand J Gastroenterol. 2013 Apr 22. [Epub ahead of print]

825.	Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B
	Tanaka E, Matsumoto A. Hepatol Res. 2013 Mar 8. doi: 10.1111/hepr.12108. [Epub ahead of print]

826.	Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B
	Suk KT, Kim HC, Namkung S, Han SH, Choi KC, Park SH, Sung HT, Kim CH, Kim SH, Ham YL, Kang HM, Kim DJ. Eur J Gastroenterol Hepatol. 2013 Apr 18. [Epub ahead of print]

827.	Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
	Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis GM, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno CF. J Med Virol. 2013 Jun;85(6):996-1004. doi: 10.1002/jmv.23567.

828.	Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent
	Wijaya I, Hasan I. Acta Med Indones. 2013 Jan;45(1):61-6.

829.	Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B
	Hagiwara S, Kudo M, Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada N, Nishida N. J Med Virol. 2013 Jun;85(6):987-95. doi: 10.1002/jmv.23564.

830.	Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B
	Yu F, Wang Y, Yuan S, Ma J, Ma N, Zhang X, Liu X, Liu D. Scand J Gastroenterol. 2013 Apr 16. [Epub ahead of print]

831.	Does Guasha Offer Hepatoprotective Effect to Chronic Inactive Hepatitis B Carriers? A Built-in Design to Control Subject Expectation
	Chan ST, Yuen JW, Gohel MD, Wong HC, Chung CP, Sun Y, Ng JN, Lie R, Kwong KK. J Altern Complement Med. 2013 Apr 11. [Epub ahead of print]

832.	Hepatitis B and C infection in international travelers
	Johnson DF, Leder K, Torresi J. J Travel Med. 2013 May;20(3):194-202. doi: 10.1111/jtm.12026. Epub 2013 Apr 4.

833.	Peginterferon-2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study
	Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.

834.	Long-term therapy for chronic hepatitis B: HBV DNA suppression leading to cirrhosis reversal
	Marcellin P, Asselah T. J Gastroenterol Hepatol. 2013 Apr 11. doi: 10.1111/jgh.12213. [Epub ahead of print]

835.	Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study
	Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, Acalovschi M, Usluer G, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Simon K; the AI; Longitudinal Study Group. Antivir Ther. 2013 Apr 10. doi: 10.3851/IMP2573. [Epub ahead of print]

836.	Coinfection with Hepatitis B and D: Epidemiology, Prevalence and Disease in Patients in Northern California
	Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, Winters MA, Proudfoot J, Glenn JS. J Gastroenterol Hepatol. 2013 Apr 11. doi: 10.1111/jgh.12217. [Epub ahead of print]

837.	Update in the management of chronic hepatitis B
	Tujios SR, Lee WM. Curr Opin Gastroenterol. 2013 May;29(3):250-6. doi: 10.1097/MOG.0b013e32835ff1e9.

838.	Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B
	Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. J Gastroenterol. 2013 Mar 26. [Epub ahead of print]

839.	Liver transplantation in hepatitis B core negative recipients using livers from hepatitis B core positive donor: 13 years experience
	Bohorquez HE, Cohen AJ, Girgrah N, Bruce DS, Carmody IC, Joshi S, Reichman TW, Therapondos G, Mason AL, Loss GE. Liver Transpl. 2013 Mar 22. doi: 10.1002/lt.23644. [Epub ahead of print]

840.	Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease
	Chen FW, Coyle L, Jones BE, Pattullo V. Liver Int. 2013 Mar 2. doi: 10.1111/liv.12154. [Epub ahead of print]

841.	Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination
	Gessoni G, Beggio S, Barin P, Favarato M, Galli C, Valverde S, Nata MB, Salvadego MM, Marchiori G. Blood Transfus. 2013 Feb 21:1-6. doi: 10.2450/2013.0227-12. [Epub ahead of print]

842.	Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response
	Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Liver Int. 2013 Mar 7. doi: 10.1111/liv.12150. [Epub ahead of print]

843.	Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles
	Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26385. [Epub ahead of print]

844.	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
	Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatol Int. 2013 Mar;7(1):88-97. Epub 2012 Mar 23.

845.	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
	Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatol Int. 2013 Mar;7(1):88-97. Epub 2012 Mar 23.

846.	Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers
	Sodhi JS, Wani N, Jeelani S, Geelani S, Akhtar F, Javid G, Yattoo GN, Shah A, Gulzar GM, Khan MA, Parveen S, Saif RU, Showkat A. Indian J Gastroenterol. 2013 Mar 20. [Epub ahead of print]

847.	Association Between Metabolic Syndrome and Its Individual Components With Viral Hepatitis B
	Jinjuvadia R, Liangpunsakul S. Am J Med Sci. 2013 Mar 19. [Epub ahead of print]

848.	Role of maternal viremia and placental infection in hepatitis B virus intrauterine transmission
	Chen Y, Wang L, Xu Y, Liu X, Li S, Qian Q, Hu B, Zhou A, Chen T, Zhao Y. Microbes Infect. 2013 Mar 14. pii: S1286-4579(13)00037-3. doi: 10.1016/j.micinf.2013.02.008. [Epub ahead of print]

849.	Immunoglobulin g4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review
	Zhao XY, Rakhda MI, Wang TI, Jia JD. Transplant Proc. 2013 Mar;45(2):824-7. doi: 10.1016/j.transproceed.2012.02.049.

850.	APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B
	Ucar F, Sezer S, Ginis Z, Ozturk G, Albayrak A, Basar O, Ekiz F, Coban S, Yuksel O, Armutcu F, Akbal E. Eur J Gastroenterol Hepatol. 2013 Mar 18. [Epub ahead of print]

851.	The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients
	Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, Koca Y. Scand J Clin Lab Invest. 2013 Mar 20. [Epub ahead of print]

852.	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir
	Gish RG, Chang TT, Lai CL, de Man RA, Gadano A, Llamoso C, Tang H. Antivir Ther. 2013 Mar 19. doi: 10.3851/IMP2559. [Epub ahead of print]

853.	Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection
	Gressner OA, Fang M, Li H, Lu LG, Gressner AM, Gao CF. Clin Chim Acta. 2013 Mar 15;421C:126-131. doi: 10.1016/j.cca.2013.02.029. [Epub ahead of print]

854.	Assessing Adherence to Accepted National Guidelines for Immigrant and Refugee Screening and Vaccines in an Urban Primary Care Practice: A Retrospective Chart Review
	Waldorf B, Gill C, Crosby SS. J Immigr Minor Health. 2013 Mar 20. [Epub ahead of print]

855.	Adefovir treatment for chronic hepatitis B in heart transplant recipients
	Durante-Mangoni E, Iossa D, Pinto D, Molaro R, Agrusta F, Amarelli C, Ragone E, Grimaldi M, Maiello C, Utili R. Clin Transplant. 2013 Mar 21. doi: 10.1111/ctr.12109. [Epub ahead of print]

856.	Telbivudine treatment in chronic hepatitis B: experience from China
	You H, Jia J. J Viral Hepat. 2013 Apr;20 Suppl 1:3-8. doi: 10.1111/jvh.12058.

857.	Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence
	Yan Q, Ni J, Zhang GL, Yao X, Yuan WB, Zhou L, Zheng SS. Chin Med J (Engl). 2013 Mar;126(5):855-9.

858.	Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy
	Saitta C, Musolino C, Marabello G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G. Dig Liver Dis. 2013 Mar 11. pii: S1590-8658(13)00042-X. doi: 10.1016/j.dld.2013.01.022. [Epub ahead of print]

859.	Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection
	Gatanaga H, Hayashida T, Tanuma J, Oka S. Clin Infect Dis. 2013 Mar 28. [Epub ahead of print]

860.	Ocular effects of pegylated interferon-? in patients with chronic hepatitis B
	Koktekir BE, Sumer S, Bakbak B, Gedik S, Gonul S, Ural O. Cutan Ocul Toxicol. 2013 Mar 12. [Epub ahead of print]

861.	Mother-to-Infant Transmission of Hepatitis B Virus Infection: Significance of Maternal Viral Load and Strategies for Intervention
	Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. J Hepatol. 2013 Feb 25. pii: S0168-8278(13)00137-2. doi: 10.1016/j.jhep.2013.02.015. [Epub ahead of print]

862.	Individualized treatment of HBeAg-negative CHB using peg-interferon alfa-2a as first-line and week 12 HBV-DNA\HBsAg stopping rule. A cost-effectiveness analysis
	Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

863.	Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients
	Wang GQ, Ding YP, Dong YH. J Viral Hepat. 2013 Apr;20 Suppl 1:9-17. doi: 10.1111/jvh.12059.

864.	Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil
	Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. J Viral Hepat. 2013 Apr;20 Suppl 1:40-5. doi: 10.1111/jvh.12062.

865.	Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy
	Liu M, Cai H, Yi W. J Viral Hepat. 2013 Apr;20 Suppl 1:65-70. doi: 10.1111/jvh.12066.

866.	Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil
	Li Y, Zhang Y, Wang JP, Lian JQ, Bai XF. J Viral Hepat. 2013 Apr;20 Suppl 1:46-51. doi: 10.1111/jvh.12063.

867.	Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study
	Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z. J Viral Hepat. 2013 Apr;20 Suppl 1:52-7. doi: 10.1111/jvh.12064.

868.	Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis
	Han Z, Shi Y, Zhu J, Chen Y, Yin F, Xia L, Luo G, Gao Z, Liu J, Jia G, Li C, Zhou X, Han Y. J Viral Hepat. 2013 Apr;20 Suppl 1:58-64. doi: 10.1111/jvh.12065.

869.	IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B
	Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. PLoS One. 2013;8(2):e58071. doi: 10.1371/journal.pone.0058071. Epub 2013 Feb 28.

870.	Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy
	Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Hepatology. 2013 Mar 6. doi: 10.1002/hep.26376. [Epub ahead of print]

871.	Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
	Winther TN, Bang-Berthelsen CH, Heiberg IL, Pociot F, Hogh B. PLoS One. 2013;8(3):e58236. doi: 10.1371/journal.pone.0058236. Epub 2013 Mar 4.

872.	Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life
	Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472. Epub 2013 Mar 1.

873.	Acute Hepatitis B in an Urban Tertiary Care Hospital in the United States: A Cohort Evaluation
	Sharif O, Krishnan PV, Thekdi AD, Gordon SC. J Clin Gastroenterol. 2013 Mar 6. [Epub ahead of print]

874.	Abnormal regional homogeneity of resting-state brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy
	Lv XF, Qiu YW, Tian JZ, Xie CM, Han LJ, Su HH, Liu ZY, Peng JP, Lin CL, Wu MS, Jiang GH, Zhang XL. Liver Int. 2013 Mar;33(3):375-83. doi: 10.1111/liv.12096.

875.	Cost-minimization analysis of the U.S. Army accession screening and immunization program
	Tzeng J, Jankosky C, Hughes H. Mil Med. 2012 Dec;177(12):1508-12.

876.	Association of cytokine gene polymorphisms and serum concentrations with the outcome of chronic hepatitis B
	Conde SR, Feitosa RN, Freitas FB, Hermes RB, Demachki S, Araújo MT, Soares MC, Ishak R, Vallinoto AC. Cytokine. 2013 Feb 5. pii: S1043-4666(13)00034-3. doi: 10.1016/j.cyto.2013.01.004. [Epub ahead of print]

877.	Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C
	Sturm N, Marlu A, Arvers P, Zarski JP, Leroy V. Liver Int. 2013 Mar;33(3):428-38. doi: 10.1111/liv.12092.

878.	Chronic hepatitis B: What should be the goal for new therapies?
	Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT. Antiviral Res. 2013 Feb 4. pii: S0166-3542(13)00021-1. doi: 10.1016/j.antiviral.2013.01.006. [Epub ahead of print]

879.	Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection
	Kondo Y, Ninomiya M, Kakazu E, Kimura O, Shimosegawa T. ISRN Gastroenterol. 2013;2013:935295. doi: 10.1155/2013/935295. Epub 2013 Jan 16.

880.	Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?
	Sherman M. Hepatology. 2013 Feb 11. doi: 10.1002/hep.26317. [Epub ahead of print]

881.	Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients
	Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H, Chayama K. J Gastroenterol. 2013 Feb 9. [Epub ahead of print]

882.	Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma
	Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y. Liver Int. 2013 Jan 12. doi: 10.1111/liv.12112. [Epub ahead of print]

883.	Hepatitis B
	Tong MJ, Trieu J. J Dig Dis. 2013 Feb 21. doi: 10.1111/1751-2980.12051. [Epub ahead of print]

884.	Towards complete eradication of hepatitis B infection from perinatal transmission: review of the mechanisms of in utero infection and the use of antiviral treatment during pregnancy
	Cheung KW, Seto MT, Wong SF. Eur J Obstet Gynecol Reprod Biol. 2013 Mar 4. pii: S0301-2115(13)00087-0. doi: 10.1016/j.ejogrb.2013.02.001. [Epub ahead of print]

885.	Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation
	Seo JY, Kim W, Kwon JH, Jin EH, Yu SJ, Kim HY, Jung YJ, Kim D, Kim YJ, Yoon JH, Lee HS. Liver Int. 2013 Jan 30. doi: 10.1111/liv.12132. [Epub ahead of print]

886.	Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure
	Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, Mao YL, Xin SJ, Hu JH. World J Gastroenterol. 2013 Feb 21;19(7):1104-10. doi: 10.3748/wjg.v19.i7.1104.

887.	Use of the International Classification of Diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance
	Mahajan R, Moorman AC, Liu SJ, Rupp L, Klevens RM; for the Chronic Hepatitis Cohort Study (CHeCS) investigators*. J Am Med Inform Assoc. 2013 Mar 5. [Epub ahead of print]

888.	Expression of Interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection
	Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, Chen SJ. Diagn Pathol. 2013 Feb 28;8:40. doi: 10.1186/1746-1596-8-40.

889.	A randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal post-liver transplant
	Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Liver Transpl. 2013 Feb 27. doi: 10.1002/lt.23628. [Epub ahead of print]

890.	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
	Su TH, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen CL, Chen PJ, Kao JH, Chen DS. PLoS One. 2013;8(2):e55916. doi: 10.1371/journal.pone.0055916. Epub 2013 Feb 20.

891.	Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates
	Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Liver Transpl. 2013 Mar;19(3):268-74. doi: 10.1002/lt.23600.

892.	Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: Current standards of care
	Giles ML, Grace R, Tai A, Michalak K, Walker SP. Aust N Z J Obstet Gynaecol. 2013 Mar 4. doi: 10.1111/ajo.12061. [Epub ahead of print]

893.	NK cells: a double-edged sword in chronic hepatitis B virus infection
	Maini MK, Peppa D. Front Immunol. 2013;4:57. doi: 10.3389/fimmu.2013.00057. Epub 2013 Mar 1.

894.	Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C
	Efe C, Wahlin S, Ozaslan E, Purnak T, Muratori L, Quarneti C, Tatar G, Simsek H, Muratori P, Schiano TD. Scand J Gastroenterol. 2013 Mar 1. [Epub ahead of print]

895.	Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine
	Lo AO, Wong VW, Wong GL, Chan HY, Cheung CM, Chan HL. Antivir Ther. 2013 Mar 5. doi: 10.3851/IMP2526. [Epub ahead of print]

896.	Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?
	Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M, Yasuda Y, Nakayama E, Miyake Y, Ikeda F, Shiraha H, Nouso K, Fujiwara T, Yamamoto K. J Gastroenterol. 2013 Feb 23. [Epub ahead of print]

897.	Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
	Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, Netto-Cardoso AC, Lada O, Batrla R, Krause F, Asselah T, Marcellin P. J Hepatol. 2013 Jan 28. pii: S0168-8278(13)00075-5. doi: 10.1016/j.jhep.2013.01.028. [Epub ahead of print]

898.	Invasive fungal infections secondary to acute-on-chronic liver failure: a retrospective study
	Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Mycoses. 2013 Feb 1. doi: 10.1111/myc.12044. [Epub ahead of print]

899.	Infectivity of blood products from donors with occult hepatitis B virus infection
	Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Transfusion. 2013 Jan 30. doi: 10.1111/trf.12096. [Epub ahead of print]

900.	Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease
	Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Transplantation. 2013 Jan 30. [Epub ahead of print]

901.	Comparative Efficacy of Oral Nucleoside or Nucleotide Analog Monotherapy Used in Chronic Hepatitis B: A Mixed-Treatment Comparison Meta-analysis
	Wiens A, Lenzi L, Venson R, Correr CJ, Rotta I, Pedroso ML, Pontarolo R. Pharmacotherapy. 2013 Feb;33(2):144-51. doi: 10.1002/phar.1188. Epub 2013 Jan 28.

902.	Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis b with high baseline viral load (? 9 log10 copies/mL)
	Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Hepatology. 2013 Jan 30. doi: 10.1002/hep.26277. [Epub ahead of print]

903.	Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance
	Song MN, Hong MZ, Luo DQ, Huang WQ, Min F, Fan RH, Wu WB, Zhang L. World J Hepatol. 2012 Dec 27;4(12):389-93. doi: 10.4254/wjh.v4.i12.389.

904.	Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis
	Huang R, Hao Y, Zhang J, Wu C. Hepatol Res. 2013 Jan 10. doi: 10.1111/hepr.12058. [Epub ahead of print]

905.	IL21 and IL21R polymorphisms and their interactive effects on serum IL-21 and IgE levels in patients with chronic hepatitis B virus infection
	Li N, Zhu Q, Li Z, Han Q, Chen J, Lv Y, Wang Y, Zeng X, Chen Y, Yang C, Liu Z. Hum Immunol. 2013 Jan 24. pii: S0198-8859(13)00016-5. doi: 10.1016/j.humimm.2013.01.005. [Epub ahead of print]

906.	The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients
	Ali S, Mealing S, Hawkins N, Lescrauwaet B, Bjork S, Mantovani L, Lampertico P. BMJ Open. 2013 Jan 24;3(1). pii: e001309. doi: 10.1136/bmjopen-2012-001309. Print 2013.

907.	Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010
	Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, Holmberg SD. Hepatology. 2013 Jan 28. doi: 10.1002/hep.26286. [Epub ahead of print]

908.	Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection
	Ma J, Jiang Y, Gong G. Eur J Gastroenterol Hepatol. 2013 Jan 24. [Epub ahead of print]

909.	Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
	Kwak MS, Kim D, Chung GE, Kang SJ, Park MJ, Kim YJ, Yoon JH, Lee HS. Clin Mol Hepatol. 2012 Dec;18(4):383-90. doi: 10.3350/cmh.2012.18.4.383. Epub 2012 Dec 21.

910.	Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China
	Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, Lu P, Hsia CC, Wang N, Xu L, Lu L, Huang F, Zhu Y, Lu J, Ni Z, Zhang Q, Wu Y, Liu G, Wu Z, Qu C, Gail MH. Carcinogenesis. 2013 Jan 14. [Epub ahead of print]

911.	Efficacy of pegylated interferon alpha2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy
	Zhang XQ, Zhang HY, You JP, Mao Q. Virol J. 2013 Jan 15;10(1):21. [Epub ahead of print]

912.	Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues
	Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. World J Gastroenterol. 2012 Dec 28;18(48):7149-57. doi: 10.3748/wjg.v18.i48.7149.

913.	Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B?
	Ceylan B, Fincanci M, Yardimci C, Eren G, Tözalgan U, Müderriso?lu C, Pa?ao?lu E. Eur J Gastroenterol Hepatol. 2013 Jan 15. [Epub ahead of print]

914.	Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B
	Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. World J Gastroenterol. 2012 Dec 21;18(47):6987-95. doi: 10.3748/wjg.v18.i47.6987.

915.	Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures
	Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. World J Gastroenterol. 2012 Dec 21;18(47):6996-7002. doi: 10.3748/wjg.v18.i47.6996.

916.	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis
	Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Crit Rev Oncol Hematol. 2013 Jan 10. pii: S1040-8428(12)00250-8. doi: 10.1016/j.critrevonc.2012.12.004. [Epub ahead of print]

917.	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D
	Boglione L, D'Avolio A, Cariti G, Gregori G, Burdino E, Baietto L, Cusato J, Ghisetti V, De Rosa FG, Perri GD. Liver Int. 2012 Dec 12. doi: 10.1111/liv.12091. [Epub ahead of print]

918.	Knowledge and Behaviors Toward Hepatitis B and the Hepatitis B Vaccine in the Laotian Community in Minnesota
	Xiong M, Nguyen RH, Strayer L, Chanthanouvong S, Yuan JM. J Immigr Minor Health. 2013 Jan 11. [Epub ahead of print]

919.	HBV infection increases the risk of pancreatic cancer: a meta-analysis
	Luo G, Hao NB, Hu CJ, Yong X, Lü MH, Cheng BJ, Zhang Y, Yang SM. Cancer Causes Control. 2013 Jan 10. [Epub ahead of print]

920.	Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature
	Bertino G, Ardiri AM, Calvagno GS, Bertino N, Ruggeri MI, Malaguarnera M, Malaguarnera G, Toro A, Di Carlo I. Clin Ter. 2012 Nov;163(6):e429-34.

921.	Clin Dev Immunol. 2012;2012:843134. doi: 10.1155/2012/843134. Epub 2012 Dec 13. Rapid Immunization Scheme for Spouses of Individuals Estabilished as Hepatitis B Carriers during Premarital Tests.
	Tosun S, Yücetürk M, Dönmez AB, Gündüz T.

922.	Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
	Zoulim F, Locarnini S. Liver Int. 2013 Feb;33 Suppl 1:116-24. doi: 10.1111/liv.12069.

923.	Impact of therapy on the outcome of chronic hepatitis B
	Liaw YF. Liver Int. 2013 Feb;33 Suppl 1:111-5. doi: 10.1111/liv.12057.

924.	Antiviral therapy for patients with chronic hepatitis B with multi-drug resistance to nucleoside analogues
	Ozeki I, Hige S, Karino Y, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Ohmura T, Sato T, Toyota J. Nihon Shokakibyo Gakkai Zasshi. 2013;110(1):44-55.

925.	IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED-INTERFERON-α
	Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Visvanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ. J Gastroenterol Hepatol. 2013 Jan 9. doi: 10.1111/jgh.12110. [Epub ahead of print]

926.	The role of HBsAg quantification for monitoring natural history and treatment outcome
	Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. Liver Int. 2013 Feb;33 Suppl 1:125-32. doi: 10.1111/liv.12075.

927.	Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-virginia, 2010
	Bender TJ, Wise ME, Utah O, Moorman AC, Sharapov U, Drobeniuc J, Khudyakov Y, Fricchione M, White-Comstock MB, Thompson ND, Patel PR. PLoS One. 2012;7(12):e50012. doi: 10.1371/journal.pone.0050012. Epub 2012 Dec 26.

928.	Trends in viral hepatitis cost-effectiveness studies
	Saab S, Choi Y, Rahal H, Li K, Tong M. Am J Manag Care. 2012 Dec;18(12):790-8.

929.	Association of chronic liver disease with depression: a population-based study
	Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younossi ZM. Psychosomatics. 2013 Jan;54(1):52-9. doi: 10.1016/j.psym.2012.09.005.

930.	Lack of association between hepatitis B virus pre-S mutations and recurrence after surgical resection in hepatocellular carcinoma
	Heo NY, Lee HC, Park YK, Park JW, Lim YS, Kim KM, Shim JH, Lee YJ. J Med Virol. 2013 Jan 7. doi: 10.1002/jmv.23502. [Epub ahead of print]

931.	Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma
	Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH. Liver Int. 2013 Feb;33(2):244-54. doi: 10.1111/liv.12036.

932.	Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma
	Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, Deng Q, Lan K, Zhou W. Protein Cell. 2013 Jan;4(1):71-81. doi: 10.1007/s13238-012-2067-9. Epub 2012 Dec 22.

933.	Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation
	Chen J, Liu C, Chen H, Liu Q, Yang B, Ou Q. J Clin Lab Anal. 2013 Jan;27(1):5-11. doi: 10.1002/jcla.21554. Epub 2013 Jan 4.

934.	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy
	Kim BK, Oh HJ, Park JY, Kim do Y, Ahn SH, Han KH, Park Y, J Yoo E, Park YN, Kim SU. Liver Int. 2013 Feb;33(2):180-9. doi: 10.1111/liv.12020.

935.	Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus
	Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. J Infect. 2012 Dec 31. pii: S0163-4453(12)00389-1. doi: 10.1016/j.jinf.2012.12.008. [Epub ahead of print]

936.	Hepatitis B Screening in US Travelers Seen at the Boston Area Travel Medicine Network
	Chen LH, Barnett ED, Wilson ME, Macleod W, Yanni EA, Ooi W, Karchmer AW, Kogelman L, Marano N, Hamer DH. J Travel Med. 2013 Jan;20(1):29-36. doi: 10.1111/jtm.12002.

937.	IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection
	Li N, Zhu Q, Li Z, Han Q, Zhang G, Chen J, Lv Y, Xing F, Chen Y, Zeng X, Liu Z. Mol Carcinog. 2012 Dec 31. doi: 10.1002/mc.21992. [Epub ahead of print]

938.	Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection
	Li Z, Li N, Zhu Q, Zhang G, Han Q, Zhang P, Xun M, Wang Y, Zeng X, Yang C, Liu Z. Infect Genet Evol. 2013 Jan 2. pii: S1567-1348(12)00390-5. doi: 10.1016/j.meegid.2012.12.008. [Epub ahead of print]

939.	Trends in viral hepatitis cost-effectiveness studies
	Saab S, Choi Y, Rahal H, Li K, Tong M. Am J Manag Care. 2012 Dec;18(12):790-8.

940.	The Diversity and Management of Chronic Hepatitis B Virus Infections in the UK - A Wake up Call
	Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G, Chokshi S, Wong T, Rosenberg G, Moreea S, Bassendine M, Jacobs M, Mills PR, Mutimer D, Ryder S, Bathgate A, Hussaini H, Dillon J, Wright M, Bird G, Collier J, Anderson M, Johnson A; for the CUSHIB Study Group. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]

941.	Hepatitis B screening: who to target? A French Sexually Transmitted Infection Clinic Experience
	Spenatto N, Boulinguez S, Mularczyk M, Molinier L, Bureau C, Saune K, Viraben R. J Hepatol. 2012 Dec 5. pii: S0168-8278(12)00914-2. doi: 10.1016/j.jhep.2012.11.044. [Epub ahead of print]

942.	Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis
	Lin CW, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, Lo GH, Chen YS, Yen YC, Hu JT, Yu ML, Lee PH, Lin JT, Yang SS. J Hepatol. 2012 Dec 6. pii: S0168-8278(12)00916-6. doi: 10.1016/j.jhep.2012.11.045. [Epub ahead of print]

943.	Long-term Hepatitis B Surface Antigen (HBsAg) Kinetics during Nucleoside/Nucleotide Analogue Therapy: Finite Treatment Duration Unlikely
	Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. J Hepatol. 2012 Dec 3. pii: S0168-8278(12)00909-9. doi: 10.1016/j.jhep.2012.11.039. [Epub ahead of print]

944.	Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
	Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Lancet. 2012 Dec 7. pii: S0140-6736(12)61425-1. doi: 10.1016/S0140-6736(12)61425-1. [Epub ahead of print]

945.

Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma

Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L. Nat Genet. 2012 Dec 16;45(1):72-5. doi: 10.1038/ng.2483. Epub 2012 Dec 16.

946.	Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion
	Cheng Y, Guindon S, Rodrigo A, Wee LY, Inoue M, Thompson AJ, Locarnini S, Lim SG. Gut. 2012 Dec 15. [Epub ahead of print]

947.	Influence of Information Sources on Hepatitis B Screening Behavior and Relevant Psychosocial Factors Among Asian Immigrants
	Tanaka M, Strong C, Lee S, Juon HS. J Immigr Minor Health. 2012 Dec 13. [Epub ahead of print]

948.	Safety of lamivudine treatment for chronic hepatitis B in early pregnancy
	Yi W, Liu M, Cai HD. World J Gastroenterol. 2012 Dec 7;18(45):6645-50. doi: 10.3748/wjg.v18.i45.6645.

949.	Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs
	Petersen J, Buti M. Expert Rev Gastroenterol Hepatol. 2012 Dec;6(6):683-94. doi: 10.1586/egh.12.52.

950.	A Predictive Scoring System for the Seroclearance of HBsAg in HBeAg-seronegative Chronic Hepatitis B Patients with Genotype B or C Infection
	Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. J Hepatol. 2012 Dec 12. pii: S0168-8278(12)00954-3. doi: 10.1016/j.jhep.2012.12.006. [Epub ahead of print]

951.	Hepatitis B and C in liver transplantation: new strategies to combat the enemies
	Beckebaum S, Kabar I, Cicinnati VR. Rev Med Virol. 2012 Dec 13. doi: 10.1002/rmv.1734. [Epub ahead of print]

952.	The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis
	Zhang Q, Chen X, Zang Y, Zhang L, Chen H, Wang L, Niu Y, Ren X, Shen Z, Shang L. PLoS One. 2012;7(12):e50919. doi: 10.1371/journal.pone.0050919. Epub 2012 Dec 7.

953.	Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection
	Atay AE, Seven G, Yalcin K, Pasa S, Degertekin H. J Int Med Res. 2012;40(5):1891-6.

954.	Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine
	Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M. Vaccine. 2012 Dec 1. pii: S0264-410X(12)01630-1. doi: 10.1016/j.vaccine.2012.11.037. [Epub ahead of print]

955.	Liver stiffness measurement in cirrhotic patient - Implications of disease activity and treatment efficacy
	Xu HW, Lu SN, Hung CH, Chang KC, Hu TH, Wang JH. Kaohsiung J Med Sci. 2012 Dec;28(12):641-8. doi: 10.1016/j.kjms.2012.04.032. Epub 2012 Aug 1.

956.	The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes
	Langness JA, Hindman JT, Johnson SC, Kiser JJ. J Pharm Pract. 2012 Dec 2. [Epub ahead of print]

957.	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
	Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26180. [Epub ahead of print]

958.	Atypical serological profiles in hepatitis B virus infection
	Pondé RA. Eur J Clin Microbiol Infect Dis. 2012 Nov 29. [Epub ahead of print]

959.	Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study
	Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN. J Hepatol. 2012 Nov 27. pii: S0168-8278(12)00894-X. doi: 10.1016/j.jhep.2012.11.025. [Epub ahead of print]

960.	Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study
	Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Scand J Gastroenterol. 2012 Nov 30. [Epub ahead of print]

961.	Reactivation of hepatitis viruses following immunomodulationg systemic chemotherapy
	Watanabe T, Tanaka Y. Hepatol Res. 2012 Oct 30. doi: 10.1111/hepr.12014. [Epub ahead of print]

962.	The Short-Term Efficacy of Entecavir in Lamivudine-Resistant Chronic Hepatitis B: Influence of Sequential Adefovir-Refractoriness
	Kim JH, Kim YS, Jung YK, Kim YS, Kwon OS, Ku YS, Choi DJ, Kim JH. Hepatogastroenterology. 2012 Nov 28;60(125). doi: 10.5754/hge12917. [Epub ahead of print]

963.	Reactivation of Hepatitis B Virus in Patients Receiving Chemotherapy
	Ikeda M. Jpn J Clin Oncol. 2012 Nov 25. [Epub ahead of print]

HBV

HCC

HCV

Hepatorenal Syndrome

NASH

PBC

OTHER

About CLDF

Board of Advisors/Faculty

CLDF Sponsors & Supporters

Other Resources

Liver News Library

Journal Abstracts

Hep C Link to Care

Centers of
Educational Expertise

Hepatology

Substance Use Disorder

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.